

# ADLM 2024

## BOLD MOVE.

**PROGRAM & POSTER  
ABSTRACTS GUIDE**

**ADLM** Association for  
Diagnostics &  
Laboratory Medicine™

**Christina Pierre**  
PhD, DABCC, FADLM



# WHERE GREAT MINDS MEET

WELCOME TO CHICAGO FOR ADLM 2024 – THE PREMIER DESTINATION FOR GLOBAL LEADERS WHO ARE HERE TO ELEVATE EVERY FACET OF THE INDUSTRY, BOTH IN THE LAB AND BEYOND.

Once a year, we come together as one global laboratory medicine community to observe, collaborate, innovate, share, discover and connect. This is our time to explore what's possible in the future and what's practical and ready to implement in the lab here and now.

Let's talk breaking science with the greatest clinical minds of our time. From AI capabilities to new technologies to patient-centric models of care, we have the will and the way to move our profession forward.

## **JOIN US.**

- 900+ exhibitors, 200+ product categories and live demos
- 250+ educational sessions, lectures, roundtables and plenary sessions
- Networking opportunities to connect with industry peers and leaders
- New technologies competing for this year's Disruptive Tech Award
- And so much more!

# CONTENTS

## GENERAL MEETING INFORMATION

- 2 Registration Hours  
Offices & Meeting Services
- 3 ADLM Clinical Lab Expo  
Hours & Events
- 4 Shuttle Schedule
- 6 2024 Sponsors
- 7 2024 Annual Meeting Organizing Committee
- 8 ADLM Board of Directors
- 9 2024 Award Recipients
  - ADLM Awards & Grants
  - Academy Awards
  - Academy Fellows
  - Other Awards
- 13 Continuing Education Credit &  
Certificate of Attendance
- 18 Session Information
- 19 Pathways
- 22 Schedule-at-a-Glance
- 24 Mobile App

## SESSIONS BY DAY

- 25 Sunday, July 28
- 31 Monday, July 29
- 47 Tuesday, July 30
- 59 Wednesday, July 31
- 71 Thursday, August 1

## POSTER ABSTRACTS

- 77 Poster Abstracts Titles

## GENERAL MEETING INFORMATION

All locations are in the McCormick Place Convention Center unless otherwise noted.

### REGISTRATION

#### Main Registration

Location: Grand Concourse

Sunday 7:30 a.m. - 6:30 p.m.

Monday - Wednesday 7:00 a.m. - 5:00 p.m.

Thursday 8:00 a.m. - 12:00 p.m.

#### Satellite Registration

Location: Transportation Lobby

Saturday 12:00 p.m. - 5:00 p.m.

Sunday 7:30 a.m. - 6:30 p.m.

Monday 7:00 a.m. - 5:00 p.m.

Tuesday 7:00 a.m. - 2:00 p.m.

#### Satellite Registration

Location: Marriott Marquis 2nd Floor

Saturday 12:00 p.m. - 5:00 p.m.

Sunday 7:30 a.m. - 6:30 p.m.

Monday 7:00 a.m. - 5:00 p.m.

### INFORMATION DESK

Location: South Building, Level 3

Sunday 7:30 a.m. - 5:30 p.m.

Monday - Wednesday 7:30 a.m. - 4:30 p.m.

Thursday 8:00 a.m. - 12:00 p.m.

### ADLM HEADQUARTERS OFFICE

Location: North Building, N427cd

Phone: 312-791-6700

Sunday 7:30 a.m. - 6:30 p.m.

Monday - Wednesday 7:00 a.m. - 5:00 p.m.

Thursday 8:00 a.m. - 1:00 p.m.

### COAT & LUGGAGE CHECK

Location: South Building,

South Level One Lobby

Sunday 7:00 a.m. - 8:00 p.m.

Monday - Wednesday 7:00 a.m. - 6:00 p.m.

Thursday 7:00 a.m. - 1:00 p.m.

Coat \$4, bag or poster \$5

### LOST & FOUND

Location: N429

### FIRST AID

Location: South Building, Level 2.5

Emergency Phone Number: 6060 from any telephone in the convention center.

### MOTHER'S ROOM

Location: South Building, Level 2.5

McCormick Place installed private nursing pods called Mamava Lactation Suites. These nursing pods can be locked and unlocked by utilizing the free Mamava mobile app. Please download the Mamava Mobile App at [mamava.com/mobile-app](http://mamava.com/mobile-app).



### SPEAKER READY ROOM

Location: South Building, S401c

Saturday 1:00 p.m. - 5:00 p.m.

Sunday 7:30 a.m. - 5:00 p.m.

Monday - Wednesday 7:30 a.m. - 5:00 p.m.

Thursday 7:30 a.m. - 11:00 a.m.

### PRESS OFFICE

Location: South Building, S102bc

Phone: 312-791-6705

Sunday 9:00 a.m. - 5:00 p.m.

Monday - Wednesday 8:00 a.m. - 5:00 p.m.

Thursday 8:00 a.m. - 1:00 p.m.

### PHOTOGRAPHY

Except for photography specifically authorized by ADLM, use of video and photographic equipment is prohibited on the exhibit floor and in the meeting rooms. Photography of poster sessions is permitted only with expressed permission of the presenting author.

## EXPO EVENTS

### ICE CREAM SOCIAL

Tuesday, July 30 | 2:00 p.m. - 3:00 p.m.

Enjoy a frozen treat on the Expo floor. Please note that these are first come, first served. Available until supplies last.

### NETWORKING LUNCH

Wednesday, July 31 | 12:30 p.m. - 1:30 p.m.

Join us in the Expo Hall for a boxed lunch. Please note that these are first come, first served. Available until supplies last.

### COFFEE BREAK

Thursday, August 1 | 10:00 a.m. - 11:00 a.m.

Enjoy coffee on the last day of the Clinical Lab Expo provided by Choose Chicago.

### DxPx US

Investor & Industry Partnering Conference & Startup City



Tuesday, July 30 - Thursday, August 1

ADLM is a proud Gold Sponsor of DxPx: An Industry + Investor Partnering Conference for the Diagnostics, Digital Health, Precision Medicine, and Life Science Tools industries, presented by Brown Gibbons Lang & Company (BGL).

DxPx U.S. is hosted on the floor of the ADLM 2024 Clinical Lab Expo and is *the* place for startups and growth-stage companies to meet with investors and industry participants for licensing, financing, co-development, and M&A opportunities. DxPx is also home to the 42PLUS1 Pitch Competition, which offers Startups the chance to compete for up to \$2 million in funding.

### SPECIAL EVENTS

Various Dates and Times

Attend and meet up with colleagues from across the globe. Visit special events on the mobile app for more.

### ADLM CLINICAL LAB EXPO

Location: South Building, Exhibit Hall A

Tuesday - Wednesday  
9:30 a.m. - 5:00 p.m.

Thursday  
9:30 a.m. - 12:00 p.m.

*Refer to the Exhibit Guide or the mobile app for exhibit listings and booth descriptions.*

ADLM permits individuals age 16 and 17 with a photo ID to attend, if accompanied by a registered adult. Children under 16 are not permitted on the exhibit floor or in the educational sessions at any time.



# SHUTTLE SERVICES

Date	Service Hours	Departures
<b>Sunday, July 28</b>	6:30 a.m. - 10:00 a.m.	Every 20 minutes
	10:00 a.m. - 4:00 p.m.	Every 30 minutes
	4:00 p.m. - 8:30 p.m.*	Every 20 minutes
<b>Monday, July 29</b>	6:00 a.m. - 10:00 a.m.	Every 15 minutes
	10:00 a.m. - 4:00 p.m.	Every 30 minutes
	4:00 p.m. - 6:30 p.m.*	Every 15 minutes
<b>Tuesday, July 30</b>	6:00 a.m. - 10:00 a.m.	Every 15 minutes
	10:00 a.m. - 4:00 p.m.	Every 30 minutes
	4:00 p.m. - 8:00 p.m.*	Every 15 minutes
<b>Wednesday, July 31</b>	6:00 a.m. - 10:00 a.m.	Every 15 minutes
	10:00 a.m. - 4:00 p.m.	Every 30 minutes
	4:00 p.m. - 8:00 p.m.*	Every 15 minutes
<b>Thursday, August 1</b>	7:00 a.m. - 10:00 a.m.	Every 15 minutes
	10:00 a.m. - 12:00 p.m.	Every 30 minutes
	12:00 p.m. - 4:00 p.m.*	Every 15 minutes

\* Indicates the last time the shuttle is departing from McCormick Place to hotels. The last shuttle departs from the hotels coming to the center one hour before this time.



If you need to arrange wheelchair-accessible transportation, please call 877-875-2455 at least 12 hours prior to requested pick-up time.



### Shuttles May Vary Due to Traffic & Weather Conditions

For real-time shuttle pickup information, scan the QR code or navigate to the shuttle tracker link within the ADLM mobile app!

### ADLM MEMBERSHIP

Not a member? Benefit immediately from ADLM membership — stop by either ADLM booth #1879 during Expo hours or the ADLM Conference Registration Desk for a special membership offer. Dues are as follows: Professional \$264; Professional Affiliate \$156; Transitional \$90; Express \$65; Trainee \$44.

### Member Lounge

ADLM members are invited to visit the Member Lounge located at the ADLM booth #1879 on the Clinical Lab Expo show floor during Expo hours. This exclusive member benefit provides a place to recharge between sessions, mingle with colleagues, and enjoy light refreshments.

# 2024

## 29<sup>TH</sup> ADLM INTERNATIONAL CPOCT SYMPOSIUM

September 25–27, 2024 | San Diego, CA



The world of critical and point-of-care testing (CPOCT) is driven by the need for accurate, rapid diagnosis that is integrated into healthcare systems. CPOCT technologies are continually advancing the field to meet this need.

**Join us at the Association for Diagnostics & Laboratory Medicine's (formerly AACC) International CPOCT Symposium in San Diego, CA.**

For two days:

- Learn the latest in POCT from **interdisciplinary experts**
- Engage with companies in the **exhibit hall**
- And network with peers during **poster hall receptions**  
(Poster abstracts submissions due August 5)

**Register by Monday, August 19 for the best rate!**

Don't miss this unique and engaging conference specifically geared toward CPOCT advancements.



**EARLY REGISTRATION  
ENDS AUGUST 19**

**ADLM**

Association for  
Diagnostics &  
Laboratory Medicine™  
Formerly AACC

## THANK YOU 2024 SPONSORS as of June 13, 2024

Abbott  
Advanced Instruments  
Anbio Biotechnology  
ARK Diagnostics, Inc.  
ARUP  
BD  
Beckman Coulter, Inc.  
BIOLYPH, LLC  
bioMerieux, Inc.  
BioPorto Diagnostics A/S  
Bio-Rad Laboratories  
BIOSYNTH  
Bio-Techne  
Brooks Automation  
Chronus Health Inc.  
DiaSorin Inc.  
Diazyme Laboratories, Inc.  
DxPx  
Enplas Life Tech  
Eurotrol, Inc.  
Fapon Biotech Inc.  
Fortis Life Sciences  
GenScript USA Inc.  
Golden West Biologicals, Inc.  
Greiner Bio-One  
Haemonetics Corporation  
Hamilton Company  
Helena Laboratories Corporation  
HemoSonics  
Hettich  
Indigo BioAutomation  
IQVIA  
Jackson ImmunoResearch Laboratories  
KNF Neuberger Inc.  
LabCorp  
MEDTOX Diagnostics, Inc.  
MeMed  
Meridian BioScience, Inc.  
Microbiologics  
New England Biolabs, Inc.  
Nova BioMedical Corporation  
Omega Bio-Tek  
Orchard Software Corp.  
Peripheral Resources, Inc.  
Polymedco, Inc.  
Porex Life Sciences Institute  
QuidelOrtho  
Randox Laboratories  
Roche Diagnostics  
Sapio Sciences LLC  
SARSTEDT  
Sebia  
Seegene, Inc.  
Sekisui Diagnostics LLC  
SCIEX  
Siemens Healthineers  
SpeeDx Pty Ltd  
Sysmex  
Tecan Trading AG  
Techcyte, Inc.  
Telcor  
The Lee Company  
Thermo Fisher Scientific  
Tosoh Bioscience  
TriMar Strategies GmbH  
UCLA Health  
Waters Corporation  
Werfen  
Whitehat Communications  
ZeptoMetrix

# ANNUAL MEETING ORGANIZING COMMITTEE

## CHAIR

- **Mark Marzinke**, PhD, DABCC, FADLM  
*Johns Hopkins University  
Baltimore, MD*

## VICE CHAIRS

- **Darci Block**, PhD, DABCC, FADLM  
*Mayo Clinic  
Rochester, MN*
- **Joely Straseski**, PhD, MT (ASCP),  
DABCC, FADLM  
*University of Utah/ARUP  
Salt Lake City, UT*

## PLENARY COORDINATOR

- **David Sacks**, MB ChB, FRCPath  
*National Institutes of Health  
Bethesda, MD*

## SCIENTIFIC SESSION COORDINATORS

- **Allison Chambliss**, PhD, DABCC, FADLM  
*University of California, Los Angeles  
Los Angeles, CA*
- **Mari DeMarco**, PhD, DABCC,  
FADLM, FCACB  
*St. Paul's Hospital  
Vancouver, BC (Canada)*
- **Jane Dickerson**, PhD, DABCC  
*Seattle Children's Hospital  
Seattle, WA*
- **Patrick Kyle**, PhD, ABFT, DABCC, FADLM  
*University of Mississippi Medical Center  
Jackson, MS*

## ROUNDTABLE COORDINATORS

- **K. Aaron Geno**, PhD, DABCC  
*Dartmouth-Hitchcock Medical Center  
Lebanon, NH*
- **Jaime Noguez**, PhD, DABCC  
*University Hospitals Cleveland  
Medical Center  
Cleveland, OH*

## POSTER ABSTRACT COORDINATORS

- **Joshua Hayden**, PhD, DABCC, FADLM  
*Norton Healthcare  
Louisville, KY*
- **Christina Pierre**, PhD, DABCC, FADLM  
*Lancaster General Hospital  
Lancaster, PA*

ADLM's Annual Meeting Organizing Committee (AMOC) is comprised of 12 experts representing the breadth of laboratory medicine. AMOC members attend to all the details of making each year's conference a must-attend education and networking event. The committee oversees the planning, development, and ultimate delivery of a timely and engaging scientific program that serves the diverse community of laboratory medicine professionals.



2024 AMOC

# ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (ADLM) BOARD OF DIRECTORS

## PRESIDENT

- **Octavia M. Peck Palmer, PhD, FADLM**  
*University of Pittsburgh Medical Center  
University of Pittsburgh School of Medicine  
Pittsburgh, PA*

## PRESIDENT-ELECT

- **Anthony Killeen, MD, BCh, PhD, DABCC, FADLM**  
*University of Minnesota  
Minneapolis, MN*

## PAST PRESIDENT

- **Shannon Haymond, PhD, DABCC, FADLM**  
*Ann & Robert H. Lurie Children's Hospital of Chicago  
Northwestern University Feinberg School of Medicine  
Chicago, IL*

## SECRETARY

- **Christopher McCudden, PhD, DABCC, FADLM, FCACB**  
*University of Ottawa  
Eastern Ontario Regional Laboratory Association  
The Ottawa Hospital  
Ottawa, ON, Canada*

## TREASURER

- **Y. Victoria Zhang, MBA, PhD, DABCC, FADLM**  
*University of Rochester Medical Center  
Rochester, NY*

## DIRECTORS

- **Joe M. El-Khoury, PhD, DABCC, FADLM**  
*Yale School of Medicine  
Yale-New Haven Health  
New Haven, CT*
- **Daniel T. Holmes, MD, FRCPC**  
*University of British Columbia  
St. Paul's Hospital  
Vancouver, BC, Canada*
- **Stanley F. Lo, PhD, DABCC, FADLM**  
*Medical College of Wisconsin  
Children's Wisconsin  
Milwaukee, WI*
- **Christina Lockwood, PhD, DABCC, DABMGG, FADLM**  
*UW Medicine  
Seattle, WA*
- **M. Laura Parnas, PhD, DABCC, FADLM**  
*Roche Diagnostics  
Indianapolis, IN*
- **Bonny Lewis Van PhD, FADLM, HCLD(ABB)**  
*J. Michael Consulting LLC  
Roswell, GA*

## EX-OFFICIO WITH VOTE, PRESIDENT OF THE ACADEMY

- **Allison Chambliss, PhD, DABCC, FADLM**  
*David Geffen School of Medicine at UCLA  
Los Angeles, CA*

## EX-OFFICIO WITH VOTE, CHAIR, CLINICAL LAB SCIENTISTS COUNCIL

- **Kacy Peterson, MBA, MLS (ASCP)<sup>CM</sup>, DLM (ASCP)**  
*Avera McKennan Hospital & University Health Center  
Sioux Falls, SD*

## EX-OFFICIO

- **Mark J. Golden, FASAE, CAE**  
*ADLM  
Washington, DC*

## ADLM AWARDS & GRANTS

Each year, the ADLM Awards Committee selects outstanding individuals for the awards, grants, and fellowships presented by ADLM. These awards are given to recognize the superior achievements by these individuals. In addition, they encourage excellence within the profession and enhance recognition of clinical laboratory science. The ADLM awards program makes it possible for ADLM to honor these exceptional individuals and demonstrates ADLM's strong commitment to the growth and advancement of the field of clinical laboratory science.

### COMMITTEE MEMBERS

**Uttam Garg, PhD, DABCC, FADLM, FABFT; Chair**

**Pradip Datta, PhD**

**Ann M. Gronowski, PhD, DABCC**

**Brett Holmquist, PhD, ASCP, DABCC, FADLM**

**Stefani Thomas, PhD**

### AWARD WINNERS



#### **Wallace H. Coulter Lectureship Award**

**Patrick M. Bossuyt, PhD**

*Amsterdam UMC  
University of Amsterdam  
Amsterdam, The Netherlands*



#### **Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine**

**Thomas Annesley, PhD, DABCC**

*University of Michigan  
Ann Arbor, MI*



#### **Outstanding Contributions Through Service to the Profession of Clinical Chemistry**

**David G. Grenache, PhD, MT (ASCP), DABCC, FADLM**

*TriCore Reference Laboratories  
Albuquerque, NM*

## ADLM AWARDS & GRANTS



### **Outstanding Contributions to Education in Clinical Chemistry**

**James H. Nichols, PhD, DABCC, FADLM**  
*Vanderbilt University School of Medicine  
Nashville, TN*



### **Outstanding Scientific Achievements by a Young Investigator**

**Mark A. Zaydman, MD, PhD**  
*Washington University School of Medicine  
St. Louis, MO*



### **Clinical Laboratory Scientist Achievement Award**

**David Shiembob, MBA, C(ASCP)**  
*ARUP Laboratories  
Salt Lake City, UT*



### **Past President's Award**

**Shannon Haymond, PhD, MSPA, DABCC, FADLM**  
*Ann & Robert H. Lurie Children's Hospital of Chicago  
Northwestern University Feinberg School of Medicine  
Chicago, IL*

## GRANT WINNERS



### **ADLM General Research Grant**

**Cristina Andrea Figueroa Villalba, MD**  
*Yale School of Medicine  
New Haven, CT*



### **Helen Free Travel Grant**

**Kaitlyn Bolte, MS, MLS (ASCP)<sup>CM</sup>**  
*The Children's Hospital of Philadelphia  
Philadelphia, PA*

## ACADEMY AWARDS

The Academy of Diagnosis and Laboratory Medicine's mission is to elevate the science and practice of laboratory medicine by promoting research, education and professional development in the field. The Academy (formerly AACC Academy and NACB) celebrates the achievements of colleagues who have made significant contributions through scholarship and service to the profession. The Academy's Awards Committee wishes to thank the sponsors of these awards and to congratulate the 2024 Academy Award Recipients.

### COMMITTEE MEMBERS

**Gyorgy Abel**, MD, PhD, FADLM, Chair

**Zhimin (Tim) Cao**, PhD, MD, DABCC, FADLM

**Uttam Garg**, PhD, ABFT, DABCC, NRCC, FADLM

**Xander Van Wijk**, PhD, DABCC, FADLM


**Carmen Wiley**, PhD, DABCC, FADLM

### AWARD WINNERS



#### **Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research**

**Amitava Dasgupta**, PhD, DABCC, FADLM  
*University of Kansas Medical Center  
 Kansas City, KS*



#### **Academy Professor Alvin Dubin Award for Outstanding Contributions to the Profession and the Academy**

**Yusheng Zhu**, PhD, MS, DABCC (CC, TC, MD), FADLM, FACS  
*Penn State University Hershey Medical Center  
 and College of Medicine  
 Hershey, PA*



#### **Academy George Grannis Award for Excellence in Research and Scientific Publication Award**

**Mary Kathryn Bohn**, PhD  
*University of Toronto  
 Toronto, ON, Canada*

## ACADEMY FELLOWS

The Academy is proud to announce its Academy Fellows. As members of the Academy of Diagnostics & Laboratory Medicine, these distinguished scientists are all doctorate-level professionals dedicated to enhancing the scholarship and practice of laboratory medicine. New Fellows will be honored during the Academy Awards Luncheon on Wednesday, July 31, during ADLM 2024.

The Academy honors the achievements of its members and through an active education and publication program enlists their support and expertise to bring about positive change in the current practice of laboratory Medicine. To learn more about the Academy and its activities, visit [myadlm.org/community/academy-of-diagnostics-and-laboratory-medicine](http://myadlm.org/community/academy-of-diagnostics-and-laboratory-medicine).

### NEW ACADEMY FELLOWS ACCEPTED SINCE JUNE 1, 2023

as of May 14, 2024

#### FULL ACADEMY FELLOWS

Jennifer Brown, PhD, FADLM

John Buchweitz, PhD, FADLM

Melissa Budelier, PhD, FADLM

Teralee Burton, PhD, FADLM

Vishnu Chaturvedi, PhD, FADLM

Rejwi Dahal, PhD, FADLM

Alpa Dherai, PhD, FADLM

Behnam Emami, PhD, FADLM

Hoda Hagrass, MD, PhD, FADLM

Stacy Kenyon, PhD, FADLM

Frank LaDuca, PhD, FADLM

Jennifer Powers Carson, PhD, FADLM

Pratistha Ranjitkar, PhD, FADLM

Maryam Salehi, PhD, FADLM

Grace Williams, PhD, FADLM

Min Yu, MD, PhD, FADLM

#### ASSOCIATE FELLOWS

Rinini Dastidar, PhD

Siew Kim Ong, EdD

## OTHER ADLM AWARDS

Student Research and Academy Distinguished Abstract awards are noted in the poster abstract section of this guide. For a full list of Awards, including SYCL Awards and Division Abstract Awards, please visit [meeting.myadlm.org/awards](http://meeting.myadlm.org/awards).

## CONTINUING EDUCATION CREDIT & CERTIFICATE OF ATTENDANCE

ADLM 2024 brings together the global laboratory medicine community and provides the latest education to meet the changing needs of laboratory professionals. This conference provides attendees opportunities to connect with global leaders, learn about cutting edge technology, and stay up to date on best practices and advances in laboratory medicine. Individuals may attend ADLM 2024 educational sessions from Sunday, July 28 - Thursday, August 1, at the McCormick Place Convention Center in Chicago, Illinois (United States).

### ACCREDITATION STATEMENTS



ADLM offers ACCENT credit to laboratory professionals to document their continuing education and meet requirements

for licensure or certification. ADLM is an approved provider of continuing education for clinical laboratory professionals in the states of California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, and West Virginia. California clinical laboratory professionals requesting ACCENT credit must provide their license number for credit to be reported to the California Department of Public Health Laboratory Field Services. Florida clinical laboratory professionals requesting ACCENT credit must provide their license number for credit to be reported to CE Broker. This educational activity is designated for a maximum of 28.0 ACCENT credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**For information about ACCENT credit per session, visit the mobile app or [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).**



ADLM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity is designated for a maximum of 23.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about *AMA PRA Category 1 Credits™* per session, visit the mobile app or [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).

### LEARNING OBJECTIVES

At the end of this activity, participants will be able to:

1. Discuss state-of-art research and technologies in laboratory medicine.
2. Apply updated knowledge of laboratory protocols, practice guidelines, and regulatory requirements in laboratory medicine.
3. Incorporate laboratory management strategies that ensure staff competency, enhance workflows, and support accurate and effective testing to improve treatment decisions and patient outcomes.
4. Implement up-to-date laboratory testing methods, technologies, and data-driven approaches in preanalytical, analytical, and postanalytical phases of sample handling.
5. Select appropriate testing methods and advise clinicians on appropriate testing that takes benefits, limitations, and patient outcomes into consideration.
6. Facilitate interprofessional communication with the broader healthcare team to demonstrate the value of laboratory medicine and its role in treatment decisions and patient outcomes.

# CONTINUING EDUCATION CREDIT & CERTIFICATE OF ATTENDANCE

## TARGET AUDIENCE

ADLM 2024 is a global scientific/medical conference designed for clinical laboratory professionals, physicians, research scientists, and other professionals from around the world focused on laboratory medicine, clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas progressing laboratory science and medicine.

## STATEMENT OF INDEPENDENCE

As a provider of continuing education, ADLM has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of ADLM's Annual Meeting Organizing Committee (AMOC).

## DISCLOSURE POLICY

The faculty, planning committee members, and staff who are in a position to control the content of this activity are required to disclose to ADLM and to learners any financial relationship(s) of the individual that have occurred within the last 24 months with any ACCME-defined ineligible companies. An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are defined by remuneration in any amount from the ineligible companies in the form of honoraria; consulting fees; grants or research support; payments for participation in advisory boards, boards of directors, committees, or speakers' bureaus; stocks, bonds, other ownership interests; salary; intellectual property or royalties; or other financial benefits. The intent of this disclosure is not to prevent faculty with financial relationships from planning or

delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity regarding exposition or conclusion. ADLM has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

*The following activity planners reported the following financial relationship(s):*

- **Allison Chambliss**  
Honorarium/Expenses:  
Cardinal Health  
Consultant Fees, Committee/Board:  
Roche Diagnostics
- **Mari DeMarco**  
Honorarium/Expenses:  
Roche Diagnostics Corporation  
Consultant Fees, Committee/Board:  
Siemens Healthcare Diagnostics Inc.;  
Waters Corporation  
Grant/Research Support:  
Roche Diagnostics Corporation
- **Jane Dickerson**  
Consultant Fees, Committee/Board:  
BD
- **Joshua Hayden**  
Consultant Fees, Committee/Board:  
BioPorto
- **Patrick Kyle**  
Honorarium/Expenses:  
Abbott Diagnostics  
Grant/Research Support:  
Ark Diagnostics
- **Mark Marzinke**  
Consultant Fees, Committee/Board:  
Bio-Rad  
Grant/Research Support:  
Merck; Gilead; ViiV/GSK
- **Jaime Noguez**  
Grant/Research Support:  
Becton Dickinson and Company

- **Christina Pierre**  
Consultant Fees, Committee/Board:  
Borderlife Medical Laboratory Trinidad  
and Tobago
- **David Sacks**  
Grant/Research Support:  
Trinity Biotech, Sebia IP/Royalty Income:  
Patent on Anti-Calmodulin Antibody
- **William Winter**  
Consultant Fees, Committee/Board:  
Becton-Dickinson

*The following activity planners reported no financial relationships:*

**Darci Block, Saswati Das, Aaron Geno, Edmunds Reineks, Joely Straseski, Clayton Wilburn, and Gabrielle Winston-McPherson**

A summary of the disclosures is available at [meeting.myaldm.org](http://meeting.myaldm.org). All faculty will display their disclosure information at the beginning of each session, verbally and/or on their presentation slides. Faculty disclosures are also available via the mobile app. All ADLM staff involved in the planning of this activity reported no financial relationships.

## CONTENT VALIDITY

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; and/or all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

## DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of ADLM.

## Use of Professional Judgment

The educational content in this activity relates to basic principles of clinical laboratory medicine and does not substitute for individual assessment based on the health care professional's examination of the patient, laboratory data, and other factors unique to the patient. Standards in medicine change as new data becomes available.

## Drugs and Dosages

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

## TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.



Scan the code for a chance to win a \$250 Amazon gift card.



## CLAIM CE BY OCT 31

Evaluate sessions and claim ACCENT and/or CME credit by October 31. Scan the code or visit [meeting.myaldm.org/claimcredits](http://meeting.myaldm.org/claimcredits).

# CONTINUING EDUCATION CREDIT & CERTIFICATE OF ATTENDANCE

## **POLICY ON UNLABELED/ OFF-LABEL USE**

The association has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the U.S. Food and Drug Administration (FDA). The association requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

## **PRIVACY AND CONFIDENTIALITY STATEMENT**

The association will record learner's personal information as provided on continuing education evaluations to allow for issuance and tracking of CE certificates. The association may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its continuing education program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

## **ACKNOWLEDGMENT OF COMMERCIAL SUPPORT**

This activity is not supported by educational grant(s) or other funds from any commercial supporter(s).

## **ELIGIBILITY TO EARN CONTINUING EDUCATION CREDIT**

You must be registered for ADLM 2024\* to be eligible to earn continuing education credit (ACCENT or AMA PRA Category 1 Credit™) for the following sessions of ADLM 2024: ADLM University, Plenary, Meet-the-Expert, Scientific Sessions, and Roundtables. Continuing education certificates are provided to registered participants based on completion of the activity, in its entirety, including the activity evaluation.

*\* Individuals registered as Guest/Spouse or Expo Only are not eligible to earn credit for these sessions.*

## **SYSTEM REQUIREMENTS**

To claim continuing education credit, participants must have access to a computer or mobile device with an Internet connection and use an up-to-date version of any major Web browser, such as Microsoft Edge, Firefox, Safari, or Google Chrome. Internet Explorer is no longer supported. Browser cookies and Javascript must be enabled.

**For information about ACCENT credit per session, visit the mobile app or [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).**

## INSTRUCTIONS TO CLAIM CE/CME AND CERTIFICATE OF ATTENDANCE

1. To claim your credits and/or to obtain a Certificate of Attendance, click the Claim CE/CME tile on the meeting mobile app or go to [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).
2. Log in using your last name and ADLM ID (or badge number).
3. For Certificate of Attendance, you must complete an overall meeting evaluation.
4. For CE/CME certificate(s), you must also evaluate each session attended.
5. Ticketed and scanned sessions may automatically appear in the list for evaluation. You may also add additional sessions or remove unwanted sessions.
6. Credits may be claimed using a computer, laptop, tablet, smartphone, or other electronic device at any time (immediately after a session, at the end of end day, or following the meeting).
7. Credits for ADLM 2024 must be claimed by October 31, 2024.

RELEASE DATE: July 28, 2024

EXPIRATION DATE: October 31, 2024  
(date after which continuing education credit cannot be claimed for this activity).

For questions regarding continuing education, please email [education@myadlm.org](mailto:education@myadlm.org).

## Registration Resource Center

Access your handouts, obtain CE credit, and get a copy of your receipt.

### 1. OPEN THE RESOURCE CENTER

Go to [myadlm.org/handouts](https://myadlm.org/handouts) OR  
Scan the QR code on your badge

### 2. LOGIN

Enter the following to login:

#### A. BADGE NUMBER:

Listed on left side of badge

#### B. LAST NAME:

Exactly as entered when registering



### CLAIM CE BY OCT 31

Evaluate sessions and claim ACCENT and/or CME credit by October 31.  
Scan the code or visit [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).

## SESSION INFORMATION

### SESSION LEVEL CONTENT

- **Basic:** Introductory content appropriate for participants who lack previous training or experience in the subject, or whose previous experience or training is minimal.
- **Intermediate:** Requires knowledge of the basic theory applicable to the general subjects as well as some prior training and education in the subject.
- **Advanced:** Specialized content appropriate for those with working knowledge of current theory and practices and who wish to refine their skills or learn the newest principles and techniques.

### ADLM UNIVERSITY COURSES AND ROUNDTABLES

ADLM University Courses are offered on Sunday at an additional cost. This immersive educational experience is typically case-based and often includes hands-on exercises and tutorials in small-group formats. Courses focus on practical application of key skills that will advance participants' careers.

Roundtables take place Monday - Wednesday as 1-hour interactive small group discussions with up to 10 participants. Interact directly with the presenter during these engaging sessions. These highly engaging courses are a special ticketed price at \$35 per session onsite.



**DOWNLOAD THE MOBILE APP**  
[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

### AWARDS AND PLENARY SESSIONS

The Wallace H. Coulter Lectureship Awardee delivers the opening plenary on Sunday, July 28 from 5:00 p.m. - 6:30 p.m. All award presentations take place, at this time. Plenary sessions, Monday - Thursday, are from 8:45 a.m. - 10:00 a.m. and are designed for all levels, and feature visionaries in clinical practice, research, business, and policy. This year there is a Meet the Expert Session for the opening plenary. (Details on page 35).

### SCIENTIFIC SESSIONS

These sessions are presented by highly regarded speakers, offering in-depth learning about specific areas of clinical laboratory practice. This includes the ADLM President's Invited Session that takes place on Monday, July 29, from 10:30 a.m. - 12:00 p.m. (Details on page 35) and the Chair's Invited Session that takes place on Monday, July 29, from 12:30 p.m. - 2:00 p.m. (Details on page 39).

### SESSION RECORDINGS

Sessions at ADLM 2024 will be recorded. Access is complimentary to members with All Access conference registration and is available for purchase for others as an 11-month access that will commence September 16, 2024, and close July 31, 2025. ADLM University Courses and Roundtables are not included in Session Recordings. Price: \$199 with registration or at the meeting/\$299 after close of the meeting (August 1, 2024, 12:00 p.m. US Central Time). To purchase and find more details, visit [meeting.myadlm.org/recordings](https://meeting.myadlm.org/recordings) or go to Conference Registration in the lobby.

## PATHWAYS

Pathways represent dynamic and timely topic areas of clinical laboratory medicine. Use these pathways as a guide to explore the sessions that support your area of interest and to make the most of your educational experience this year. For more, visit [meeting.myadlm.org/pathways](http://meeting.myadlm.org/pathways).

BIOMARKER DISCOVERY			
SESSION	TITLE	DATE/TIME	ROOM
32109	The Nexus of Innovation: How Laboratory Medicine Supports Cellular and Gene Therapy Advancements	Monday, July 29 10:30 a.m. - 12:00 p.m.	S505
32222	Emerging Diagnostics to Differentiate Type 1 From Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury	Monday, July 29 2:30 p.m. - 4:00 p.m.	S403
33224	Acute Kidney Injury Biomarkers: Ready for Primetime?	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S404cd
34221	Alzheimer's Disease and the New Therapeutic Age	Wednesday, July 31 2:30 p.m. - 4:00 p.m.	S402
34223	New Diagnostic Laboratory Assessments in Polycystic Ovary Syndrome	Wednesday, July 31 2:30 p.m. - 4:00 p.m.	S404ab
35102	Preeclampsia in the United States: Clinical Details, Best Practices in Laboratory Medicine, and Impact of Foundational Support	Thursday, August 1 10:30 a.m. - 12:00 p.m.	S403

DATA SCIENCE			
SESSION	TITLE	DATE/TIME	ROOM
191205	Visualizing Laboratory Data: The Good, the Bad, and the Ugly	Sunday, July 28 1:30 p.m. - 4:30 p.m.	S404ab
32102	Bad, Better, Best: Putting Data Visualizations to the Test	Monday, July 29 10:30 a.m. - 12:00 p.m.	S403
32225	Operationalizing AI in Lab Medicine: Approaches for Effective Machine Learning Integration and Deployment	Monday, July 29 2:30 p.m. - 4:00 p.m.	S501abc
33226	Getting Started with Data Analytics: Indirect Reference Intervals as a Case Study	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S501abc
34102	Ensuring Equity and Fairness in Machine Learning and Data Analytics*	Wednesday, July 31 10:30 a.m. - 12:00 p.m.	S403
35105	The Use of Intelligent Algorithms and AI in Pathology: Applications and Apprehensions	Thursday, August 1 10:30 a.m. - 12:00 p.m.	S501abc

\* Denotes health equity related session. ADLM is proud to offer DEI inspired plenary sessions and educational opportunities throughout the meeting. Visit [myadlm.org/dei](http://myadlm.org/dei) to learn more.

## PATHWAYS

MANAGEMENT & LEADERSHIP			
SESSION	TITLE	DATE/TIME	ROOM
191208	The Fee-for-Service Payment System for Lab Tests: A Challenge for Labs, Patients, Physicians, and Insurers	Sunday, July 28 1:30 p.m. - 4:30 p.m.	S504abc
32101	Community Engagement, Research, and Healthcare: Laboratory Medicine's Lead Role in Ensuring Health Equity*	Monday, July 29 10:30 a.m. - 12:00 p.m.	S402
32443	Moving Beyond Sensitivity and Specificity: Showing the Value of Lab Medicine Through Outcome Measures	Monday, July 29 12:30 p.m. - 2:00 p.m.	S404ab
33105	Improv and the Art of Medicine: Adaptable Skills for an Uncertain World	Tuesday, July 30 10:30 a.m. - 12:00 p.m.	S405
33221	Speaking Their Language: Communicating to Hospital Leadership the Essential Role of the Laboratory in Value-Based Care	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S402
35101	Effective Communication with C-Suite Executives: A Chief of Operations and a Department Chair Perspective	Thursday, August 1 10:30 a.m. - 12:00 p.m.	S402

MICRO & MOLECULAR			
SESSION	TITLE	DATE/TIME	ROOM
191101	Next Generation Sequencing for Laboratorians: Understanding the Essentials	Sunday, July 28 9:30 a.m. - 12:00 p.m.	S403
32228	The Gift of Life: The Remarkable Role the Clinical Laboratory Plays in Organ Donation	Monday, July 29 2:30 p.m. - 4:00 p.m.	S504abc
33228	Microbes Meet Machines: Total Laboratory Automation in Clinical Microbiology	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S503
33229	Navigating Constitutional Genomic Disorders Throughout the Exome	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S504abc
34103	Changing the Sexually Transmitted Infection Control Paradigm: Novel Diagnostic and Treatment Strategies	Wednesday, July 31 10:30 a.m. - 12:00 p.m.	S404ab
34228	Current and Future State of Metagenomics for Infectious Diseases Testing	Wednesday, July 31 2:30 p.m. - 4:00 p.m.	S504abc

\* Denotes health equity related session. ADLM is proud to offer DEI inspired plenary sessions and educational opportunities throughout the meeting. Visit [myadlm.org/dei](http://myadlm.org/dei) to learn more.

## PATHWAYS

NEAR PATIENT TESTING: POINT-OF-CARE TO CRITICAL CARE TESTING			
SESSION	TITLE	DATE/TIME	ROOM
191310	Solving Problems and Resolving Challenges in Point-of-Care Testing	Sunday, July 28 9:00 a.m. - 4:30 p.m.	S402
32108	Accelerating Point-of-Need Diagnostics to Meet the Growing Demand for Acute and Advanced Care at Home	Monday, July 29 10:30 a.m. - 12:00 p.m.	S504abc
32445	Pathogen Detection, Machine Learning, or Host Biomarkers: Can Any of These Technologies Help Address the Challenge of Sepsis?	Monday, July 29 12:30 p.m. - 2:00 p.m.	S502
32229	Advances and Limitations of Consumer-Initiated Laboratory Testing	Monday, July 29 2:30 p.m. - 4:00 p.m.	S505
33227	Metabolic Emergencies in the Pediatric Patient: Laboratory Differentiation of Inborn Errors of Metabolism and Acute Drug Exposure	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S502
34108	Point-of-Care Testing Challenges in Traditional and Non-Traditional Settings	Wednesday, July 31 10:30 a.m. - 12:00 p.m.	S504abc

TOXICOLOGY: FROM PEDIATRICS TO PUBLIC HEALTH			
SESSION	TITLE	DATE/TIME	ROOM
191102	Toxicology Roadmap: Everything You Need to Know About Successfully Running a Urine Drug Testing Service	Sunday, July 28 9:00 a.m. - 12:00 p.m.	S404ab
32103	Real-Time Mass Spectrometry: Strategies for Rapid Drug and Metabolite Detection to Enhance Clinical Decision Making	Monday, July 29 10:30 a.m. - 12:00 p.m.	S404ab
32221	Responding to the Threat of Xylazine and Drug Supply Adulteration: Clinical Testing Strategies and Empowering Point-of-Service Community Drug Checking	Monday, July 29 2:30 p.m. - 4:00 p.m.	S402
33223	Unexpected Toxicology Results as Real-Time Opportunities for Collaboration	Tuesday, July 30 2:30 p.m. - 4:00 p.m.	S404ab
34105	Clinical Toxicology in the Courtroom: How to Serve as an Expert Witness	Wednesday, July 31 10:30 a.m. - 12:00 p.m.	S405
35104	The Toxicological Problem Accumulating Inside of Us All: Breaking Down the Uses, Abuses, and Growing Public Health Concerns over PFAS	Thursday, August 1 10:30 a.m. - 12:00 p.m.	S404cd

# SCHEDULE-AT-A-GLANCE

## SUNDAY, JULY 28

6:00	
7:00	
7:30	
8:30	
8:45	
9:00	<b>ADLM University MORNING</b> S402-S505 <b>T</b>
	<b>ADLM University FULL DAY</b> S402-S505 <b>T</b>
12:00	
1:30	<b>ADLM University AFTERNOON</b> S402-S505 <b>T</b>
4:30	
5:00	<b>Opening Plenary</b> Clinical Trials of Lab Tests Grand Ballroom (S100)
6:30	<b>Opening Mixer</b> Lakeside East Terrace
8:00	

## MONDAY, JULY 29

6:00	<b>UNI5K</b> Lakeside Center (Registration Req.)
7:00	
7:30	<b>Roundtables</b> S406a <b>T</b>
8:30	
8:45	<b>Opening Plenary</b> Lymphoma Biomarkers Grand Ballroom (S100)
9:30	<b>Student Research Award Posters on Display</b> S405
10:00	
10:30	<b>Scientific Sessions</b> S402-S505
12:00	
12:30	<b>Scientific Sessions</b> S402-S505
1:30	<b>Roundtables</b> S406a <b>T</b>
2:00	<b>Student Research Award Oral Presentation Competition</b> (1 p.m. - 2 p.m.) 404c
2:30	<b>Scientific Sessions</b> S402-S505
	<b>Student Research Award Poster Competition</b> S405
4:00	
4:30	<b>Disruptive Technology Award Competition</b> Grand Ballroom (S100)
6:00	



Ticketed Event

● EDUCATION

● SPECIAL EVENTS

● SPECIAL SESSIONS

● EXPO

# SCHEDULE-AT-A-GLANCE

## TUESDAY, JULY 30


6:00		
7:00		<b>Hotel Industry Workshops</b>
7:30	<b>Roundtables</b> <b>T</b> <i>S406a</i>	
8:30		
8:45	<b>Opening Plenary</b> PGx-based Testing <i>Grand Ballroom (\$100)</i>	<b>Clinical Lab Expo &amp; Poster Hall</b>
9:30		
10:00		
10:30	<b>Scientific Sessions</b> <i>S402-S505</i>	
12:00		
12:30	<b>Roundtables</b> <b>T</b> <i>S406a</i>	<b>ePoster Discussions</b>
1:30	<b>Poster Presenters at Boards</b>	
2:30	<b>Scientific Sessions</b> <i>S402-S505</i>	
3:30		
4:00		
4:30	<b>LDT Special Session</b> <i>Grand Ballroom (\$100)</i>	
5:00		
6:00		
7:30		<b>Hotel &amp; Center Industry Workshops</b>

## WEDNESDAY, JULY 31

6:00		
7:00		<b>Hotel Industry Workshops</b>
7:30	<b>Roundtables</b> <b>T</b> <i>S406a</i>	
8:30		
8:45	<b>Opening Plenary</b> HIV Prevention <i>Grand Ballroom (\$100)</i>	<b>Clinical Lab Expo &amp; Poster Hall</b>
9:30		
10:00		
10:30	<b>Scientific Sessions</b> <i>S402-S505</i>	
12:00		
12:30	<b>Roundtables</b> <b>T</b> <i>S406a</i>	<b>ePoster Discussions</b>
1:30	<b>Poster Presenters at Boards</b>	
2:30	<b>Scientific Sessions</b> <i>S402-S505</i>	<b>ePoster Discussions</b>
3:30		
4:00		
4:30	<b>ADLM Lab Feud</b> <i>Clinical Lab Expo (Theater 2)</i>	
5:00		
6:00		
7:30		<b>Hotel &amp; Center Industry Workshops</b>

# SCHEDULE-AT-A-GLANCE

## THURSDAY, AUGUST 1



Ticketed Event

● EDUCATION

● SPECIAL EVENTS

● SPECIAL SESSIONS

● EXPO

## THE 2024 MOBILE APP

- **VIEW** details on the Opening Mixer, ancillary events and networking opportunities.
- **PLAN** each day with a built-in calendar.
- **GET** the most up-to-date, accurate information.
- **ACCESS** detailed session and speaker information.
- **PARTICIPATE** in session polling and view live session presentations through the interactive audience engagement technology.
- **BROWSE EXHIBITORS** and map out your path through the Expo Hall.
- **BROWSE THROUGH NEW PRODUCTS** available at the Expo Hall.
- **ORGANIZE** your notes about exhibitors or check off which ones you've visited.
- **PLAY** the Scavenger Hunt, navigating the Expo Hall by visiting booths and answering questions to earn prizes.
- **FOLLOW** social media about the meeting.

### TO DOWNLOAD:

- Visit [meeting.myadlm.org/2024app](http://meeting.myadlm.org/2024app)
- Search ADLM 2024 on the Apple App Store, Google Play or scan the barcode.



# PLENARY+ SCIENTIFIC SESSIONS

SUNDAY, JULY 28



**Patricia Slev**  
PhD, DABCC

## PLENARY SESSION 11001

**SUNDAY, JULY 28**

**5:00 p.m. - 6:30 p.m.**

LOCATION: Grand Ballroom (S100)

LEVEL: Basic

CREDITS: ACCENT: 1.0, CME: 1.0

**2024 WALLACE H. COULTER LECTURESHIP AWARDEE**

### **Why We Need More Strong Clinical Trials of Laboratory Tests**



**Patrick M. Bossuyt, PhD**

*Full Professor, Clinical Epidemiology  
Amsterdam UMC  
University of Amsterdam  
Amsterdam, The Netherlands*

It is very well recognized that new pharmaceuticals should be properly evaluated in strong clinical trials, preferably in large and representative groups sampled from the intended use population. Clinical trials are also used to evaluate other interventions in clinical medicine, such as surgical strategies. In contrast, to date, laboratory medicine has not experienced serious pressure to provide evidence of clinical performance, or clinical utility, of laboratory tests based on clinical trials. In this presentation, we will present arguments, based on our research, why we need clinical trials of laboratory tests – and of other medical tests – to support evidence-based clinical practice guidelines, reimbursement decisions, and other recommendations. Strong clinical trials with pre-specified protocols can prevent “spin”, will introduce rigor and discipline in study design and methods, and may be able to reduce the bias in the evaluation of laboratory medicine.

## ADLM UNIVERSITY



Morning | 9:00 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
191101	<b>Next Generation Sequencing for Laboratorians: Understanding the Essentials</b>	S403	3.0	3.0	<b>B</b>
<i>In cooperation with the ADLM Molecular Pathology Division</i>					
<ul style="list-style-type: none"> <li>• <b>Molecular Testing: Proficiency and Precision</b> <i>Christina Lockwood, PhD, DABMGG, DABCC, University of Washington, Seattle, WA</i></li> <li>• <b>NGS Applications for Germline Testing</b> <i>Runjun Kumar, MD, PhD, University of Washington, Seattle, WA</i></li> <li>• <b>The Molecular Landscape of Cancer Testing</b> <i>Vera Paulson, MD, PhD, University of Washington, Kirkland, WA</i></li> </ul>					
Moderator					
191102	<b>Toxicology Roadmap: Everything You Need to Know About Successfully Running a Urine Drug Testing Service</b>	S404ab	3.0	3.0	<b>B</b>
<ul style="list-style-type: none"> <li>• <b>So You've Inherited a Urine Drug Testing Lab...</b> <i>Claire Knezevic, PhD, DABCC, Johns Hopkins Medical Institutes, Baltimore, MD</i></li> <li>• <b>So You Want to Expand Your Test Menu and Assays...</b> <i>Bridgit Crews, BA, DPhil, DABCC, Washington University in St. Louis, St. Louis, MO</i></li> <li>• <b>So You Need to Effectively Communicate With Clinicians...</b> <i>Jessica Boyd, PhD, DABCC, University of Utah/ARUP Laboratories, Salt Lake City, UT</i></li> </ul>					
Moderator					
191103	<b>Navigating Laboratory Errors in the Preanalytical, Analytical, and Postanalytical Phases of Testing</b>	S504 abc	3.0	3.0	<b>B</b>
<ul style="list-style-type: none"> <li>• <b>Analytical Errors and Post-Analytical Challenges in LC-MS/MS Analysis</b> <i>Jacqueline Hubbard, PhD, C(ASCP), DABCC, NRCC, Three Rivers Diagnostics, Pittsburgh, PA</i></li> <li>• <b>Preanalytical Errors: Case Based Examples and Troubleshooting Tools</b> <i>Alison Woodworth, PhD, DABCC, FADLM, CTI Clinical Trials &amp; Consulting, Cincinnati, OH</i></li> <li>• <b>Patient-Based Real-Time Quality Control: Background and Real-World Examples</b> <i>Mark Cervinski, PhD, DABCC, FADLM, Dartmouth-Hitchcock Medical Center, Lebanon, NH</i></li> </ul>					
Moderator					



ADLM University courses are ticketed. Visit ADLM Registration to inquire about ticket availability and purchasing.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
191310	<b>Solving Problems and Resolving Challenges in Point-of-Care Testing</b>	S402	6.0	0	<b>I</b>

*In cooperation with the ADLM Critical and Point-of-Care Testing Division*

- **Point-of-Care Competency Is Mission Possible: Learn, Apply, Document!**  
*Peggy Mann, MS, MT (ASCP), CPP, University of Texas Medical Branch, Galveston, TX*
- **It's 2024: Using Partnerships to Integrate Quality and Compliance Into Point-of-Care Testing**  
*Kimberly Skala, BA, MT (ASCP), Werfen, Oak Lawn, IL*
- **Staying Connected in an Increasingly Remote World: Tips and Tricks to Help Keep Your Point-of-Care Program Interfaced**  
*Kerstin Halverson, MS, Werfen, Farmington, MN*
- **Operational Management Strategies in Point-of-Care Testing: New Test Requests to Quality Indicators**

Moderator *Jeanne Mumford, BS, MLS, MT (ASCP), Johns Hopkins Hospital, Baltimore, MD*

191311	<b>Unlocking the Power of Laboratory Informatics: Integrating New Tests, Optimizing Test Ordering, and Leveraging Data Analytics</b>	S404cd	6.0	6.0	<b>I</b>
--------	--	--------	-----	-----	----------

- **Integrating New Tests Into the Laboratory Information System**  
*Athena Petrides, PhD, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA*
- **Using Data Science and Clinical Decision Support to Transform Your Laboratory**  
*Anand Dighe, MD, PhD, Mass General Brigham, Somerville, MA*
- **Leveraging Laboratory Data for Analytics**  
*Long Le, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA*

191312	<b>LC-MS/MS Operations in the Clinical Laboratory</b>	S503	6.0	0	<b>I</b>
--------	---	------	-----	---	----------

*Russell Grant, PhD, Labcorp, Burlington, NC*

Moderator *Brian Rappold, BS, Labcorp, Raleigh, NC*



ADLM University courses are ticketed. Visit ADLM Registration to inquire about ticket availability and purchasing.

## ADLM UNIVERSITY



Afternoon | 1:30 p.m. - 4:30 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
191204	<b>Protein Electrophoresis: Best Practices for Everyday Interpretation</b>	S403	3.0	3.0	1

- **Fundamentals of Protein Electrophoresis**

Moderator *Katherine Turner, PhD, DABCC, Corewell Health, Ada, MI*

- **Indications for Monoclonal Protein Testing and Impact of Detection**

*David Manthei, MD, PhD, University of Michigan, Ann Arbor, MI*

- **Case Presentations Addressing the Best Practices of Protein Electrophoresis**

*Maria Alice Willrich, PhD, MSc, DABCC, FADLM, Mayo Clinic, Rochester, MN*

191205	<b>Visualizing Laboratory Data: The Good, the Bad, and the Ugly</b>	S404ab	3.0	3.0	1
--------	---	--------	-----	-----	---

- **Communicating Laboratory Data Through Effective Visualizations**

*Nicholas Spies, MD, Washington University in St. Louis, St. Louis, MO*

- **Capturing Geospatial Data: Tools and Techniques for Visualizing Laboratory Data Beyond the Walls of the Core Laboratory**

*Vahid Azimi, MD, Washington University in St. Louis, St. Louis, MO*

- **Crafting Compelling Stories With Data: Best Practices in Presentation and Dashboard Design**

Moderator *Dustin Bunch, PhD, DABCC, Nationwide Children's Hospital, Columbus, OH*

191206	<b>Troubleshooting LC-MS/MS: Identifying Method Problems and Building Robustness</b>	S501 abc	3.0	3.0	1
--------	--	-------------	-----	-----	---

*In cooperation with the ADLM Mass Spectrometry and Separation Sciences Division and the Mass Spectrometry & Advances in the Clinical Lab*

- **Can the Design of an MS/MS Detection Method Add Robustness?**

Moderator *Deborah French, PhD, DABCC, FADLM, University of California, San Francisco, San Francisco, CA*

- **Building Robustness Into LC Methods**

*Deborah French, PhD, DABCC, FADLM, University of California, San Francisco, San Francisco, CA*

- **Building Robustness Into Sample Preparation**

*Grace van der Gugten, BS, Alberta Precision Labs, Edmonton, AB, Canada*

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
191207	<b>Fundamentals of Method Evaluation and Validation</b>	S502	3.0	3.0	<b>B</b>

- **The Essence of Method Evaluation and the Wisdom of Establishing Performance Standards Early in the Process**

*David Koch, PhD, DABCC, FADLM, Emory University/Grady Memorial Hospital, Atlanta, GA*

- **Developing the Validation Plan and Evaluating the Data in Terms of Allowable Total Error**

*Kornelia Galior, PhD, DABCC, University of Wisconsin, Madison, Madison, WI*

- **Navigating Practical Challenges During Method Verification: Experiences From Non-Academic Laboratories**

Moderator *Stacy Kenyon, PhD, DABCC, NRCC, Phoenix Children's, Phoenix, AZ*

191208	<b>The Fee-for-Service Payment System for Lab Tests: A Challenge for Labs, Patients, Physicians, and Insurers</b>	S504 abc	3.0	3.0	<b>B</b>
--------	---	-------------	-----	-----	----------

*In cooperation with the Patient Centered Laboratory Utilization Guidance Service*

- **The Fee-for-Service Payment System for Lab Tests: A Challenge for Patients, Labs, Physicians, and Insurers**

Moderator *Michael Astion, MD, PhD, Seattle Children's Hospital, Seattle, WA*

- **Foundations of Financial Competence: Costing and Pricing a Laboratory Test**

*Nikola Baumann, PhD, DABCC, Mayo Clinic, Rochester, MN*

191209	<b>Cracking the CBC Code: Essentials of CBC Testing and Unmasking Leukemia, Anemia, and Mimics Through Smear Sleuthing</b>	S505	3.0	3.0	<b>B</b>
--------	--	------	-----	-----	----------

- **Introduction: Basics of Hematology**

*David Maciak, MHA, MLS(ASCP)<sup>CM</sup>, Washington University in St. Louis School of Medicine, St. Louis, MO*

- **Focus on Leukocytes and Signs of Neoplasia with Virtual Slide Review**

*Nam Ku, MD, ABPath, University of California, Los Angeles, Los Angeles, CA*

Moderator *Mark Girton, MD, University of Michigan, Ann Arbor, MI*

- **Red Blood Cells and Platelets with Virtual Slide Review**

*Maria (Ria) Vergara-Lluri, MD, ABPath, Keck School of Medicine of USC, Los Angeles, CA*

# PLENARY+ SCIENTIFIC SESSIONS

MONDAY, JULY 29



**Chris Farnsworth**  
PhD, DABCC

## PLENARY SESSION 12001

**MONDAY, JULY 29**

**8:45 a.m. - 10:00 a.m.**

LOCATION: Grand Ballroom (S100)

LEVEL: Basic

CREDITS: ACCENT: 1.0, CME: 1.0

### **Lymphoma Biomarkers and Therapeutic Targets from Mass Spectrometry-driven Proteomics**



**Kojo S.J. Elenitoba-Johnson, MD**

*Chair, Department of Pathology and Laboratory Medicine*

*James Ewing Alumni Chair of Pathology*

*Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences*

*Member, Human Oncology & Pathogenesis Program (HOPP)*

*Memorial Sloan Kettering Cancer Center*

*New York, NY, USA*

Cancer remains a leading cause of morbidity and mortality and the identification of novel disease biomarkers and therapeutic targets is an increasing need in improving outcomes. Mass spectrometry-driven proteomics is rapidly emerging as a powerful strategy for the discovery of diagnostic biomarkers and therapeutic targets and enabler of precision oncology. MS-based proteomics affords the opportunity for unbiased and targeted interrogation of proteins in complex mixtures from cells and tissues. The ability to unambiguously identify post-translational modifications further affords detailed investigation of the signaling consequences of cellular perturbations in a large variety of biologic conditions including cancer. This session will discuss the basic functional aspects of mass spectrometry and its applications to proteomics and the promising prospects for leveraging MS-based strategies for diagnostics and identification of therapeutic targets.

## ROUNDTABLE SESSIONS



7:30 a.m. - 8:30 a.m. (40000 Series) -or- 12:30 p.m. - 1:30 p.m. (50000 Series)

Location: S406a • Credits: ACCENT: 1.0, CME: Not eligible

Most roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. Coffee is provided and concession stands are available to purchase food.

AM SESSION PM SESSION	TITLE	LEVEL
42101 52201	<b>Health Equity in the Laboratory: Re-evaluating the Role of Sex and Race in Reference Interval Determinations</b> <i>Katie Troike, PhD, Cleveland Clinic, Cleveland, OH</i>	<b>B</b>
42102 52202	<b>Preanalytical Factors in Blood Gas Analysis</b> <i>Xander van Wijk, PhD, DABCC, FADLM, Van Wijk Consulting, LLC, Houston, TX</i>	<b>B</b>
42103 52203	<b>Advancing Inclusivity in Healthcare: Enhancing Clinical Laboratory Practices for Transgender Patient Care</b> <i>Leah Militello, MD, MBA, Yale University, Hamden, CT</i>	<b>B</b>
42104 52204	<b>Standardization of Testosterone and Estradiol Measurements by the CDC Clinical Standardization Programs: A Comprehensive Approach Going Beyond Calibration</b> <i>Tatiana Buchanan, BS, Centers for Disease Control and Prevention, Atlanta, GA</i>	<b>B</b>
42105 52205	<b>Heavy Alcohol Use: How to Identify it in the Lab</b> <i>Jacob Nielsen, PhD, Houston Methodist Hospital, Houston, TX</i>	<b>B</b>
42106 52206	<b>A Roadmap for Developing LC-MS/MS Methods for Large Pain Management Drug Test Panels</b> <i>Sheng Feng, PhD, DABCC, Boston University, Boston, MA</i>	<b>I</b>
42107 52207	<b>A Practical Guide to Implementing Moving Averages</b> <i>Sheng-Ying Lo, PhD, DABCC, Geisinger Medical Laboratories, Danville, PA</i>	<b>B</b>
42108 52208	<b>Future-proofing Your Clinical Instrumentation Upgrade: A Roadmap for Optimizing Clinical Instrumentation to Meet Tomorrow's Challenges</b> <i>Xu Li, PhD, ASCP, NRCC, Emory University, Atlanta, GA</i>	<b>I</b>
42109 52209	<b>Collect It Yourself! Hands-on Overview of Diverse Specimen Collection Devices for Home Use and the Role of the Clinical Laboratory</b> <i>Ria Fyffe-Freil, PhD, University of Nebraska Medical Center, Omaha, NE</i>	<b>B</b>
42110 52210	<b>Unveiling Toxicological Enigmas: Interpreting Complex Toxicology Cases in Different Matrices</b> <i>Ibrahim Choucair, PhD, University of Kentucky College of Medicine, Lexington, KY</i>	<b>B</b>
42111 52211	<b>Evaluation of Fentanyl and Xylazine in Emergency Department Patients</b> <i>Catherine Mills, PhD, Medical University of South Carolina, Charleston, SC</i>	<b>I</b>
42112 52212	<b>Translating Theory into Action: Practical Approaches for Optimizing Therapeutic Drug Monitoring Services</b> <i>William Butler, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA</i>	<b>B</b>
42113 52213	<b>ANA Testing on HEp-2 Cells: How Automation and ICAP Can Help With Standardization</b> <i>Vincent Ricchiuti, PhD, ABB, FADLM, Labcorp, Dublin, OH</i>	<b>I</b>
42114 52214	<b>Maximizing the Potential of Gene Therapy: The Clinical Laboratory's Role in Pre-screening Patients for Adeno-associated Virus Serotype 9 (AAV9) Vector Immunity</b> <i>Jingcai Wang, MD, PhD, ASCP, NRCC, Nationwide Children's Hospital, Columbus, OH</i>	<b>I</b>
42115 52215	<b>Process Improvement for Protein Electrophoresis and Immunofixation: Workflow Automation and Remote Sign-out</b> <i>Xiaochun Zhang, MD, PhD, DABCC, ABMLI, HCLD, University Hospitals Cleveland Medical Center, Cleveland, OH</i>	<b>I</b>

# ROUNDTABLE SESSIONS



AM SESSION PM SESSION	TITLE	LEVEL
42116 52216	<b>Laboratory Assessment of Acquired Thrombocytopenia: A Case Based Approach</b> <i>Olajumoke Oladipo, MD, MSc, DABCC, FADLM, Penn State Milton S. Hershey Medical Center, Hershey, PA</i>	1
42117 52217	<b>Current Trends in Thyroid Auto-Antibodies Testing</b> <i>Damien Gruson, PhD, Cliniques Universitaires St-Luc, Bruxelles, Belgium</i>	1
42118 52218	<b>Ensuring Quality Measurements of Emerging and Traditional Biomarkers for Cardiovascular Diseases: The CDC Cardiovascular Disease Biomarker Standardization Programs</b> <i>Alicia Lyle, PhD, FAHA, Centers for Disease Control and Prevention, Atlanta, GA</i>	1
42119 52219	<b>Strategies for Effective Laboratory Test Utilization</b> <i>Ridwan Ibrahim, PhD, Baylor College of Medicine/Texas Children's Hospital, Houston, TX</i>	B
42120 52220	<b>CSI DIY: Leveraging Your Laboratory Information System to Establish Methods for Conducting Specimen Integrity Investigations</b> <i>Ashley Rackow, PhD, Johns Hopkins University, Baltimore, MD</i>	B
42121 52221	<b>Implementing a New Test or a New Instrument? A Crash Course on Method Validation</b> <i>Kornelia Galior, PhD, DABCC, University of Wisconsin, Madison, Madison, WI</i>	B
42122 52222	<b>Laboratory Stewardship: Tests Pending at Discharge</b> <i>Andrew Fletcher, MD, MBA, CPE, CHCQM, Eutilogic Consulting, Salt Lake City, UT</i>	B
42123 52223	<b>Improving the Timeliness of Test Results: A Symphony of Process, TAT, and Quality!</b> <i>Vrajesh Pandya, PhD, DABCC, University of Utah/ARUP Laboratories, Salt Lake City, UT</i>	B
42124 52224	<b>How Often to Repeat the Test: Importance and Challenges of Minimal Retesting Interval</b> <i>Asmita Hazra, MD, All India Institute of Medical Sciences, Kalyani, Basantapur, West Bengal, India</i>	1
42125 52225	<b>Host-Response Serum Biomarkers to Distinguish Bacterial From Viral Infections: Clinical and Economic Impact Analysis of the MeMed BV Assay</b> <i>Alejandro Zuretti, MD, SUNY Downstate, New York, NY</i>	1
42126 52226	<b>BNP or NT-proBNP: Which is the Better Biomarker for Heart Failure in the Angiotensin Receptor/Nepriylisin Inhibitor Era?</b> <i>Madhusudhanan Narasimhan, PhD, MHA, UT Southwestern Medical Center, Dallas, TX</i>	1
42127 52227	<b>Leaving No One Behind: Management of Hyperbilirubinemia in Preterm Infants Less Than 35 Weeks' Gestation with Clinical Decision Support Tools</b> <i>Yi Xiao, PhD, DABCC, CLS, Children's Hospital Los Angeles, Los Angeles, CA</i>	B
42128 52228	<b>Data Analysis in R: Lowering the Barrier to Entry for the Clinical Laboratory</b> <i>Benjamin Andress, PhD, MLS(ASCP), Mayo Clinic, Rochester, M</i>	B
42129 52229	<b>Quality Control in Molecular Biology Laboratories</b> <i>Ashwini Kumar Nepal, MS, MLS(ASCP), PPD, part of Thermo Fisher Scientific, Oxford, OH</i>	B
42130 52230	<b>Emerging Technologies to Enable Remote Sampling for Greater Health Equity</b> <i>Stephanie Lee, PhD, Thermo Fisher Scientific, San Jose, CA</i>	1

## MEET THE EXPERT

Morning | 10:30 a.m. - 11:30 a.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
62001	Why We Need More Strong Clinical Trials of Laboratory Tests	S101b	1.0	0	B

Moderator *David Sacks, MB ChB, FRCPath, National Institutes of Health, Bethesda, MD*  
*Patrick M. Bossuyt, PhD, University of Amsterdam/Amsterdam UMC, Amsterdam, The Netherlands*

## PRESIDENT'S INVITED SESSION

Morning | 10:30 a.m. - 12:00 p.m.

32101	Community Engagement, Research, and Healthcare: Laboratory Medicine's Lead Role in Ensuring Health Equity	S402	1.5	1.5	B
-------	---	------	-----	-----	---

Moderator *Octavia Peck Palmer, PhD, FADLM, University of Pittsburgh Medical Center, Pittsburgh, PA*

- **Addressing Health Equity Throughout the Total Laboratory Testing Process**  
*Vahid Azimi, MD, Washington University in St. Louis, St. Louis, MO*
- **Point-of-Care Diagnostics Provide Equitable Access to Healthcare**  
*Omai Garner, PhD, ABMM, MT (ASCP), University of California, Los Angeles, Los Angeles, CA*
- **Interdisciplinary Approaches to Eliminate Maternal Health Inequities**  
*Esa Davis, MD, MPH, FAAFP, University of Maryland School of Medicine, Baltimore, MD*



### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.



### FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

# SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32102	<b>Bad, Better, Best: Putting Data Visualizations to the Test</b>	S403	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>A Journey in Data Visualization: You be the Judge!</b> <i>T. Scott Isbell, PhD, DABCC, FADLM, St. Louis University School of Medicine, St. Louis, MO</i></li> <li>• <b>Case Presentations: Data Visualizations for Presentations and Reports</b> <i>Shannon Haymond, PhD, DABCC, FADLM, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL</i></li> <li>• <b>Case Presentations: Enhancing the Accessibility of Data Visualizations</b> <i>Christopher McCudden, PhD, DABCC, FADLM, FCAC, The Ottawa Hospital General Campus, Ottawa, ON, Canada</i></li> </ul>				
32103	<b>Real-Time Mass Spectrometry: Strategies for Rapid Drug and Metabolite Detection to Enhance Clinical Decision Making</b>	S404ab	1.5	1.5	<b>I</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Past, Present, and Future Clinical Mass Spectrometry Applications</b> <i>Stephen Roper, PhD, DABCC, NRCC, Washington University School of Medicine, St. Louis, MO</i></li> <li>• <b>Design and Implementation of Direct to Mass Spectrometry Drug Screening in Children</b> <i>Stephen Roper, PhD, DABCC, NRCC, Washington University School of Medicine, St. Louis, MO</i></li> <li>• <b>Internal vs. External Calibration for Determination of Plasma Methotrexate by LC-MS/MS</b> <i>Dennis Dietzen, PhD, DABCC, FADLM, Washington University School of Medicine, St. Louis, MO</i></li> <li>• <b>Rapid Metabolic Detection of Mutant Isocitrate Dehydrogenase Using LC-MS/MS: Application to Human Gliomas</b> <i>Dennis Dietzen, PhD, DABCC, FADLM, Washington University School of Medicine, St. Louis, MO</i></li> </ul>				
32104	<b>Emerging Nano-Engineering Technologies for the Management of Chronic Diseases and Cancers</b>	S404cd	1.5	0	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Performance Characteristics and Validation in Non-Blood Analysis</b> <i>Lakshmi Ramanathan, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY</i></li> <li>• <b>Saliva Based Technologies for the Management of Chronic Disease and Cancer</b> <i>Chamindie Punyadeera, PhD, Griffith University, Nathan, QLD, Australia</i></li> <li>• <b>Application of Nano-Engineering Technologies in Cancer</b> <i>Mijin Kim, PhD, Georgia Institute of Technology, Atlanta, GA</i></li> </ul>				

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32105	<b>Ethical Decision Making for Laboratory Professionals</b>	S501 abc	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Ethical Issues in Laboratory Medicine</b> <i>Ann Gronowski, PhD, DABCC, Washington University School of Medicine, St. Louis, MO</i></li> <li>• <b>Ethical Issues Arising From Direct-to-Consumer Genetic Testing</b> <i>Valerie Gutman Koch, JD, Health Law and Policy Institute, University of Houston, Houston, TX</i></li> </ul>				
32106	<b>Is Bad Testing Better Than No Testing?</b>	S502	1.5	1.5	<b>B</b>
Moderator	<p><i>Steven Cotten, PhD, DABCC, FADLM, University of North Carolina at Chapel Hill, Chapel Hill, NC</i></p> <ul style="list-style-type: none"> <li>• <b>Critical Crossroads: Decision Making in Clinical Testing</b> <i>Sarah Hackenmueller, PhD, DABCC, FADLM, Providence Regional Laboratories, Portland, OR</i></li> <li>• <b>Decision Dynamics: Testing, Requests, and Patient Care</b> <i>Yachana Kataria, PhD, DABCC, Boston University Chobanian and Avedisian School of Medicine, Boston, MA</i></li> </ul>				
32107	<b>Tools for Recognizing and Eliminating Preanalytical Error</b>	S503	1.5	1.5	<b>I</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Impact of Preanalytical Errors on Patient Care</b> <i>Joe El-Khoury, PhD, DABCC, FADLM, Yale University, West Haven, CT</i></li> <li>• <b>Harnessing the Power of Modern Tools to Reduce Preanalytical Error</b> <i>Christopher Farnsworth, PhD, DABCC, Washington University in St. Louis, St. Louis, MO</i></li> </ul>				



**FIND SESSION DESCRIPTIONS.  
STAY UP TO DATE.**

Download the mobile app at  
[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32108	<b>Accelerating Point-of-Need Diagnostics to Meet the Growing Demand for Acute and Advanced Care at Home</b>	S504 abc	1.5	1.5	<b>I</b>
Moderator	<ul style="list-style-type: none"> <li><b>Hospital at Home: Current Diagnostic Realities and Emerging Opportunities</b> <i>Jared Conley, MD, PhD, MPH, Massachusetts General Hospital, Boston, MA</i></li> <li><b>Emergency Department at Home: Leveraging Current Technologies to Improve Rapid, Convenient Diagnosis</b> <i>David Whitehead, MD, Massachusetts General Hospital, Boston, MA</i></li> </ul>				
32109	<b>The Nexus of Innovation: How Laboratory Medicine Supports Cellular and Gene Therapy Advancements</b>	S505	1.5	1.5	<b>B</b>

- Moderator
- Rewards and Challenges of Point-of-Care Cell Manufacturing and Delivery of Novel Gene Modified Cell Therapies**  
*Amittha Wickrema, PhD, University of Chicago, Chicago, IL*
  - mRNA-Based CAR T Manufacturing and Testing**  
*Yen-Michael Hsu, MD, PhD, Gift of Life Marrow Registry, Boca Raton, FL*
  - Characterization of a Patient's Pre-existing Immunity to Viral Vectors in Gene Therapy: Implications and Forward Thinking**  
*Zhen Zhao, PhD, DABCC, FADLM, Weill Cornell Medicine, New York, NY*

### Student Research Awards Oral Presentation Competition

Monday, July 29 | 1:00 p.m. - 2:00 p.m.  
Room S404c

The Student Research Awards oral presentation competition includes presentations from four top-scoring students on topics across laboratory medicine.



## CHAIR'S INVITED SESSION

Mid-day | 12:30 p.m. - 2:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32441	<b>Operationalizing Changes to LDT Oversight: Building Roadmaps When the Rubber Hits the Road</b>	S402	1.5	1.5	<b>B</b>

Moderator *Mark Marzinke, PhD, DABCC, FADLM, Johns Hopkins University, Baltimore, MD*

- **Developing Tools to Manage Decreased Access to LDTs**  
*Stephen Master, MD, PhD, FADLM, Children's Hospital of Philadelphia, Philadelphia, PA*
- **LDTs as Medical Devices? Strategies for Prioritization and Regulatory Compliance**  
*Jonathan Genzen, MD, PhD, ARUP Laboratories, Salt Lake City, UT*
- **Biomarkers and Bureaucracy: Impact of FDA Regulation of Molecular Diagnostics LDTs**  
*Eric Konnick, MD, University of Washington, Seattle, WA*

## SCIENTIFIC SESSIONS

Mid-day | 12:30 p.m. - 2:00 p.m.

32442	<b>Unexpected Results: Using Proficiency Testing to Improve Toxicology and Pharmacogenetic Testing in Your Lab</b>	S403	1.5	1.5	<b>I</b>
-------	--	------	-----	-----	----------

*In cooperation with the ADLM TDM and Toxicology Division and the College of American Pathologists Toxicology Committee*

- Moderator *Christine Snozek, PhD, DABCC, FADLM, Mayo Clinic, Phoenix, AZ*
- **Evolution of Toxicology Proficiency Testing Programs in Response to the Changing Landscape of Drug Testing**  
*Gwendolyn McMillin, PhD, DABCC, University of Utah/ARUP Laboratories, Salt Lake City, UT*
  - **Evolution of PGx Proficiency Testing Programs to Align With Laboratory Practice and Unmet Needs**  
*Nicholas Heger, PhD, NRCC, Tufts Medical Center, Boston, MA*

## THE ACADEMY COFFEE BREAK

Monday, July 29 | 2:00 p.m. | Vista Room Lobby (S406)

Join fellow attendees and members of the Academy for a coffee break and to learn more about the Academy of Diagnostics & Laboratory Medicine.

## SCIENTIFIC SESSIONS

Mid-day | 12:30 p.m. - 2:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32443	<b>Moving Beyond Sensitivity and Specificity: Showing the Value of Lab Medicine Through Outcome Measures</b>	S404ab	1.5	1.5	<b>B</b>
	<ul style="list-style-type: none"> <li>• <b>Using Outcomes Studies/Measures to Improve the Delivery of Care</b> <i>David Grenache, PhD, MT (ASCP), DABCC, FADLM Tricare Reference Laboratories, Albuquerque, NM</i></li> <li>• <b>The Important Differences Between Observational and Implementation Studies</b> <i>Allan Jaffe, MD, Mayo Clinic, Rochester, MN</i></li> <li>• <b>Beyond the Lab: Transforming Patient Care Through Impactful Testing Outcomes</b> <i>Zhen Zhao, PhD, DABCC, FADLM, Weill Cornell Medicine, New York, NY</i></li> </ul>				
Moderator					
32444	<b>Implementation of Equations to Estimate Glomerular Filtration Rate at a Pediatric Institution</b>	S501 abc	1.5	1.5	<b>A</b>
	<ul style="list-style-type: none"> <li>• <b>Reporting Estimated Glomerular Filtration Rate in Pediatrics: A Laboratory Perspective</b> <i>Angela Ferguson, PhD, DABCC, FADLM, Children's Mercy Hospital, Kansas City, MO</i></li> <li>• <b>Reporting Estimated Glomerular Filtration Rate in Pediatrics: A Clinician Perspective</b> <i>Darcy Weidemann, MD, MHS, Children's Mercy Kansas City, Kansas City, MO</i></li> </ul>				
Moderator					
32445	<b>Pathogen Detection, Machine Learning, or Host Biomarkers: Can Any of These Technologies Help Address the Challenge of Sepsis?</b>	S502	1.5	1.5	<b>I</b>
	<ul style="list-style-type: none"> <li>• <b>Transcriptomics, Cell Structure, or Machine Learning: An Overview of the Tools for Detection of Septic Patients</b> <i>Nathan Ledeboer, PhD, ABMM, FAAM, Medical College of Wisconsin, Milwaukee, WI</i></li> <li>• <b>The Need for Sepsis Biomarkers and Rapid Pathogen Detection: A Perspective From the Emergency Department</b> <i>Chadd Kraus, DO, Lehigh Valley Health Network, Allentown, PA</i></li> <li>• <b>Is Sepsis Detection the Next Troponin and Can the Laboratory Provide the Results at the Time of Need?</b> <i>Alison Woodworth, PhD, DABCC, FADLM, CTI Clinical Trials &amp; Consulting, Cincinnati, OH</i></li> </ul>				
Moderator					

## SCIENTIFIC SESSIONS

Mid-day | 12:30 p.m. - 2:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32446	<b>Automating Digital Workflows in the Clinical Laboratory Using Robotic Process Automation</b>	S503	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Expert Faculty</b>  <i>Simone Arvais-Anhalt, MD, University of California, San Francisco, San Francisco, CA</i>  <i>Daniel Holmes, MD, St Paul's Hospital Providence Health Care, Vancouver, BC, Canada</i></li> </ul>				
32447	<b>Gestational Diabetes Mellitus: Thinking Beyond Current Testing Guidelines</b>	S504 abc	1.5	1.5	<b>I</b>
	<i>In cooperation with the ADLM Clinical Societies Collaboration Committee and the American Diabetes Association</i>				

Moderator *David Sacks, MB ChB, FRCPath, National Institutes of Health, Bethesda, MD*

- **Chill Out! Missed Diagnoses of Gestational Diabetes Mellitus Due to Lax Specimen Handling**  
*Michael Turner, MD, University College Dublin, Dublin, Ireland*
- **Can We Move Beyond the OGTT for Diagnosis of Gestational Diabetes Mellitus and Postpartum Testing?**  
*Cuilin Zhang, PhD, Yong Loo Lin School of Medicine/National University of Singapore, Singapore*
- **Is 24 Weeks Too Late? Who Should Be Screened Earlier and What Is the Impact on Outcomes?**  
*David Simmons, MBBS, MA, Western Sydney University, Campbelltown, NSW, Australia*



### CLAIM CE BY OCT 31

Evaluate sessions and claim ACCENT and/or CME credit by October 31.  
 Scan the code or visit [meeting.myadlm.org/claimcredits](https://meeting.myadlm.org/claimcredits).



### FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

# SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32221	<b>Responding to the Threat of Xylazine and Drug Supply Adulteration: Clinical Testing Strategies and Empowering Point-of-Service Community Drug Checking</b>	S402	1.5	1.5	<b>B</b>

- **Best Practices and Testing Strategies in Overdose Patient Management**  
*Rachel Wightman, MD, FACMT, Alpert Medical School of Brown University, Providence, RI*

Moderator **Leveraging Clinical Comprehensive Drug Testing in the Age of Drug Supply Adulteration**  
*Adina Badea, PhD, DABCC, Lifespan Health/Rhode Island Hospital/Brown University, Providence, RI*

- **Assessing Accuracy and Utility of FTIR Testing and Xylazine Test Strips as Community Drug Checking Tools**  
*Traci Green, PhD, MSc, Brandeis University/Rhode Island Hospital, Brown University, Providence, RI*

32222	<b>Emerging Diagnostics to Differentiate Type 1 From Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury</b>	S403	1.5	1.5	<b>I</b>
-------	--	------	-----	-----	----------

*In cooperation with the ADLM Biomarkers of Acute Cardiovascular Diseases Division and ADLM Industry Division*

- **Distinguishing Type 2 Myocardial Infarction From Myocardial Injury and Type 1 Myocardial Infarction**  
*Allan Jaffe, MD, Mayo Clinic, Rochester, MN*

Moderator **Serum Biomarkers and Algorithms to Differentiate Myocardial Infarction Types**  
*Xander van Wijk, PhD, DABCC, FADLM, Van Wijk Consulting, LLC, Houston, TX*

- **Analysis of Microvesicles for Cardiac Troponin to Detect Reversible Injury and Demand Ischemia**  
*Alan Wu, PhD, University of California at San Francisco, San Francisco, CA*

32223	<b>Navigating Challenges in Tumor Marker Testing: Insights and Solutions</b>	S404ab	1.5	1.5	<b>B</b>
-------	--	--------	-----	-----	----------

Moderator *Joyce Liao, PhD, DABCC, University of Washington, Seattle, WA*

- **Journey of Body Fluid Tumor Marker Testing: Crossing Sample Variability and Interference**  
*Jonathan Genzen, MD, PhD, ARUP Laboratories, Salt Lake City, UT*

- **Continuous Transitions: Strategies for Consistent Tumor Marker Testing Across Platforms**  
*J Shirley Li, PhD, MD, DABCC, NRCC, Ohio State University Wexner Medical Center, Columbus, OH*

- **Beyond Intended Use: Designing Validation Protocols for Accurate Tumor Marker Testing in Diverse Patient Populations**  
*Qian Sun, PhD, DABCC, Corewell Health, Novi, MI*

## SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32224	<b>International Quality Indicators: Experiences, Opportunities, and Challenges</b>	S404cd	1.5	0	B
Moderator	<ul style="list-style-type: none"> <li><b>Benchmarking of Laboratory Processes: IFCC WG-LEPS Guidelines and the Canadian Experience</b> <i>Vincent De Guire, PhD, MSc, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada</i></li> <li><b>Benchmarking of Laboratory Processes: The Brazilian Indicators Program</b> <i>Fernando Berlitz, MBA, Controllab, Porto Alegre, RS, Brazil</i></li> </ul>				
32225	<b>Operationalizing AI in Lab Medicine: Approaches for Effective Machine Learning Integration and Deployment</b>	S501 abc	1.5	1.5	B
Moderator	<p><i>Stephen Master, MD, PhD, FADLM, Children's Hospital of Philadelphia, Philadelphia, PA</i></p> <ul style="list-style-type: none"> <li><b>Beyond the Buzz: Practical Pathways to AI Deployment in Clinical Laboratories</b> <i>Thomas Durant, MD, Yale University, New Haven, CT</i></li> <li><b>Are You Prepared? Appraisal and Evaluation of AI Applications for Laboratory Medicine</b> <i>David McClintock, MD, Mayo Clinic, Rochester, MN</i></li> <li><b>From Theory to Practice: Lessons Learned in Implementation of a Machine Learning Solution for Preanalytical Error Detection</b> <i>Nicholas Spies, MD, Washington University in St. Louis, St. Louis, MO</i></li> </ul>				
32226	<b>Improving Lead Testing Access: Leaning Into Decision Support Tools and Lead Screening by Dried-Blood Spots</b>	S502	1.5	1.5	B
Moderator	<ul style="list-style-type: none"> <li><b>Leveraging Informatics to Identify Children at Risk of Lead Toxicity and Increase Screening Rates</b> <i>Roopa Thakur, MD, Cleveland Clinic, Cleveland, OH</i></li> <li><b>The Role of the Clinical Laboratory in Local Lead Testing Surveillance Programs: A Pilot Study Using Dried Blood Spots</b> <i>Jessica Colon-Franco, PhD, DABCC, FADLM, Cleveland Clinic, Cleveland, OH</i></li> </ul>				



**FIND SESSION DESCRIPTIONS.  
STAY UP TO DATE.**

Download the mobile app at  
[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

# SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
32227	<b>Practical Update on Laboratory Testing for Bleeding Problems: Adapting to New Evidence, Guidelines and Therapies, With Illustrative Cases</b>	S503	1.5	1.5	<b>I</b>
	<ul style="list-style-type: none"> <li>• <b>Update on von Willebrand Disease Testing</b> <i>Catherine Hayward, MD, PhD, FRCPC, McMaster University, Hamilton, ON, Canada</i></li> <li>• <b>Platelet Disorders: Diagnostic Testing</b> <i>Geoffrey Wool, MD, PhD, University of Chicago, Chicago, IL</i></li> <li>• <b>Factor Deficiencies: Diagnostic and Treatment Monitoring Testing</b> <i>Morayma Reyes-Gil, MD, PhD, Cleveland Clinic, Cleveland, OH</i></li> </ul>				
Moderator					
32228	<b>The Gift of Life: The Remarkable Role the Clinical Laboratory Plays in Organ Donation</b>	S504 abc	1.5	1.5	<b>B</b>
	<ul style="list-style-type: none"> <li>• <b>The Unique Requirements for Organ and Tissue Donor Screening Assays</b> <i>Amber Carriker, BS, C(ASCP), Mid America Transplant, St. Louis, MO</i></li> <li>• <b>Compatibility Testing: I'll Accept That (Human and Xeno)!</b> <i>Sam Ho, PhD, ABHI, Gift of Hope Organ &amp; Tissue Donor Network, Itasca, IL</i></li> <li>• <b>Managing Brain Dead Donors in a Non-Traditional Setting</b> <i>Selena Warden, MSc, ASCP, Southwest Transplant Alliance, Dallas, TX</i></li> </ul>				
Moderator					
32229	<b>Advances and Limitations of Consumer-Initiated Laboratory Testing</b>	S505	1.5	0	<b>B</b>
	<ul style="list-style-type: none"> <li>• <b>How Is This Lab Different From Yours? The Ins and Outs of a Laboratory Where Consumer-Initiated Testing Is the Norm</b> <i>Dina Greene, PhD, DABCC, University of Washington, Burien, WA</i></li> <li>• <b>Your Results Are Back! Clinical Support for Consumer-Initiated Testing</b> <i>Avantika Waring, MD, 9amHealth, Seattle, WA</i></li> <li>• <b>Ethical Considerations for Consumer-Initiated Testing</b> <i>Melissa Budelier, PhD, DABCC, TriCore Reference Laboratories, Albuquerque, NM</i></li> </ul>				
Moderator					

# STUDENT RESEARCH AWARD COMPETITIONS

Monday, July 29 | Rooms S405 & S404c

The Student Research Award Competitions showcase the field's finest young scientists and is intended for students, trainees, and postdoctoral fellows who are presenting authors of accepted poster abstracts for the Annual Meeting. The competition consists of two parts, the Student Oral Presentation Competition and Student Poster Competition. Winners are announced at the ABCC-SYCL Awards and Recognition Reception. Visit [meeting.myadlm.org/abstracts](http://meeting.myadlm.org/abstracts) to learn more about the competition, competitors, and winner announcements.

## POSTER COMPETITION

On display 9:30 a.m. - 4:00 p.m.

Judging takes place 2:30 p.m. - 4:00 p.m.

Room: S405


Visit over 50 student posters that will be on display showcasing student research for all conference participants and reviewed by in-person judges. Explore the science and network with peers and leaders in the field.

## ORAL PRESENTATION COMPETITION

1:00 p.m. - 2:00 p.m.

Room: S404c

Hear presentations from the four top-scoring student abstracts from across the field of laboratory medicine. Competitors will present their research to a panel of judges in a brief presentation. The competition is open to conference participants.



## 2024 DISRUPTIVE TECHNOLOGY AWARD COMPETITION

Afternoon | 4:30 p.m. - 6:00 p.m.

Location: Grand Ballroom (S100)

*Sponsored by LabCorp*

ADLM's Disruptive Technology Award Competition (DTAC) aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care. DTAC grants the diagnostic and laboratory medicine community an early look at innovative and impactful products that address current gaps in the field and/or improve upon existing solutions. In this special session, three finalists will deliver presentations that explain their leading-edge technology and showcase supporting evidence for the performance and impact of their novel development. Each presentation will be followed by a brief Q&A with an expert panel of judges who will rank disruptiveness, innovation, and impact among other factors. The winner will be announced at the close of the event.

### MASTER OF CEREMONIES

**Stephen R. Master, MD, PhD, FADLM**, *Children's Hospital of Philadelphia*

### FINALISTS:

**Dawn Mattoon, PhD**

*Mercy Bioanalytics, Inc. | The Enlighten Test*

**Andrea Cubitt, PhD**

*Dionysus Digital Health, Inc. | Mercy Halo™ Ovarian Cancer Screening Test*

**Luuk Giesen, MD**

*Vitestro | Vitestro Autonomous Blood Drawing Device*



# PLENARY+ SCIENTIFIC SESSIONS

TUESDAY, JULY 30



**Jamie Acero**  
BS, MHA, CPP

## PLENARY SESSION 13001

**TUESDAY, JULY 30**

**8:45 a.m. - 10:00 a.m.**

LOCATION: Grand Ballroom (S100)

LEVEL: Basic

CREDITS: ACCENT: 1.0, CME: 1.0

### **Implementation of PGx-based Testing in Precision Health: Do You Have Your DNA-passport?**



**Ron H.N. van Schaik, PhD, FADLM, EuSpLM**

*Professor, Pharmacogenetics*

*Head of Department of Clinical Chemistry*

*Erasmus University Medical Center*

*Rotterdam, The Netherlands*

The discovery that the metabolism of drugs is highly variable among patients, but can be predicted by DNA analysis of genes encoding drug metabolizing enzymes or drug transporters, motivated the incorporation of pharmacogenetics into clinical care. The initial focus was on cytochrome P450 enzymes: genotyping for CYP2D6 (involved in the metabolism of 20% of all drugs, but deficient in 5-10% of the population) and CYP2C19 (involved in metabolism of 20% of drugs, while 2-11% of the population is deficient) could benefit psychiatry, cardiology and oncology therapies. Currently, 15-30 genes for drug metabolizing enzymes and drug transporters can be (and are) used clinically for optimizing personalization of drug therapy. Pharmacogenetics is maturing as a clinical diagnostic tool, in which we see a shift from reactive single-gene testing to pre-emptive panel-based testing. In this presentation, successes and challenges for implementing pharmacogenetics into routine health care will be highlighted.

## ROUNDTABLE SESSIONS



7:30 a.m. - 8:30 a.m. (40000 Series) -or- 12:30 p.m. - 1:30 p.m. (50000 Series)

Location: S406a • Credits: ACCENT: 1.0, CME: Not eligible

Most roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. Coffee is provided and concession stands are available to purchase food.

AM SESSION PM SESSION	TITLE	LEVEL
43101 53201	<b>The Cardiopulmonary Bypass Adjustment at the Point-of-Care Measurement of Hematocrit and Hemoglobin: When to Use and When Not To?</b> <i>Mustafa Barbhuiya, PhD, UMass Chan Medical School-Baystate Medical Center, South Hadley, MA</i>	1
43102 53202	<b>Party of 1 at the Point-of-Care Table? Add a Seatmate!</b> <i>In cooperation with the ADLM Critical and Point-of-Care Testing Division Peggy Mann, MS, MT (ASCP), CPP, University of Texas Medical Branch, Galveston, TX</i>	1
43103 53203	<b>Point-of-Care Testing: Figuring Out How Many Point-of-Care Staff Are Needed</b> <i>Kathleen David, BA, ASCP, MT (ASCP), Tricore Reference Laboratories, Albuquerque, NM</i>	1
42104 53204	<b>How People Try to Beat Drug Testing and Defend Positive Results</b> <i>Amitava Dasgupta, PhD, DABCC, University of Kansas Medical Center, Lenexa, KS</i>	B
43105 53205	<b>From Theory to Reality: A Closer Look at Toxicology Screens for Drugs of Abuse</b> <i>Imir Metushi, PhD, DABCC, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA</i>	B
43106 53206	<b>Where'd That Flag Come From? Therapeutic Ranges and Critical Action Values for Psychoactive Drugs</b> <i>Bernice Agana, PhD, Johns Hopkins University, Baltimore, MD</i>	B
43107 53207	<b>Designing Clinical Context-Specific Drug Test Panels</b> <i>Anil Kiran Chokkalla, PhD, Baylor College of Medicine, Houston, TX</i>	B
43108 53208	<b>Practical Guidance for Evaluating and Selecting Automated Chemistry Analyzers to Implement in Academic Clinical Laboratories</b> <i>Stefani Thomas, PhD, DABCC, NRCC, University of Minnesota, Minneapolis, MN</i>	B
43109 53209	<b>Assay Interference: Tracking Analytical Difficulties in a Central Automated Lab Setting</b> <i>Ruhan Wei, PhD, DABCC, NRCC, Duke University Health System, Durham, NC</i>	B
43110 53210	<b>Standardization and Integration of Chemistry Laboratories Across the Health System</b> <i>Melissa Ulas, MD, PhD, NRCC, SCYM(ASCP), Temple University Health System, Philadelphia, PA</i>	1
43111 53211	<b>Diagnostic Blood Loss: Why It Is of Concern and How to Minimize It</b> <i>Saptarshi Mandal, MD, MS, All India Institute of Medical Sciences, Jodhpur, India</i>	1
43112 53212	<b>Laboratory Lament: Cracking the Code on Clinical Workforce Woes</b> <i>Marc Rumppler, PhD, ASCP, DABCC, NRCC, FADLM, One Lambda Laboratories, part of Thermo Fisher Scientific, Fishers, IN</i>	B
43113 53213	<b>Lab Injuries and Exposures: The Real Data</b> <i>Dan Scungio, MLS (ASCP), SLS, CQA (ASQ), CHOP, Sentara Health, Williamsburg, VA</i>	1
43114 53214	<b>Transitioning to Green Labs: Strategies for Overcoming Challenges on the Journey to Sustainable Laboratory Practices</b> <i>Aylin Sepici Dincel, MD, PhD, Gazi University, Ankara, Turkey</i>	B


# ROUNDTABLE SESSIONS



AM SESSION PM SESSION	TITLE	LEVEL
43115 53215	<b>Understanding the Impact of Blood Collection Tube Components on Clinical Assays: A Practical Guide for Managing Supply Chain Disruptions and Beyond</b> <i>Raffick Bowen, PhD, MHA, MLT(CSMLS), DABCC, DCLCHEM, FADLM, FCACB, Stanford University, Palo Alto, CA</i>	<b>B</b>
43116 53216	<b>Investigating and Documenting Unacceptable Proficiency Testing Results</b> <i>Sheng-Ying Lo, PhD, DABCC, Geisinger Medical Laboratories, Danville, PA</i>	<b>B</b>
43117 53217	<b>Method Verification for ISO 15189:2022 Medical Laboratories: Requirements for Quality and Competence</b> <i>Alison Bransfield, MS, Cork University Hospital, Cork, Ireland</i>	<b>I</b>
43118 53218	<b>Sweat Testing: Current Practices and Quality Metrics</b> <i>Daisy Unsihuay Vila, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA</i>	<b>B</b>
43119 53219	<b>Considerations of HbA1c Measurement</b> <i>Shu-Ling Fan, PhD, DABCC, FADLM, Vanderbilt University Medical Center, Nashville, TN</i>	<b>B</b>
43120 53220	<b>Challenges in Primary Hyperparathyroidism: Unexpectedly Elevated Parathyroid Hormone Concentrations and the Importance of Careful Testing</b> <i>Shaimaa Maher, PhD, Cleveland Clinic, North Olmsted, OH</i>	<b>I</b>
43121 53221	<b>No Need to Get Testy: Breaking Down Testosterone Methodology and Utilization</b> <i>Katie Troike, PhD, Cleveland Clinic, Cleveland, OH</i>	<b>B</b>
43122 53222	<b>Gels From Hell: Overcoming Difficult-to-Interpret Serum Protein Electrophoresis and Immunofixation Test Findings</b> <i>Robert Maynard, PhD, NRCC, University of Kentucky, Lexington, KY</i>	<b>I</b>
43123 53223	<b>Methodologies for Detection of Monoclonal Immunoglobulins and Identification of Therapeutic Monoclonal Antibodies</b> <i>Vishnu Amaram Samara Simha Subhash Chandra, PhD, University of Chicago, Chicago, IL</i>	<b>I</b>
43124 53224	<b>HIV Diagnostics: What's Next?</b> <i>Vincent Ricchiuti, PhD, ABB, FADLM, Labcorp, Dublin, OH</i>	<b>I</b>
43125 53225	<b>What the HIL!?! Refining Vendor Interference Claims to Work for Your Laboratory</b> <i>Anna Merrill, PhD, DABCC, University of Iowa Hospitals and Clinics, Iowa City, IA</i>	<b>B</b>
43126 53226	<b>Unique Considerations for Method Validation and Quality Control of Semi-Quantitative Tests</b> <i>Uvaraj Uddayasankar, PhD, FCACB, LifeLabs, Toronto, ON, Canada</i>	<b>B</b>
43127 53227	<b>This Result Does Not Make Sense: Unexpected Results Related to the Patient's Condition</b> <i>Monica Ianosi-Irimie, MD, PhD, Cooper University Hospital, Philadelphia, PA</i>	<b>B</b>
43128 53228	<b>Reduced Hemolysis and Outliers in High Sensitivity Troponin Testing</b> <i>Hind Malaeb, PhD, Yale University, Lexington, KY</i>	<b>B</b>
43130 53230	<b>Digital Microscopy and Artificial Intelligence Cell Pre-Classification in the Hematology Laboratory</b> <i>Megan Nakashima, MD, Cleveland Clinic, Cleveland, OH</i>	<b>B</b>

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33101	<b>ADLM Healthcare Forum: The Impact of LDT Oversight on the Delivery of Care</b>	S402	1.5	1.5	<b>1</b>
<p><i>In cooperation with the ADLM Pediatric and Maternal-Fetal Division and the ADLM Policy and External Affairs Core Committee</i></p>					
Moderator	<p><i>Joe Wiencek, PhD, DABCC, NRCC, FADLM, Vanderbilt University Medical Center, Nashville, TN</i></p> <ul style="list-style-type: none"> <li> <b>The Necessity of LDTs in Pediatric Care: Lack of Access Leads to Compromised Patient Care</b>  <i>Patricia Jones, PhD, DABCC, FADLM, University of Texas Southwestern Medical Center, Dallas, TX</i> </li> <li> <b>LDT Oversight by the Experts: Finding Alternatives to the Proposed FDA Rule</b>  <i>Dennis Dietzen, PhD, DABCC, FADLM, Washington University School of Medicine, St. Louis, MO</i> </li> </ul>				
33102	<b>Clinical Laboratory Accreditation Agencies: What You Should Know Before, During, and After an Inspection</b>	S403	1.5	1.5	<b>B</b>
Moderator	<p><i>Veronica Luzzi, PhD, DABCC, TriCore Reference Laboratories, Albuquerque, NM</i></p> <ul style="list-style-type: none"> <li> <b>CLIA, COLA, TJC: What You Should Know but Are Afraid to Ask</b>  <i>Jude Abadie, PhD, DABCC, DABMGG, FADLM, FACMG, Texas Tech University Health Sciences Center, El Paso, TX</i> </li> <li> <b>Enhancing Laboratory Quality with ISO15189</b>  <i>Alejandro Molinelli, PhD, NRCC, St. Jude Children's Research Hospital, Memphis, TN</i> </li> </ul>				
33103	<b>Clinical Assay Issues: What Endocrinologists Will Ask You</b>	 S404ab	1.5	1.5	<b>1</b>
<p><i>In cooperation with the ADLM Clinical Societies Collaboration Committee and the Endocrine Society</i></p>					
Moderator	<p><i>David Sacks, MB ChB, FRCPath, National Institutes of Health, Bethesda, MD</i></p> <ul style="list-style-type: none"> <li> <b>Eucalcemic Hyperparathyroidism: Is it Primary Hyperparathyroidism?</b>  <i>Joseph Shaker, MD, Medical College of Wisconsin, Menomonee Falls, WI</i> </li> <li> <b>How to Accurately Diagnose Growth Hormone Abnormalities?</b>  <i>Jeannette Goguen, MD, St. Michael's Hospital, Toronto, ON, Canada</i> </li> <li> <b>Antibodies Guiding the Diagnosis of Hyperglycemia and Hypoglycemia</b>  <i>Adrian Vella, MD, Mayo Clinic, Rochester, MN</i> </li> </ul>				

# SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33104	<b>Clinical Chemistry Journal Hot Topics: A Point-Counterpoint on LDL-C Equations</b> 	S404cd	1.5	1.5	<b>I</b>

Moderator *Jason Park, MD, PhD, DABCC, Children's Medical Center, Dallas, TX*

- **The Clinical Importance of LDL-C**  
*Ian Young, MD, Queen's University Belfast, Belfast, United Kingdom*
- **Calculation of LDL-C Using the Martin-Hopkins Equation**  
*Seth Martin, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD*
- **Calculation of LDL-C Using the Sampson-NIH Equation**  
*Alan Remaley, MD, National Institutes of Health, Bethesda, MD*

33105	<b>Improv and the Art of Medicine: Adaptable Skills for an Uncertain World</b>	S406b	1.5	1.5	<b>B</b>
-------	--	-------	-----	-----	----------

Moderator *Belinda Fu, MD, Mayutica Institute/TheImprovDoc, Seattle, WA*

33106	<b>Dipping Your Toes Into the Data Analytics Pool: A Session With Laboratory Professionals Working on Informatics Projects</b>	S501 abc	1.5	1.5	<b>B</b>
-------	--	----------	-----	-----	----------

*In cooperation with the ADLM Informatics Division*

Moderator *Mark Cervinski, PhD, DABCC, FADLM, Dartmouth-Hitchcock Medical Center, Lebanon, NH*

- **Through the Shallows: Regional Quality Control and Calibrations**  
*Dustin Bunch, PhD, DABCC, Nationwide Children's Hospital, Columbus, OH*
- **Developing Machine Learning Models to Improve Test Utilization and Laboratory Stewardship**  
*He Yang, PhD, DABCC, Weill Cornell Medicine, New York, NY*
- **From Idea to Beta Testing: Use Cases to Build Your Analytics Skills**  
*Steven Cotten, PhD, DABCC, NRCC, FADLM, University of North Carolina at Chapel Hill, Chapel Hill, NC*

33107	<b>Capital Purchases and Cost Accounting for Lab Leaders: Essential Skills for Demonstrating the Value of the Laboratory</b>	S502	1.5	1.5	<b>B</b>
-------	--	------	-----	-----	----------

Moderator *David Shiembob, BS, MBA, C (ASCP), ARUP Laboratories, Salt Lake City, UT*

- **Making the Case for Capital Purchases: Translating Ideas Into Action**
- **The Cost of Doing Business: Demystifying Lab Cost Analysis**  
*Zachary Zaret, MHA, DLM(ASCP)<sup>CM</sup>, ARUP Laboratories, Salt Lake City, UT*

## SCIENTIFIC SESSIONS


Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33108	<b>Informatics and Technological Approaches for Addressing the Challenges of Large-Scale Genomic Testing</b>	S503	1.5	1.5	<b>1</b>

- **Validation of Natural Language Processing (NLP) Algorithms for Deep Phenotyping of Patients Receiving Genomic Testing**

Moderator *Kai Lee Yap, PhD, DABMGG, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*

- **Overcoming the Challenges of Whole Exome Sequencing for the Diagnosis of Patients With Monogenic Kidney Disease**  
*Daniela del Gaudio, PhD, DABMGG, University of Chicago, Chicago, IL*
- **Long-Read Whole Genome Sequencing for Solving Undiagnosed Rare Diseases**  
*Danny Miller, MD, PhD, DABMGG, University of Washington, Seattle, WA*

33109	<b>Academy Distinguished Abstracts: Innovations in Bedside-to-Bench and Back Again</b>	 S504 abc	1.5	0	<b>B</b>
-------	--	--	-----	---	----------

*In cooperation with the Academy of Diagnostics & Laboratory Medicine*

Moderator *Gyorgy Abel, MD, PhD, DABCC, FADLM, Beth Israel Lahey Health, Burlington, MA*

- **Prediction of Opioid Use Duration in Post-Surgical Orthopedic Patients Using CYP2D6 Inhibitor Index and Routine Laboratory Markers**  
*Hunter Miller, PhD, University of Louisville, Louisville, KY*
- **Turning False Positive Screening into True Positive Results**  
*Melissa Bennett, PhD, MLT, DABCC, University of Calgary, Cochrane, AB, Canada*
- **Analytical and Clinical Performance of a Novel Ovarian Cancer Screening Test in Asymptomatic Women**  
*Brendan Manning, PhD, Mercy BioAnalytics, Waltham, MA*
- **Diverse Glycosylation of Circulating Alpha Fetoprotein in Chronic Liver Diseases Profiled by Intact Mass High Resolution Mass Spectrometry**  
*Yifei Yang, PhD, DABCC, Mayo Clinic, Rochester, MN*



### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.

# SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33221	<b>Speaking Their Language: Communicating to Hospital Leadership the Essential Role of the Laboratory in Value-Based Care</b>	S402	1.5	1.5	<b>B</b>
Moderator	<i>James Crawford, MD, PhD, Northwell Health, Greenvale, NY</i>				
	<ul style="list-style-type: none"> <li>• <b>Working With Hospital and Health System Leadership: The Northwell Health Laboratories Story</b> <i>Dwayne Breining, MD, Northwell Health, New Hyde Park, NY</i></li> <li>• <b>Importance of the Hospital and Health System Laboratory From an Administrators Perspective</b> <i>Alex Hellinger, DPT, MBA, FACHE, Northwell Health, New Hyde Park, NY</i></li> </ul>				
33222	<b>You Did What Now? Addressing Questionable Laboratory Practices</b>	406b	1.5	1.5	<b>I</b>
	<ul style="list-style-type: none"> <li>• <b>Resolving Laboratory Errors</b> <i>Jacqueline Hubbard, PhD, C(ASCP), DABCC, NRCC, Three Rivers Diagnostics, Pittsburgh, PA</i></li> <li>• <b>Resolving Noncompliant Laboratory Procedures</b></li> </ul>				
Moderator	<i>Grace Williams, PhD, DABCC, Virginia Commonwealth University, Richmond, VA</i>				
33223	<b>Unexpected Toxicology Results as Real-Time Opportunities for Collaboration</b>	S404ab	1.5	0	<b>I</b>
	<ul style="list-style-type: none"> <li>• <b>Unexpected Negatives</b></li> <li>• <b>Unexpected Positives</b></li> <li>• <b>Practical Considerations for LC-MS-Based Toxicology Analysis</b></li> </ul>				
Moderator	<i>Nicholas Heger, PhD, NRCC, Tufts Medical Center, Boston, MA</i>				
	<i>Danyel Tacker, PhD, DABCC, FADLM, West Virginia University, Morgantown, WV</i>				
	<i>Steven Conklin-Lopez, PhD, NRCC, Labcorp, Boston, MA</i>				
33224	<b>Acute Kidney Injury Biomarkers: Ready for Primetime?</b>	S404cd	1.5	0	<b>I</b>
	<ul style="list-style-type: none"> <li>• <b>Moving Beyond Creatinine: A New Era in Acute Kidney Injury Diagnosis</b></li> <li>• <b>CXCL9 for Diagnosis of Acute Interstitial Nephritis</b></li> <li>• <b>NGAL for Acute Kidney Injury Diagnosis in Cirrhotic Patients</b></li> </ul>				
Moderator	<i>Robert Nerenz, PhD, DABCC, Medical College of Wisconsin, Milwaukee, WI</i>				
	<i>Dennis Moledina, MD, PhD, FASN, Yale School of Medicine, New Haven, CT</i>				
	<i>Kevin Regner, MD, MS, FASN, Medical College of Wisconsin, Milwaukee, WI</i>				

## SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33225	Care Continuum: How Hematologists, Laboratorians, and Transfusion Medicine Physicians Partner to Diagnose, Manage, and Support Patients with Sickle Cell Disease	S405	1.5	0	B

Moderator Zahra Shajani-Yi, PhD, DABCC, NRCC, FADLM, Labcorp, San Diego, CA

- **The Hematologist's View: Clinical and Hematological Effects of Sickle Cell Disease**  
Susanna Curtis, MD, PhD, Icahn School of Medicine at Mount Sinai, Manhattan, NY
- **The Laboratory View: Laboratory Methods Used to Diagnose and Manage Sickle Cell Disease**  
Sean Campbell, PhD, DABCC, FADLM, Montefiore Medical Center, Bronx, NY
- **The Transfusion Medicine Physician's View: Transfusion and Apheresis in Sickle Cell Disease Care**  
Caroline Alquist, MD, PhD, F(ACHI), FCAP, University of Cincinnati, Cincinnati, OH

33226	Getting Started with Data Analytics: Indirect Reference Intervals as a Case Study	S501 abc	1.5	1.5	B
-------	---	-------------	-----	-----	---

In cooperation with the ADLM Informatics Division

- Moderator Sarah Wheeler, PhD, FADLM, University of Pittsburgh Medical Center, Pittsburgh, PA
- **Accessing and Analyzing Laboratory Data: Tools, Techniques, and Tips**
  - **Exploring Data Analytics Through Case Studies in Indirect Reference Interval Applications**  
Kelly Doyle, PhD, DABCC, FADLM, ARUP Laboratories, Salt Lake City, UT
  - **Systematic Ways to Avoid Fantasy and Self-Deception With Indirect Reference Interval Determination**  
Daniel Holmes, MD, St. Paul's Hospital Providence Health Care, Vancouver, BC, Canada

33227	Metabolic Emergencies in the Pediatric Patient: Laboratory Differentiation of Inborn Errors of Metabolism and Acute Drug Exposure	S502	1.5	0	I
-------	---	------	-----	---	---

In cooperation with the ADLM Pediatric and Maternal-Fetal Division

- Moderator Kara Lynch, PhD, DABCC, FADLM, University of California, San Francisco, San Francisco, CA
- **Diagnostic Evaluation of Pediatric Patients with Acute Metabolic Derangements**
  - **Laboratory Game of Clue: Metabolic Disorder or Exogenous Exposure?**  
Sydney Strickland, PhD, DABCC, Labcorp, RTP, NC

## SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
33228	<b>Microbes Meet Machines: Total Laboratory Automation in Clinical Microbiology</b>	S503	1.5	1.5	<b>B</b>

Moderator *Vincent Streva, PhD, Northwell Health Laboratories, Queens, NY*

- **Digital Bacteriology: Lessons Learned From Implementing the Copan WASPLab Full Lab Automation System**  
*Caitlin Otto, PhD, New York University Tisch Hospital, New York, NY*
- **Adventures in Automation: Navigating Challenges and Successes with the BD Kiestra Total Lab Automation System**  
*Jamie Lemon, PhD, Northwell Health Laboratories, Queens, NY*

33229	<b>Navigating Constitutional Genomic Disorders Throughout the Exome</b>	S504 abc	1.5	1.5	<b>B</b>
-------	---	-------------	-----	-----	----------

*In cooperation with the ADLM Molecular Pathology Division*

- **Building Exome Testing Infrastructure to Explore Clinical Genetic Cases**  
*Joel Lefferts, PhD, DABCC, ABB, Dartmouth-Hitchcock Medical Center, Lebanon, NH*
- **Interpretation of Exome Sequencing to End the Diagnostic Odyssey**

Moderator *Jude Abadie, PhD, DABCC, DABMGG, FADLM, FACMG, Texas Tech University Health Sciences Center, El Paso, TX*

### Visit the Poster Hall

**Tuesday, July 30 | 1:30 p.m. - 2:30 p.m.**

Posters are on display from 9:30 a.m. - 5:00 p.m. in the Poster Hall on the Expo floor. Presenting authors will be in attendance from 1:30 p.m. - 2:30 p.m. Visit the Poster Hall to see the latest science and network with colleagues and thought-leaders from across the world. *Open to all attendees.*

See page 78 for more details.



#### FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

## SPECIAL SESSION

Afternoon | 4:30 p.m. - 6:00 p.m.  
Grand Ballroom (S100)

### How FDA Oversight of LDTs will Affect Patient Care: A Conversation with ADLM, the American Medical Association, the Children's Hospital Association, and a Patient Advocate

The US Food and Drug Administration released a final rule expanding agency oversight of laboratory developed tests (LDTs). This regulatory action will significantly impact patient care, limiting the ability of physicians to order rare and modified diagnostic tests. In addition, the new rule will result in many laboratories discontinuing LDTs, forcing them to send their critical tests offsite and thereby further delaying diagnosis and treatment. Representatives from ADLM, the American Medical Association, and the Children's Hospital Association will discuss how these challenges will affect their members' ability to provide quality patient care. Attendees of this special session will also hear from a caregiver and patient advocate on the importance of LDTs in diagnosing medical conditions. The session will close with a panel of our experts taking questions directly from the audience.

*The ADLM special session on LDTs is open to all conference attendees with a valid ADLM 2024 badge. This includes Chicago All Access, Exhibitor, and Expo only.*

#### MODERATOR:

Octavia Peck Palmer, PhD, FADLM  
University of Pittsburgh Medical Center, Pittsburgh, PA

#### SPEAKERS:

##### The New FDA Rule on LDTs: A Physician Perspective

Geoff Hollett, PhD  
American Medical Association Representative, Chicago, IL

##### What the New FDA Rule Means for Pediatric Care

Meghan Delaney, DO, MPH  
Children's Hospital Association Representative, Washington, DC

##### The Value of LDTs: A Parent's Perspective

Sarah Braswell  
Caregiver and Patient Advocate, Sterling, VA

#### ADDITIONAL PANELISTS:

Olivia Braswell  
Patient Representative, Sterling, VA

Dennis Dietzen, PhD, DABCC, FADLM  
Washington University School  
of Medicine, St. Louis, MO



## JOIN ADLM

Get member-exclusive discounts on educational offerings and meetings like ADLM 2024, access to the popular Member Lounge, and other perks.

Stop by ADLM Booth #1879 for a special membership offer.



### THREE MORE REASONS TO JOIN

- 1. Community:** Reconnect with your colleagues at ADLM meetings, Local Section events, or virtually through The Artery, ADLM's online community.
- 2. Knowledge:** Refresh your knowledge with the latest innovations in clinical laboratory medicine at ADLM 2025, save \$300+ on registration and more. Stay current with webinars, online courses, and Certificate Programs.
- 3. Research:** Access peer-reviewed original research in clinical laboratory medicine through *Clinical Chemistry*, *The Journal of Applied Laboratory Medicine*, *Clinical Laboratory News*, and more.



BRING THE  
WONDER

ADLM  
2025

SEE YOU  
NEXT YEAR  
IN CHICAGO



SAVE THE DATE  
JULY 27-31, 2025  
CHICAGO, IL

# PLENARY+ SCIENTIFIC SESSIONS

WEDNESDAY, JULY 31



**Elia Mears**  
MS, MLS (ASCP)SM

# PLENARY SESSION 14001

**WEDNESDAY, JULY 31**

**8:45 a.m. - 10:00 a.m.**

LOCATION: Grand Ballroom (S100)

LEVEL: Basic

CREDITS: ACCENT: 1.0, CME: 1.0

## Empowering Choice by Providing More Options in HIV Prevention



### **Sharon L. Hillier, PhD**

*Richard Sweet Professor of Reproductive Infectious Disease and Vice-Chair for Faculty Affairs, University of Pittsburgh School of Medicine*

*Departments of Obstetrics, Gynecology and Reproductive Sciences and Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine*

*Director Reproductive Infectious Disease Research, Magee-Womens Research Institute  
Pittsburgh, PA, USA*

Antiretroviral drugs containing a combination of the antiretroviral drugs tenofovir and emtricitabine used as oral daily pre-exposure prophylaxis has effectively reduced HIV in some populations but not others. An injectable form of the drug cabotegravir has been proven to be very effective in preventing HIV, but its expense and availability have limited its impact. Women, especially those living in Sub Saharan Africa who have the highest incidence of HIV, have expressed a preference for a range of products which could better meet their needs. Men who have sex with men and transgender people also have a high incidence of HIV who have expressed a desire for a broader range of prevention options. This session will explore the development of new products for HIV prevention, including those that can be used “on demand” and those that would minimize systemic exposure to antiretroviral drugs.



## ROUNDTABLE SESSIONS

7:30 a.m. - 8:30 a.m. (40000 Series) -or- 12:30 p.m. - 1:30 p.m. (50000 Series)

Location: S406a • Credits: ACCENT: 1.0, CME: Not eligible

Most roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. Coffee is provided and concession stands are available to purchase food.

AM SESSION PM SESSION	TITLE	LEVEL
44101 54201	<b>Delta Check Performance Assessment by Using Real-World Data and Receiver Operating Characteristic Curves</b> <i>Melissa Ulas, MD, PhD, NRCC, SCYM(ASCP), Temple University Health System, Philadelphia, PA</i>	1
44102 54202	<b>Computerized Provider Order Entry Decision Support Tool for Monoclonal Gammopathies Screening</b> <i>Hoi-Ying Yu, PhD, DABCC, FADLM, Geisinger Health System, Danville, PA</i>	B
44103 54203	<b>Prostate-Specific Antigen Testing in Men Under 50: Challenging the Limitations and Shaping the Future of Prostate Cancer Screening</b> <i>Lechuang Chen, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX</i>	B
44104 54204	<b>Enhancing Analytical Testing Efficiency with Sigma Metrics in Emergency Laboratories</b> <i>Amani Gusti, PhD, MSc, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia</i>	1
44107 54207	<b>The Impact of Multiplex Molecular Panel Utilization on the Healthcare Continuum</b> <i>Andrew Fletcher, MD, MBA, CPE, CHCQM, Eutilogic Consulting, Salt Lake City, UT</i>	B
44108 54208	<b>Missing Specimens: Lessons Learned and Continuous Quality Improvement</b> <i>Siew-Kim Ong, BS, MS, MBA, EDD, ASCP, Sengkang General Hospital, Singapore</i>	1
44109 54209	<b>New Electronic Health Record System: CAP Requirements, Validation Process, and Post Go-Live Discoveries</b> <i>Kyle Lund, PhD, DABCC, Landstuhl Regional Medical Center, Reichenbach-Steegen, Germany</i>	B
44110 54210	<b>Optimizing Laboratory Medicine Through Strategic Planning</b> <i>Mahesheema Ali, PhD, NRCC, FADLM, The Metro Health, Cleveland, OH</i>	1
44111 54211	<b>Get More Accomplished: Sharing Ways to Improve Operational Efficiency</b> <i>Susan Dawson, MBA, BA, MT (ASCP), Swedish Hospital part of NorthShore Edwards Elmhurst Health, Chicago, IL</i>	B
44112 54212	<b>Standardizing Vitamin D Tests: Progress and Challenges Observed by the CDC Clinical Standardization Programs</b> <i>Otoe Sugahara, BS, Centers for Disease Control and Prevention, Atlanta, GA</i>	1
44113 54213	<b>Unlocking the Mind: Alzheimer's Disease Biomarkers for Early Detection and Treatment</b> <i>Hannah Brown, PhD, Washington University in St. Louis, St. Louis, MO</i>	B
44114 54214	<b>I Know I Should Use a Reference Material, But How?</b> <i>Karen Phinney, PhD, National Institute of Standards and Technology, Gaithersburg, MD</i>	1

# ROUNDTABLE SESSIONS



AM SESSION PM SESSION	TITLE	LEVEL
44115 54215	<b>How Blood Tests Are Affected by Transfusion or Apheresis</b> <i>Saptarshi Mandal, MD, MS, All India Institute of Medical Sciences, Jodhpur, India</i>	1
44116 54216	<b>The Ever-Increasing Challenges of Detecting and Interpreting Monoclonal Proteins</b> <i>John Oyelakin-Ogunbileje, PhD, MSc, DABCC, NRCC, ASCP(SC), Indiana University, Indianapolis, IN</i>	1
44117 54217	<b>Serology Tests for Celiac Disease Diagnosis in Children</b> <i>Run Zhang Shi, MD, PhD, Stanford Medical Center Clinical Laboratories, Palo Alto, CA</i>	B
44118 54218	<b>Implementing Best Practices for CYP2D6 Pharmacogenetic Testing</b> <i>James Canner, PhD, NRCC, Gravity Diagnostics, Covington, KY</i>	1
44119 54219	<b>Heparin-Induced Thrombocytopenia Testing, Method Selections, and Need of Confirmatory Testing</b> <i>Mustafa Barbhuiya, PhD, UMass Chan Medical School-Baystate Medical Center, South Hadley, MA</i>	A
44120 54220	<b>Capillary Electrophoresis for Hemoglobin Evaluation: A Case-Based Approach to Learning Hemoglobinopathy and Thalassemia Basics</b> <i>Mark Girton, MD, University of Michigan, Ann Arbor, MI</i>	1
44121 54221	<b>Mass Spectrometry Assays for Protein Quantification in the Clinical Laboratory</b> <i>Yanchun Lin, PhD, Washington University in St. Louis, St. Louis, MO</i>	B
44122 54222	<b>A Step-by-Step Guide for Small Molecule LC-MS/MS Method Development and Validation</b> <i>Cody Orahoske, PhD, University of California, San Francisco, San Francisco, CA</i>	B
44123 54223	<b>So, You Want to Test for Fentanyl in Your Lab?</b> <i>Marlen Menlyadiev, PhD, NRCC, Geisinger Health System, Danville, PA</i>	B
44124 54224	<b>Establishing a Toxicology Laboratory: Lessons Learned Along the Way</b> <i>Rejwi Dahal, PhD, DABCC, NRCC, Indiana University School of Medicine, Zionsville, IN</i>	B
44125 54225	<b>Recent Developments in Improving Pediatric Reference Intervals</b> <i>Li Zha, PhD, DABCC, NRCC, Beth Israel Deaconess Medical Center, Boston, MA</i>	B
44126 54226	<b>Newborn Screening and Follow-up for Metabolic Disorders</b> <i>Uttam Garg, PhD, DABCC, NRCC, FABFT, FADLM, Children's Mercy Hospital, Kansas City, MO</i>	1
44127 54227	<b>Advancing Thyroid Function Testing Through the CDC Standardization Programs: Improving Accuracy and Reliability of Measurements</b> <i>Uliana Danilenko, PhD, Centers for Disease Control and Prevention, Atlanta, GA</i>	1
44128 54228	<b>Unraveling the Intricacies of Adrenal Venous Sampling (AVS): Challenges, Best Practices, and the Path Forward in Laboratory Integration</b> <i>Guanmin Chen, PhD, The University of Chicago, Chicago, IL</i>	1

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
34101	<b>International Regulatory Considerations for Laboratory-Developed Tests: Opportunities and Risks for Patient Care</b>	S402	1.5	1.5	<b>B</b>
	<i>In cooperation with the IFCC</i>				
Moderator	<ul style="list-style-type: none"> <li>• <b>Impact of Diagnostic Regulations on Laboratory-Developed Tests in the United States</b> <i>Christina Lockwood, PhD, DABMGG, DABCC, University of Washington, Seattle, WA</i></li> <li>• <b>Regulatory Considerations for Laboratory-Developed Tests From the European Perspective</b> <i>Patrick M. Bossuyt, PhD, University of Amsterdam/Amsterdam UMC, Amsterdam, The Netherlands</i></li> <li>• <b>Off-Label Diagnostics: An Analogy to Individualized Therapeutic Medicine: The Oncology Case</b> <i>Ettore Capoluongo, PhD, University of Naples Federico II, Naples, Italy</i></li> </ul>				
34102	<b>Ensuring Equity and Fairness in Machine Learning and Data Analytics</b>	S403	1.5	1.5	<b>I</b>
	<i>In cooperation with the ADLM Health Equity and Access Division</i>				
Moderator	<ul style="list-style-type: none"> <li>• <b>Conceptualizing and Measuring Algorithmic Fairness</b> <i>Mark Zaydman, MD, PhD, Washington University in St. Louis, St. Louis, MO</i></li> <li>• <b>How Machine Learning Algorithms Incorporate Biases and Make Unfair Predictions</b> <i>Weishen Pan, PhD, Weill Cornell Medicine, New York, NY</i></li> <li>• <b>Strategies and Tools for Engineering Algorithmic Fairness</b> <i>Jenny Yang, MSc, BASC, University of Oxford, Oxford, United Kingdom</i></li> </ul>				
34103	<b>Changing the Sexually Transmitted Infection Control Paradigm: Novel Diagnostic and Treatment Strategies</b>	S404ab	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Changing Access to Sexually Transmitted Infection Diagnostics: Improving Reach With New Technologies and Applications</b> <i>Barbara Van Der Pol, PhD, MPH, University of Alabama at Birmingham, Birmingham, AL</i></li> <li>• <b>Diagnostics and Enhanced Laboratory Approaches to Combat Neisseria Gonorrhoeae Antimicrobial Resistance</b> <i>Olusegun Soge, PhD, MSc, University of Washington, Seattle, WA</i></li> <li>• <b>Anticipating and Monitoring Antibiotic Resistance in the Era of Doxycycline PEP</b> <i>Aniruddha Hazra, MD, University of Chicago Medicine, Chicago, IL</i></li> </ul>				

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
34104	<b>Clinical Laboratory Investigation of Lipid Disorders: A Practical Approach</b>	S404cd	1.5	1.5	<b>I</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Laboratory Tests for Lipid Disorders: Navigating the Panels</b> <i>Tahir Pillay, MD, PhD, University of Pretoria, Pretoria, GP, South Africa</i></li> <li>• <b>Practical Case Studies of Common Dyslipidemias</b> <i>Patrick Twomey, MD, Chemical Pathology, St Vincent's University Hospital, Dublin, Ireland</i></li> <li>• <b>Alignment of Laboratory Testing With Management and Treatment Guidelines for Dyslipidemias</b> <i>Amy Saenger, PhD, DABCC, FADLM, Hennepin County Medical Center, Minneapolis, MN</i></li> </ul>				
34105	<b>Clinical Toxicology in the Courtroom: How to Serve as an Expert Witness</b>	S405	1.5	1.5	<b>I</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Presiding Judge</b> <i>Eric Haner, JD, Kentucky Administrative Office of the Courts, Louisville, KY</i></li> <li>• <b>Defense and Plaintiff Attorney</b> <i>Bo Bolus, JD, Bolus Law Office, Louisville, KY</i> <i>Matthew Gay, JD, Boehl Stopher and Graves, LLP, Louisville, KY</i></li> <li>• <b>Expert Witness</b> <i>Alan Wu, PhD, University of California at San Francisco, San Francisco, CA</i> <i>Saeed Jortani, PhD, DABCC, FADLM, University of Louisville, Louisville, KY</i></li> </ul>				
34106	<b>The Changing Landscape for Cystic Fibrosis Testing and Treatment</b>	S502	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li>• <b>Diagnostic Guidelines and Challenges for Cystic Fibrosis</b> <i>Heather Nelson, PhD, DABCC, ARUP Laboratories, Salt Lake City, UTD</i></li> <li>• <b>The Impact of Novel Therapies on the Laboratory Testing Results: A Collaborative Study With a Cystic Fibrosis Care Center</b> <i>Tatiana Yuzuyuk, PhD, DABMGG, ARUP Laboratories, Salt Lake City, UT</i></li> <li>• <b>Inequalities in Cystic Fibrosis Outcomes and Care</b> <i>Catherine McDonald, PhD, RDN, Primary Children's Hospital, Salt Lake City, UT</i></li> </ul>				

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.


SESSION	TITLE	ROOM	CREDITS:		LEVEL
			ACCENT/CME		
34107	<b>JALM Hot Topics: Current Challenges and Future Promise in Molecular Diagnostics</b> 	S503	1.5	1.5	1
<ul style="list-style-type: none"> <li>• <b>Optimizing Molecular Diagnostics: Stewardship for Precision Testing, Minimizing Costs, and Enhancing Clinical Relevance in Infectious Disease Management</b> <i>Erin Graf, PhD, D(ABMM), Mayo Clinic Arizona, Phoenix, AZ</i></li> <li>• <b>Genomic Data Optimization: Cost-Effective Utilization and Future Opportunities in Germline Sequencing for Enhanced Patient Care and Diagnostic Resolution</b> <i>Ann Moyer, MD, PhD, Mayo Clinic, Rochester, MN</i></li> <li>• <b>Genomic Testing Equity: Ensuring Fair and Inclusive Access for All in the Pursuit of Personalized Healthcare Advancements</b></li> </ul>					
Moderator	<i>Nikoletta Sidiropoulos, MD, University of Vermont Medical Center, Burlington, VT</i>				
34108	<b>Point-of-Care Testing Challenges in Traditional and Non-Traditional Settings</b>	S504 abc	1.5	1.5	1
<ul style="list-style-type: none"> <li>• <b>Documenting Critical Results Without the Laboratory Information System</b> <i>Heather Stieglitz, PhD, DABCC, Ohio State University Medical Center, Columbus, OH</i></li> <li>• <b>Influencing Without Authority: Strengthening Point-of-Care Testing Oversight Across a Healthcare System</b> <i>Nichole Korpi-Steiner, PhD, DABCC, University of North Carolina, Chapel Hill, Chapel Hill, NC</i></li> <li>• <b>Point-of-Care Testing in Unusual Healthcare Settings</b> <i>Sarah Wheeler, PhD, FADLM, University of Pittsburgh Medical Center, Pittsburgh, PA</i></li> </ul>					
Moderator					

### Visit the Poster Hall

Wednesday, July 31 | 1:30 p.m. - 2:30 p.m.

Posters are on display from 9:30 a.m. - 5:00 p.m. in the Poster Hall on the Expo floor. Presenting authors will be in attendance from 1:30 p.m. - 2:30 p.m. Visit the Poster Hall to see the latest science and network with colleagues and thought-leaders from across the world. *Open to all attendees.*

See page 78 for more details.



# SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
34221	<b>Alzheimer's Disease and the New Therapeutic Age</b>	S402	1.5	1.5	<b>B</b>
	<ul style="list-style-type: none"> <li><b>Progress on Therapeutics for Alzheimer's Disease</b> <i>Philip Lee, PhD, FRCPC, St. Paul's Hospital, Vancouver, BC, Canada</i></li> <li><b>Biomarkers in Alzheimer's Disease: Learnings from Clinical Trials</b> <i>Leslie Shaw, PhD, DABCC, Hospital of the University of Pennsylvania, Philadelphia, PA</i></li> <li><b>Genetic and Other Biomarkers for Alzheimer's Disease: Patient and Family Counseling Considerations</b> <i>Emily Dwosh, BEd, MSc, UBC Hospital, Vancouver, BC, Canada</i></li> </ul>				
Moderator					
34222	<b>Best Practices and Innovations in Clinical and Technical Consultation by Medical Laboratory Professionals</b>	S403	1.5	0	<b>B</b>
	<ul style="list-style-type: none"> <li><b>Interpretive Comments, Clinical Decision Support, and Patient-Specific Consults to Improve Health Care Delivery</b> <i>Alejandro Molinelli, PhD, NRCC, St. Jude Children's Research Hospital, Memphis, TN</i></li> <li><b>Best Practices for Actionable and Valuable Medical Laboratory Consultations</b> <i>Nadia Ayala-Lopez, PhD, MLS (ASCP), DABCC, NRCC, Labcorp, Indianapolis, IN</i></li> </ul>				
Moderator					
34223	<b>New Diagnostic Laboratory Assessments in Polycystic Ovary Syndrome</b>	S404ab	1.5	1.5	<b>B</b>
	<ul style="list-style-type: none"> <li><b>Antimullerian Hormone as a Replacement for Ultrasound in the Diagnosis of Polycystic Ovary Syndrome</b> <i>Erica Johnstone, MD, MHS, University of Utah, Salt Lake City, UT</i></li> <li><b>The Polygenic Risk Score for Polycystic Ovary Syndrome: Implications for Comorbidities</b> <i>Corrine Welt, MD, University of Utah School of Medicine, Salt Lake City, UT</i></li> <li><b>11-Oxygenated Androgens in the Diagnosis of Polycystic Ovary Syndrome and Congenital Adrenal Hyperplasia</b> <i>Richard Auchus, MD, PhD, University of Michigan, Ann Arbor, MI</i></li> </ul>				
Moderator					



**FIND SESSION DESCRIPTIONS.  
STAY UP TO DATE.**

Download the mobile app at  
[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

## SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
34224	<b>Confronting a New Wave of Opioid Overdoses Through Surveillance Testing: Public Health Initiatives, Wastewater Epidemiology, and Comprehensive Drug Checking Analysis</b>	S404cd	1.5	1.5	B

*In cooperation with the ADLM TDM and Toxicology Division*

- **Wastewater-Based Epidemiology for Population Level Substance Use Surveillance**  
*Peter Chai, MD, MMS, Brigham and Women's Hospital, Boston, MA*
- **Insights From Biosurveillance: A Laboratory-Based Approach for Combating Rhode Island's Opioid Epidemic**  
*Louis Marchetti, PhD, TC(NRCC), Rhode Island State Health Laboratories, Providence, RI*
- **High Resolution Mass Spectrometry Comprehensive Drug Testing to Characterize Local Drug Supply**

Moderator *Adina Badea, PhD, DABCC, Lifespan Health/Rhode Island Hospital/Brown University, Providence, RI*

34225	<b>Adventures in Clinical Decision Support: Interactive Cases in Laboratory Stewardship</b>	S501 abc	1.5	1.5	B
-------	---	----------	-----	-----	---

- **Antibody Autopilot: CDS Solutions for Paraneoplastic Autoantibody Evaluations**  
*Robert Nerenz, PhD, DABCC, Medical College of Wisconsin, Milwaukee, WI*
- **Order Incontinence: CDS Solutions for Clostridium Difficile Testing**
- **Stop the Bleeding: CDS Solutions for Peripheral Smear Review Requests**  
*Joseph Rudolf, MD, University of Utah School of Medicine, Salt Lake City, UT*

Moderator *Ronald Jackups, MD, PhD, Washington University in St. Louis, St. Louis, MO*



### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.



### FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

## SCIENTIFIC SESSIONS

Afternoon | 2:30 p.m. - 4:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
34226	<b>Academy Conversations Between Clinical Laboratorians and Clinicians: Ideal Laboratory Report of Cervical Cancer Detection and Calculation of CIN3+ Risk</b>	S502	1.5	1.5	<b>I</b>
<i>In cooperation with the Academy of Diagnostics &amp; Laboratory Medicine</i>					
	<ul style="list-style-type: none"> <li><b>Ideal Laboratory Report for Cervical Cancer Detection and Calculation of Cervical Precancer or Cancer (CIN3+) Risk</b> Moderator <i>Yusheng Zhu, PhD, DABCC, Pennsylvania State University Hershey Medical Center, Hershey, PA</i></li> <li><b>Interpretation of Risk of Cervical Precancer or Cancer (CIN3+) and Individualized Patient Management Based on Risks</b> <i>Annie Leung, MD, McGill University Health Centre, Montreal, QC, Canada</i></li> </ul>				
34227	<b>The Anatomy of the Grey Zone: Ambiguous Immunofixation/Immunotyping Results and How to Objectively Approach Interpretation</b>	S503	1.5	1.5	<b>I</b>
<i>In cooperation with the ADLM Clinical and Diagnostic Immunology Division</i>					
	<ul style="list-style-type: none"> <li><b>Three's Company: Electrophoresis (Gel and Capillary) and Mass Spectrometry for the Detection and Isotyping of Monoclonal Proteins</b> <i>Ria Fyffe-Freil, PhD, University of Nebraska Medical Center, Omaha, NE</i></li> <li><b>So, You're New Here? A Case-Based Approach to the Initial Detection of Monoclonal Gammopathies and Equivocal Isotyping Results</b> Moderator <i>Robert Maynard, PhD, NRCC, University of Kentucky, Lexington, KY</i></li> <li><b>In It for the Long Haul: Your Toolbox for Accurately Detecting Remission and Relapse While Monitoring Patients With Monoclonal Gammopathies</b> <i>Shelby Hutcherson, PhD, DABCC, Memorial Sloan Kettering Cancer Center, New York, NY</i></li> </ul>				
34228	<b>Current and Future State of Metagenomics for Infectious Diseases Testing</b>	S504 abc	1.5	1.5	<b>I</b>
<i>In cooperation with the Consortium for Clinical Metagenomics in Infectious Diseases</i>					
	<ul style="list-style-type: none"> <li><b>Leveraging Clinical Impact With Metagenomic Testing</b> <i>Esther Babady, PhD, D(ABMM), FIDSA, Memorial Sloan Kettering Cancer Center, New York, NY</i></li> <li><b>Roadmap for the Future: Evidence Generation and Optimizing Diagnostic Integration</b> Moderator <i>David Gaston, MD, PhD, Vanderbilt University Medical Center, Nashville, TN</i></li> </ul>				

## Become a Member

### THREE GREAT REASONS TO JOIN THE ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (ADLM)


1. **Knowledge and Innovation** — access practical, clinically relevant resources you need to transform healthcare and advance your career.
2. **Collaborations and Connections** — rely on your community for learning, idea exchange, mentoring, and building enduring relationships.
3. **Better Patient Health** — be well-prepared and well-connected to develop effective solutions to improve patient health, and flourish professionally and personally.

Stop by ADLM Booth #1879 for a special membership offer.  
[myadlm.org/joinASM24](http://myadlm.org/joinASM24)



## ePoster Access

Visit the ePoster stations in the Poster Hall to browse the ePosters, which are available for all presented posters. Stop by at 12:30 pm or 2:30 pm to see ePosters Discussions, composed of select ePosters presented in a small group discussion setting. Chicago All Access attendees can also view ePosters anytime from now through August 30 by visiting [meeting.myadlm.org/ePosters](http://meeting.myadlm.org/ePosters) and signing in with their badge information.



### CLAIM CE BY OCT 31

Evaluate sessions and claim ACCENT and/or CME credit by October 31. Scan the code or visit [meeting.myadlm.org/claimcredits](http://meeting.myadlm.org/claimcredits).

## SPECIAL SESSION

Afternoon | 4:00 p.m. - 5:00 p.m.  
Expo Hall Theater

### 2024 Laboratory Feud: BOD vs SYCL

Celebrate innovation, evolution, and progress with Laboratory Feud. This year, the association is once again hosting its ever-popular annual Laboratory Feud — a special gameshow style event. Two teams will be made up of ADLM members who are members on the Board of Directors (BOD) or the Society for Young Clinical Laboratorians (SYCL), and will compete in a Family Feud-style game format, in a throwback to the original match-up used the first year of the competition. The questions will cover various areas of laboratory medicine including molecular testing, nutrition, hematology, biomarkers, point-of-care testing, MS tests, data analytics, therapeutic drugs, and more. Don't miss out — join us for this special event and play along with the BOD vs SYCL Laboratory Feud!

#### MODERATOR

Paul J. Jannetto, PhD, MT (ASCP), DABCC, FADLM, *Mayo Clinic, Rochester, MN*

#### TEAM BOD

##### Team Captain

Bonny Van

*J Michael Consulting LLC*

##### Team Members

Daniel Holmes

*St Paul's Hospital, Providence Health Care*

Laura Parnas

*Roche Diagnostics Corporation*

Joe El-Khoury

*Yale University*

#### TEAM SYCL

##### Team Captain

Yachana Kataria

*Boston Medical Center*

##### Team Members

Caroline Nottingham

*National Institutes of Health*

David Shiembob

*ARUP Laboratories*

David Maciak

*Washington University in St. Louis*



# PLENARY+ SCIENTIFIC SESSIONS

THURSDAY, AUGUST 1

**Koby Sarpong**  
PhD



## PLENARY SESSION 15001

**THURSDAY, AUGUST 1**

**8:45 a.m. - 10:00 a.m.**

LOCATION: Grand Ballroom (S100)

LEVEL: Basic

CREDITS: ACCENT: 1.0, CME: 1.0

### **Projected Health and Social Consequences of Ending the Federal Protection for Abortion in the United States**



**Diana Greene Foster, PhD (she/her/hers)**

*Professor in Residence*

*UCSF Obstetrics, Gynecology and Reproductive Sciences*

*Advancing New Standards in Reproductive Health (ANSIRH)*

*San Francisco, CA, USA*

This presentation will discuss the changing landscape of abortion law since the Dobbs decision in June 2022 and how this legal change affects access to care. With the closure of legal clinics across much of the Midwest and southern United States, people are traveling large distances and ordering medication abortion pills online. We will discuss the consequences for people who are unable to get an abortion and instead carry an unwanted or unsafe pregnancy to term, based on data from the Turnaway Study collected from nearly 1,000 pregnant people that presented for care at 30 abortion facilities across the United States. We will present mental health, physical health, and socioeconomic consequences for people who received abortions versus carry pregnancies to term, as well as for their children. Finally, we will discuss whether clinical laboratories may be called to test for use of abortion medications among pregnant people who present for care for miscarriage.

## SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
35101	<b>Effective Communication with C-Suite Executives: A Chief of Operations and a Department Chair Perspective</b>	S402	1.5	1.5	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li> <b>Overview of Healthcare Leadership Structure and C-Suite Functions</b>  <i>Victoria Zhang, PhD, MBA, DABCC, FADLM, University of Rochester Medical Center, Rochester, NY</i> </li> <li> <b>Effective Communication With Hospital C-Suite Executives: A Chief of Operations Perspective</b>  <i>Kathy Parrinello, PhD, RN, University of Rochester Medical Center, Rochester, NY</i> </li> <li> <b>Effective Communication With Hospital C-Suite Executives: A Department Chair Perspective</b>  <i>Bruce Smoller, MD, University of Rochester Medical Center, Rochester, NY</i> </li> </ul>				
35102	<b>Preeclampsia in the Unites States: Clinical Details, Best Practices in Laboratory Medicine, and Impact of Foundational Support</b>	S403	1.5	0	<b>B</b>
	<i>In cooperation with the ADLM Pediatric and Maternal-Fetal Division</i>				
Moderator	<ul style="list-style-type: none"> <li> <b>Clinical Features and Presentation of Preeclampsia</b>  <i>Emily Rosenfeld, DO, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ</i> </li> <li> <b>Laboratory Testing to Screen Women for Development of Preeclampsia and Progression to Severe Features</b>  <i>Sydney Strickland, PhD, DABCC, Labcorp, RTP, NC</i> </li> <li> <b>Current State of Preeclampsia Within the US</b>  <i>Laney Poye, MIA, Preeclampsia Foundation, Melbourne, FL</i> </li> </ul>				
35103	<b>Primer on Regulatory Aspects of In Vitro Diagnostics: How to Make Sense of the Alphabet Soup</b>	S404ab	1.5	0	<b>B</b>
Moderator	<ul style="list-style-type: none"> <li> <b>Premarket Approvals and 510(k)s: How Commercial Diagnostics Work Their Way Through the US FDA Process</b>  <i>Salvatore Salamone, PhD, Saladax Biomedical Inc, Bethlehem, PA</i> </li> <li> <b>CPTs, PLAs, and the CLFS: How Clinical Test Reimbursement is Determined</b>  <i>William Clarke, PhD, MBA, DABCC, FADLM, Johns Hopkins University School of Medicine, Eldersburg, MD</i> </li> <li> <b>LDTs, CLIA, and the FDA: The Regulatory Landscape and the Implications of Change</b>  <i>Stephen Master, MD, PhD, FADLM, Children's Hospital of Philadelphia, Philadelphia, PA</i> </li> </ul>				

# SCIENTIFIC SESSIONS

Morning | 10:30 a.m. - 12:00 p.m.

SESSION	TITLE	ROOM	CREDITS: ACCENT/CME		LEVEL
35104	The Toxicological Problem Accumulating Inside of Us All: Breaking Down the Uses, Abuses, and Growing Public Health Concerns over PFAS	S404cd	1.5	0	B

Moderator *Frederick Strathmann, PhD, MBA, DABCC, MOBILion, Chadds Ford, PA*

- **The Use of High Resolution Mass Spectrometry for the Discovery of Novel PFAS**  
*Mark Strynar, PhD, US Environmental Protection Agency, RTP, NC*
- **PFAS Human Exposure, Health Impacts, Consumer Product Testing, and Risk Communication**  
*Jenna Hua, PhD, Million Marker, El Cerrito, CA*
- **PFAS Pharmacokinetics and Laboratory Monitoring**  
*Laura Labay, PhD, ABFT, DABCC, NMS Labs, Horsham, PA*

35105	The Use of Intelligent Algorithms and AI in Pathology: Applications and Apprehensions	S501 abc	1.5	1.5	B
-------	---	----------	-----	-----	---

- Moderator *Lauren Starbrook, MSc, DClinSci, New Cross Hospital, Wolverhampton, United Kingdom*
- **Intelligent Algorithms in Biochemistry: Improving the Diagnosis of Familial Hypercholesterolaemia**
  - **Leveraging Machine Learning to Improve Detection of Analyzer Errors in a Busy Automated Laboratory**  
*Tejaskumar Kalaria, MD, MRCP, FRCPath, Wolverhampton, United Kingdom*
  - **Is ChatGPT Capable of Producing Court-Ready Reports in Post-Mortem Cases?**  
*Kate Rice-Davies, University Hospitals Leicester NHS Trust, Leicester, United Kingdom*

35106	A Pathway Towards Greater Sustainability in Lab Medicine	S503	1.5	1.5	B
-------	--	------	-----	-----	---

- Moderator *Joe Wienczek, PhD, DABCC, NRCC, FADLM, Vanderbilt University Medical Center, Nashville, TN*
- **Advancing Sustainability Practices in Clinical Chemistry**
  - **Tools for Building a Global Culture of Sustainability in Science**  
*James Connelly, My Green Lab, Spokane, WA*
  - **Exploring the Paradox of Harming Health by Delivering Health Care**  
*Ilyssa Gordon, MD, PhD, Cleveland Clinic, Cleveland, OH*



## FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

## SPECIAL EVENT

Morning | 7:30 a.m. - 10:00 a.m.  
Room S504

### 22nd Annual Point-of-Care Coordinators Forum

The POCC Forum hosted by the Critical and Point-of-Care Testing Division will discuss the role of POC in:

1. Driving big changes in operations, including accreditation compliance.
2. Setting up new locations to improve efficiency in health systems.
3. Generating data utilized for patient care improvement.



*Ticketed Event*



#### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.



# POSTER ABSTRACTS TITLES

TUESDAY, JULY 30 &  
WEDNESDAY, JULY 31



**Jingcai Wang**  
MD, PhD, CC(NRCC),  
MLS (ASCP)SH


## SCIENTIFIC POSTER SESSION SCHEDULE

Posters of accepted abstracts are on display in the Poster Hall on the Expo show floor of the McCormick Place Convention Center on Tuesday, July 30, & Wednesday, July 31. ePoster stations are also available in the Poster Hall to browse the ePosters for all presented posters.

### POSTER HALL EVENTS SCHEDULE:

#### Tuesday, July 30 & Wednesday, July 31

- 9:30 a.m. - 5:00 p.m. – Posters displayed, according to the topic schedule below.
- 12:30 p.m. - 1:30 p.m. – ePoster discussions organized by ADLM Divisions.
- 1:30 p.m. - 2:30 p.m. – Posters presented by first/presenting author.
- 2:30 p.m. - 3:30 p.m. – ePoster discussions organized by ADLM Divisions. (Wednesday, July 31 only)

**ADLM**  **ACADEMY** Posters are listed with their first/presenting author. Full author information is available in the mobile app. Posters that received the Academy's Distinguished Abstract Award are designated with the ADLM Academy icon.

Poster abstracts have been reproduced without editorial alteration from the materials supplied by the authors. Infelicities of preparation, grammar, spelling, style, syntax, and usage are the authors'.

Use of video and photographic equipment is prohibited in the Poster Hall except for photography specifically authorized by the ADLM Annual Meeting. Photography of posters is permitted only with express permission of the presenting author.

*Check the mobile app for full poster details, including abstracts.*

### POSTER SESSION TOPICS & SCHEDULED TIMES

#### TUESDAY, JULY 30 | 9:30 a.m. - 5:00 p.m.

Cardiac Markers	A-001 – A-023
Endocrinology and Metabolism	A-024 – A-082
General Clinical Chemistry and Laboratory Medicine	A-083 – A-138
Hematology and Coagulation	A-140 – A-176
Laboratory Management and Patient Safety	A-177 – A-209
Lipids, Lipoproteins, and Cardiovascular Risk Factors	A-210 – A-231
Microbiology and Infectious Disease	A-232 – A-303
Pediatric and Maternal Fetal Medicine	A-306 – A-321
Point-of-Care Testing	A-323 – A-370

#### WEDNESDAY, JULY 31 | 9:30 a.m. - 5:00 p.m.

Animal Clinical Chemistry	B-001 – B-004
Automation and Analytical Techniques	B-005 – B-040
Clinical and Diagnostic Immunology	B-043 – B-105
Data Analytics, Informatics, and Statistics	B-107 – B-144
Mass Spectrometry and Separation Sciences	B-146 – B-182
Molecular Diagnostics and Genetics	B-183 – B-237
Proteomics and Protein Markers	B-240 – B-256
Therapeutic Drug Monitoring and Toxicology	B-257 – B-304
Tumor Markers and Cancer Diagnostics	B-305 – B-358

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### CARDIAC MARKERS

- A-001** The Postprandial Levels of the Metabolites in the Metaorganismal Trimethylamine N-Oxide (TMAO) Pathway are Altered in a Diet-, Microbe-, and Sex-Specific Manner  
G. Hamilton, *Department of Cancer Biology, Lerner Research Institute of the Cleveland Clinic, Cleveland, OH*
- 
- A-002** Analytical Validation of the Zybio High Sensitivity Cardiac Troponin I CLIA Assay  
T. Ma, *Zybio, Inc, Chongqing, China*
- 
- A-003** Beckman Coulter Dxl 9000 Immunoassay Analyzer's High Sensitivity Troponin I Achieves >90% Six Sigma Performance When Assessed Against CLIA 2024 Performance Goals  
S. Westgard, *Westgard QC, Madison, WI*
- 
- A-004** Clinical and Laboratory Validation of the Atellica® vTLi Analyzer for Diagnosis of Myocardial Infarction Through High Sensitivity Cardiac Troponin I (hs-cTnI) Measurement  
B. C. Ozaki, *Siemens Healthineers, São Paulo, Brazil*
- 
- A-005** Comparison of Performance of High Sensitive Troponin I (cTNIH) by "Point-of-Care" (POC) and Automated cTNIH Immunoassays in Patients at Low Risk of Heart Attack in a Chilean Emergency Unit; Impact on E.R Department Efficiency  
B. C. Ozaki, *Siemens Healthineers, São Paulo, Brazil*
- 
- A-006** Elevated Circulating High-Sensitivity Cardiac Troponin I in Obesity and Overweight Individuals Without Cardiovascular Disease  
J. Zhao, *Medical Affairs, Core Diagnostics Abbott, Shanghai, China*
- 
- A-007** Establishing a Reference Interval for Soluble ST2 in Healthy Chinese Adults and its Analytical Performance in Chronic Kidney Disease Coexisting with Heart Failure  
S. Li, *Handan Central Hospital, Hebei Medical University, Handan, China*
- 
- A-008** Verification of Interchangeability of Results for High-Sensitivity Troponin (TNIH) Between Atellica Solution® and Atellica CI® Analyzers  
M. Ruiz-Alvarez, *Principe De Asturias University Hospital, Alcala De Henares, Spain*
- 
- A-009** Analytical Characterization of a Novel NT-proBNP Assay on a Central Laboratory Platform  
R. H. Christenson, *University of Maryland School of Medicine, Baltimore, MD*
- 
- A-010** Development and Diagnostic Utility of Immunoturbidimetric NT-proBNP Assay Based on Antibodies Targeting Glycosylation-Free Regions of NT-proBNP  
A. Havelka, *Gentian AS, Moss, Norway*
- 
- A-011** Single High-Sensitivity Cardiac Troponin I Compared to High-Sensitivity Cardiac Troponin T Measurement to Rule Out Acute Myocardial Infarction at Low Risk for 30-Day Adverse Events: CONTRAST Study  
F. S. Apple, *Hennepin Healthcare/HCMC, Minneapolis, MN*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## CARDIAC MARKERS

- A-012 Predictive Value of Baseline Alpha Defensin Level in Patients with Stable Coronary Artery Disease: A Retrospective Single Center Study**  
M. Shapira, *Hillel Yaffe Medical Center, Hadera, Israel*
- 
- A-013 Unlocking the Prognostic Power of CA125 in Heart Failure: Insights from an ABEI-Based Assay Study**  
D. Gruson, *Cliniques Universitaires St-Luc, Kraainem, Belgium*
- 
- A-014 Fifth Generation Troponin T is Unaffected by Extreme Levels of Lipemia and Icterus**  
J. A. Zakrajsek, *Cleveland Clinic, Cleveland, OH*
- 
- A-015 Changes of sST2 and NT-proBNP Levels Predict Early Cardiovascular Toxicity in Breast Cancer Patients Treated With Anthracycline-Containing Chemotherapy**  
C. Chen, *Fudan University Shanghai Cancer Center, Shanghai, China*
- 
- A-016 Can You Believe Your Troponin? Using Laboratory Automation and Programmed Rules to Reduce Non-Repeatable False Positive Troponin Results**  
B. Cook, *Henry Ford Hospital, Detroit, MI*
- 
- A-017 Clinical Performance Evaluation of the Atellica IM High-Sensitivity Troponin I Assay to Aid in Risk Stratification for All-Cause Mortality and Major Adverse Cardiac Events**  
T. Kampfrath, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-018 Diagnostic Performance of the Novel Beckman-Coulter NT-proBNP-assay in the Early Diagnosis of Acute Heart Failure**  
A. Hammerer-Lercher, *Institute of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland*
- 
- A-019 Unexpectedly High Cardiac Troponin Values in Healthy Athletes After SARS-CoV-2 Infection**  
A. Hammerer-Lercher, *Institute of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland*
- 
- A-020 Evaluation of the QuidelOrtho Diagnostics Vitros NT-proBNP II Assay**  
E. K. Leung, *Children's Hospital Los Angeles, Los Angeles, CA*
- 
- A-021 Evaluation of a Novel N Terminal Pro B Type Natriuretic Peptide Assay as an Aid in the Diagnosis of Acute Heart Failure in the Emergency Department**  
W. F. Peacock, *Baylor College of Medicine, Houston, TX*
- 
- A-022 A Pilot Study Evaluating NT-proBNP and hs-cTnI Levels in Pneumoconiosis Patients With and Without Cardiovascular Diseases**  
Q. He, *West China Fourth Hospital, Sichuan University, Chengdu, China*
- 
- A-023 Early Concentrations of Long Cardiac Troponin T Forms in Myocardial Infarction Patients**  
S. Wittfooth, *Biotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland*
-

**SCIENTIFIC POSTER SESSIONS**

9:30 a.m. - 5:00 p.m.

**ENDOCRINOLOGY & METABOLISM**

- A-024 Evaluation of the Correlation of Homeostasis Model Assessment of Insulin Resistance Index (HOMA IR) with Other Insulin Resistance Indices Based on Glucose and Lipid Metabolism**  
M. H. Castelo, *Dasa, Brasil; Instituto de Ensino e Pesquisa Dasa, Brazil, Fortaleza, CE, Brazil*
- 
- A-025 Cortisol Levels in Stimulation Tests: Is the Cutoff Point the Same for All Types of Stimuli?**  
M. C. Gurgel Castelo, *DASA, Brazil, Instituto de Ensino e Pesquisa, DASA, Brazil, Rio de Janeiro, Brazil*
- 
- A-026 Comparative Analysis of the Lipid Profile and Anthropometric Parameters of Brazilian Patients With Familial Chylomicronemia Syndrome Caused By Different Mutations**  
M. Helane Costa Gurgel Castelo, *Dasa and SBPC/ML, São José, Brazil*
- 
- A-027 Morning Salivary Cortisol and Cortisone By a Liquid Chromatography — Mass Spectrometry (LC-MS/MS) as a Promising Tool for the Diagnosis of Adrenal Insufficiency: Patient Friendly and With Analytical Advantages**  
M. C. Castelo, *Dasa, Brazil, Instituto de Ensino e Pesquisa Dasa, Brazil, Rio de Janeiro, Brazil*
- 
- A-028 Evaluation of the Analytical Performance Iron3, Vitamin B12, and Homocysteine Assays on the Atellica CI Analyzer**  
J. Frenna, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-029 Evaluation of the Analytical Performance of Four Assays Used for Diabetes on the Atellica CI Analyzer**  
J. Frenna, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-030 Evaluation of the Analytical Performance of Two Reproductive Endocrinology Related Assays on the Atellica CI Analyzer**  
M. Quintanilla, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-031 Development of Novel ELISAs for Total GDF-15 and H-specific GDF-15**  
B. Kalra, *Ansh Labs, Webster, TX*
- 
- A-032 Accuracy of Immunoassay Testosterone Assays in Low Testosterone Patients**  
M. Deebajah, *University of Pittsburgh Medical Center, Pittsburgh, PA*
- 
- A-033 Comparison of the Roche hCG STAT and hCG+ $\beta$  Assays**  
O. Chukwudebe, *Staten Island University Hospital, Staten Island, NY*
- 
- A-034 Evaluation of the Analytical Performance of Five Chemistry Assays on the Atellica CI Analyzer**  
S. Lewisch, *Siemens Healthcare Diagnostics Inc., Newark, DE*
- 
- A-035 Profiling of Circulating-microRNAs' Signatures in Pre-diabetic Versus Diabetic Patients**  
G. Rashid, *Meir Medical Center, Kfar-Saba, Israel*
- 
- A-036 Prevalence of Euthyroid Hypothyroxinaemia, Primary Hypothyroidism, Sub-Clinical Hyperthyroidism and Anti-TPO Positivity Among Infertile Women in South-Western Nigeria**  
T. A. Adedeji, *Obafemi Awolowo University, Ile-Ife, Nigeria*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## ENDOCRINOLOGY & METABOLISM

- A-037 A1c by Separation And Enzymatic Methods: What's The Difference?**  
S. Campbell, *Montefiore Medical Center, Bronx, NY*
- 
- A-038 Interlaboratory Comparison of Parathyroid Hormone Analytical Results Across Clinical Assays from 8 Manufacturers — Steps Towards Standardization**  
G. S. Lee, *CDC, Atlanta, GA*
- 
- A-039 Parathyroid Hormone and Vitamin D Follow an Inversely Correlated Serum Level**  
S. Islam, *Albany Medical Center, Albany, NY*
- 
- A-040 Association of GATA-4 and Platelet Derived Growth Factor-B in Metabolic (Dysfunction) Associated Fatty Liver Disease**  
H. J. All India Institute of Medical Sciences, *Delhi, New Delhi, India*
- 
- A-041 Metoclopramide Stimulation Test Can Rule Out Prolactinoma in Patients with Moderate Hyperprolactinemia**  
Á. González, *Clínica Universidad de Navarra, Pamplona, Spain*
- 
- A-042 Assessment of Known and Newly Discovered IGF-1 Variants by a High-throughput Clinical Reference Laboratory**  
I. Motorykin, *Quest Diagnostics Nichols Institute, San Juan Capistrano, CA*
- 
- A-043 A Fast, Novel and Analytically Sensitive Clinical Research Method for the Analysis of Free Testosterone Using UPLC-MS/MS**  
L. Calton, *Waters Corporation, Wilmslow, United Kingdom*
- 
- A-044 Hypogonadism in Diabetic Patients**  
D. Sheriff, *Anna Medical College, Mauritius, Mauritius*
- 
- A-045 Analytical and Clinical Evaluation of A1c Test by HPLC — Lifotronic™ H100Plus Analyzer — in a Brazilian Clinical Laboratory**  
D. Canali, *Diagnóstico da América, São José, Brazil*
- 
- A-046 Quantification of Corticosteroids and Androgens in Serum, Utilizing Waters MassTrak™ Steroid Serum Sets 2 & Sets 3 for Clinical Research**  
L. Moran, *Waters Technology, IDA Business Park, Drinagh, Wexford, Y35 D431, Ireland*
- 
- A-047 Comparison of Two Immunoassays for Measuring Anti-Mullerian Hormone**  
W. Tamimi, *King Abdulaziz Medical City, Riyadh, Saudi Arabia*
- 
- A-048 Reference Interval and Clinical Performance Studies for Vitros® Immunodiagnostic Products Intact PTH II Assay to Aid in Diagnosis of Calcium and Parathyroid Disorders and Intraoperative Testing**  
B. M. Hirsch, *QuidelOrtho, Rochester, NY*
- 
- A-049 Effect of Supplementation With Prebiotics on Levels of 25-Hydroxy Vitamin D and on Biomarkers of Bone Remodelling-Results From the OSTEOME Clinical Trial**  
K. Makris, *Diamedica PC, Athens, Greece*
- 
- A-050 Reference Intervals for Plasma Concentrations of C-Terminal Telopeptide of Type-I Collagen (CTX) for Greek Adult Population**  
K. Makris, *KAT General Hospital, Kifissia, Greece*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### ENDOCRINOLOGY & METABOLISM

- A-051 Validation and Implementation of the Stanbio Beta-Hydroxybutyrate Assay on Roche c502 Analyzer**  
K. Nogier, *Saskatchewan Health Authority, Saskatoon, Canada*
- 
- A-052 Clinical Usefulness of ADAMS A1c HA-8190V Automatic Switching Mode for the HbA1c Measurement in Hb Variants**  
Y. Yun, *Konkuk University School of Medicine, Seoul, Korea, Republic of*
- 
- A-053 Evaluation of the Analytical Performance of Atellica CH Prealbumin and  $\beta$ 2-Microglobulin Chemistry Assays on the Atellica CI Analyzer**  
J. Huff, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-054 Vitamin D Status of Adults and its Relationships With Gender, Age, and Season in Guizhou Province**  
S. Wei, *Affiliated Hospital of Guizhou Medical University, Guiyang, China*
- 
- A-055 Urinary Iodine Concentration and Thyroid Function in Pregnant Women in Eastern Nepal**  
A. Nepal, *BP Koirala Institute of Health Sciences, Dharan, Nepal*
- 
- A-056 Investigating Iodine Contrast Contamination in Cortisol and Aldosterone Samples**  
K. Troike, *Cleveland Clinic, Cleveland, OH*
- 
- A-057 Assessing Direct Renin Stability in EDTA Plasma Prior to Separation from Cells and Post-thaw**  
K. Troike, *Cleveland Clinic, Cleveland, OH*
- 
- A-058 Biomarkers of Nephropathy and the Angiotensin Converting Enzyme Insertion and Deletion Gene Polymorphisms Among Type 2 Diabetes Mellitus Patients at a Tertiary Hospital in Uganda**  
R. Kiconco, *Mbarara University of Science and Technology, Mbarara, Uganda*
- 
- A-059 Validation of Self-Collected Capillary Dried Blood Spot Collection for Clinical HbA1c Testing**  
A. Naranjo, *LetsGetChecked Labs, Monrovia, CA*
- 
- A-060 Assessing Glucose Stability: A Comparison of Citrate/NaF, NaF, and Gel Separator Vacuum Tubes in Routine Medical Laboratory Practice**  
S. Kosova, *Çaycuma State Hospital, ÇAYCUMA, Turkey*
- 
- A-061 Analytical Performance and R55G Mutant Detection Ability of an Improved Thyroid-Stimulating Hormone Assay, TSH3-Ultra II, on the ADVIA Centaur Immunoassay System and the Atellica IM Analyzer**  
J. Rhea-Mcmanus, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-062 Determination Neonatal 17-Hydroxyprogesterone Cutoff Levels for Congenital Adrenal Hyperplasia in Korea: 3 Years' Experience**  
Y. Yoon, *Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea, Republic of*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## ENDOCRINOLOGY & METABOLISM

- A-063 Correlation of 1,5-anhydroglucitol (AG) with A1c: Understanding This Relationship in Terms of an Established Physiological Model for AG Mass Balance as a Function of [Glucose]**  
D. Stickle, *Jefferson University Hospital, Philadelphia, PA*
- 
- A-064 Improved Insulin Production in Advanced Glycation End-products (AGEs)-induced RIN-m5F Pancreatic  $\beta$ -cells by Using a Flavonoid-Rich Medicinal Plant, Kaempferia Parviflora Treatment**  
K. Chumroonsiri, *Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand*
- 
- A-065 The CDC HoSt Certification Requirements Have Been Met for More Than Four Years by the Atellica IM, ADVIA Centaur Testosterone II and Dimension Vista LOCI Total Testosterone Immunoassays**  
C. Abou-Diwan, *Siemens Healthineers, Tarrytown, NY*
- 
- A-066 Does Essential Fatty Acid Deficiency Alter Ethanolamine Plasmalogen Concentrations in Red Blood Cells? Implications for Clinical Testing**  
I. De Biase, *Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT*
- 
- A-067 Simultaneous Measurement of Aldosterone and Plasma Renin Activity in Human Serum Using Liquid Chromatography Coupled to Tandem Mass Spectrometry for Clinical Research**  
G. Oliviero, *Waters Corporation, Wexford, Ireland*
- 
- A-068 Development of GIP ELISAs: The Next Level of Diabetes Management**  
A. Kumar, *Ansh Labs, Webster, TX*
- 
- A-069 Measurement of VitD in Patients with Multiple Myeloma: High Concentrations of Paraproteins in the Serum Could Analytically Affect the Results of the Assay?**  
A. E. Kozak, *Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*
- 
- A-070 Evaluation of Plain and Serum-Separator Blood Collection Tubes for the Measurement of Steroid Hormones by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)**  
U. Garg, *Children's Mercy Hospital, Kansas City, MO*
- 
- A-071 Macroprolactin Screening in Patients with Hyperprolactinemia: Comparison Between Different Criteria for Defining Macroprolactinemia**  
A. Correa Wengerkievicz Lopes, *DASA; Instituto de Ensino e Pesquisa Dasa, Rio de Janeiro, Brazil*
- 
- A-072 Growth Hormone Stimulation Tests: Experience of a Large Cohort From a Brazilian Diagnostic Medical Center**  
A. Correa Wengerkievicz Lopes, *Dasa and SBPC/ML, São Jose, Brazil*
- 
- A-073 Is There a Relationship of Fib 4 With Weight and Insulin Resistance In Subjects Without Type 2 Diabetes and With Normal Transaminases?**  
A. Correa Wengerkievicz Lopes, *Dasa, Instituto de Ensino e Pesquisa Dasa, São Paulo, Brazil*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### ENDOCRINOLOGY & METABOLISM

- A-074 A Laboratory Developed Serum Anti-Mullerian Hormone Electrochemiluminescent Immunoassay: Performance and Retrospective Analysis of Over 2.2 Million Tests in Females and Males Across Lifespan**  
D. Alfego, *Labcorp, Durham, NC*
- 
- A-075 Comparability of Free Testosterone Measurements — Results of the Interlaboratory Study**  
U. Danilenko, *Centers for Disease Control and Prevention, Atlanta, GA*
- 
- A-076 Basal Luteinizing Hormone (LH) but not Anti-Mullerian Hormone (AMH) as a Promising Screening Biomarker in Girls with Central Precocious Puberty**  
O. A. Abdelkarem, *Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt*
- 
- A-077 Evaluation of Diagnostic Thresholds for Adrenal Insufficiency Post-Cosyntropin Stimulation: Assessment Using Siemens Atellica Cortisol Immunoassay**  
S. Li, *The Ohio State University, Columbus, OH*
- 
- A-078 Harmonization of Immunoassay Reference Intervals with LC-MS/MS for Total and Calculated Free Testosterone Measurement**  
S. Li, *The Ohio State University, Columbus, OH*
- 
- A-079 Investigation of Gut Microbial Flavonoid Catabolites in Metabolic Diseases**  
S. Alqudah, *Cleveland State University/Cleveland Clinic, Cleveland, OH*
- 
- A-080 Morning Cortisol for Rule-in and Rule-out of Adrenal Insufficiency in an Asian Population**  
B. V. Li, *Tan Tock Seng Hospital, Singapore, Singapore*
- 
- A-081 Assessment of Serum Osteopontin, Osteoprotegerin and Bone-specific ALP as Markers of Bone Turnover in Patients with Disorders of Thyroid Function in Nigeria, Sub-Saharan Africa**  
O. E. Olukoyejo, *Department of Chemical Pathology, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria*
- 
- A-082 Establishment of Infant Free T4 Reference Interval Through Indirect Methods**  
Z. Wu, *Quest Diagnostics, Secaucus, NJ*
- 



**DOWNLOAD THE MOBILE APP**

[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## GENERAL CLINICAL CHEMISTRY & LABORATORY MEDICINE

- A-083 Performance Evaluation of Sentinel Diagnostics' ACE Assay on the Abbott Alinity c system and ARCHITECT c16000 System**  
S. Brambilla, *SENTINEL CH. SpA, Milano, Italy*
- 
- A-084 Performance Evaluation of Sentinel Diagnostics' Ammonia Ultra Assay on Beckman Coulter AU/DxC AU Systems**  
S. Brambilla, *SENTINEL CH. SpA, Milano, Italy*
- 
- A-085 Comparing CO<sub>2</sub> Stability in Patient Samples and Proficiency Testing Material**  
K. Bolte, *Children's Hospital of Philadelphia, Philadelphia, PA*
- 
- A-086 Clinical Performance of a Plasma ATN Panel for Assessment of Alzheimer's Disease**  
ADLM<sup>®</sup>  
ACADEMY  
B. B. Collier, *Labcorp, Burlington, NC*
- 
- A-087 Stability of Fecal Calprotectin Extracted with BÜHLMANN CALEX<sup>®</sup> Cap**  
C. Shaw, *BUHLMANN Diagnostics Corp, Amherst, NH*
- 
- A-088 Clinically Significant Errors Using the Diazyme Total Bile Acid Assay on the Roche c502 Analyzer: Investigating a Result Error Identifies a Novel Large-Scale Testing Error Caused by Reagent Carryover**  
L. M. Leonard, *Mayo Clinic, Rochester, MN*
- 
- A-089 Development and Implementation of an Online Learning Environment for Clinical Chemistry Resident Education: UAMS Experience**  
H. A. Haggrass, *UAMS, Little Rock, AR*
- 
- A-090 Performance of GFAP and UCH-L1 Biomarkers for Traumatic Brain Injury in the ARCHITECT i1000SR TBI Test**  
Z. Al Sahouri, *Abbott Laboratories, Core Diagnostics, Abbott Park, IL*
- 
- A-091 Evaluation of the Analytical Performance of the New Prealbumin Assay on the Atellica CH Analyzer**  
S. Lewisch, *Siemens Healthcare Diagnostics Inc., Newark, DE*
- 
- A-092 Siemens Healthineers Commitment to Quality — A Focus on Continuous Improvement and Customer Experience**  
S. Lewisch, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-093 Assessing Alkaline Phosphatase Reference Intervals Using Gamma-Glutamyl Transferase as a Surrogate for Normal Liver Function**  
H. Brown, *Washington University School of Medicine, St. Louis, MO*
- 
- A-094 Reject Or Not To Reject? Challenges of Visual Inspection of Hemolysis as the Preanalytical Check in a Cardiac Hospital, Laboratory**  
N. Sherazi, *NICVD, Karachi, Pakistan*
- 
- A-095 A New CO<sub>2</sub> Assay with Concentrated Reagent Having Superior Onboard Stability on Mindray BS-2800M Analyzer**  
J. Wang, *Shenzhen Mindray Bio-Medical Electronics Co., LTD., Shenzhen, China*
- 
- A-096 A New Direct Bilirubin (DBIL) Assay with Enhanced Performance in Anti-Hemolysis Interference on Mindray BS-2800M Analyzer**  
J. Wang, *Shenzhen Mindray Bio-Medical Electronics Co., LTD., Shenzhen, China*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### GENERAL CLINICAL CHEMISTRY & LABORATORY MEDICINE

- A-097 Body Fluid Validation for 11 Analytes on a Chemistry Analyzer**  
N. Boyert, *Cleveland Clinic, Cleveland, OH*
- 
- A-098 Reducing Hemolyzed Specimen Rejection for Aspartate Aminotransferase (AST): A Quality Improvement Initiative to Further Optimize Concentration-Specific H-index Thresholds**  
C. L. Rosemark, *Mayo Clinic, Rochester, MN*
- 
- A-099 Case Study of a Patient With Heterophile Antibodies Interfering with Both Competitive and Immunometric Assays**  
V. Palamalai, *SummaHealth, Akron, OH*
- 
- A-100 Clinical Utility of Measuring Creatine Concentration in Erythrocyte**  
T. Nakahara, *Kawasaki University of Medical Welfare, Kurashiki Okayama, Japan*
- 
- A-101 Is That Unexpected? Education on Handling Real World Complications with Tightly Controlled Analytes During Method Evaluation**  
S. A. Love, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-102 Clinical Evaluation of Novel Markers in Brain Injury**  
E. Ryan, *Advocate Clinical Laboratory, Macon, GA*
- 
- A-103 Analytical Performance Evaluation of Plasma NfL in a Clinical Diagnostic Laboratory**  
H. Frykman, *University of British Columbia, Vancouver, Canada*
- 
- A-104 Study of the Matrix Effect for Thyroglobulin and Calcitonin in Fine-Needle Aspiration of Cervical Nodules**  
D. Canali, *Diagnóstico da América, São José, Brazil*
- 
- A-105 Cherry-red Plasma: Unraveling the Impact of PV-10 on Chemistry Assays**  
L. Chen, *The University of Texas MD Anderson Cancer Center, Houston, TX*
- 
- A-106 Determination of Urinary NGAL Reference Intervals from Specimens of Healthy Adult and Pediatric Individuals**  
U. Klause, *BioPorto, Needham, MA*
- 
- A-107 Sample Matrix Matters: A Precision Study of BioRad, TechnoPath, and Patient Pooled Samples Across 20 High Volume Chemistries and Immunoassays**  
K. Sobhani, *Cedars-Sinai Medical Center, Los Angeles, CA*
- 
- A-108 Re-evaluation of Reference Intervals for Circulating Albumin, Total Calcium, and Magnesium Levels Among Subjects in Dallas County**  
I. Hashim, *UT Southwestern Medical Center, Dallas, TX*
- 
- A-109 The Impact of Adjusting Circulating Calcium Levels for Changes in Albumin**  
I. Hashim, *UT Southwestern Medical Center, Dallas, TX*
- 
- A-110 Analytical Performance Evaluation of Vitros® Immunodiagnostic Products Intact PTH II Assay**  
B. M. Hirsch, *QuidelOrtho, Rochester, NY*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## GENERAL CLINICAL CHEMISTRY & LABORATORY MEDICINE

- A-111 "Activation" of Macro-ast by Pyridoxal Phosphate Supplementation**  
L. Song, *UCLA David Geffen School of Medicine, Los Angeles, CA*
- 
- A-112 Reference Intervals for Serum Concentrations of N-Terminal Propeptide of Type-I Procollagen (PINP) for Greek Adult Population**  
K. Makris, *KAT General hospital, Kifissia, Greece*
- 
- A-113 Evaluation of Cystatin C Ordering Trends in a Quaternary Care Health System**  
B. Agana, *Johns Hopkins University, Baltimore, MD*
- 
- A-114 Protective Effect of Leukocytes in Preventing Cold Induced Hyperkalemia**  
S. Mandal, *AIIMS Jodhpur, Jodhpur, India*
- 
- A-115 Iron Assay Improvement: The Need for Thiourea Addition in Ferene/Ferrozine Reagent Cartridge**  
M. Narasimhan, *UT Southwestern Medical Center, Dallas, TX*
- 
- A-116 Pleural Fluid pH — Are We Collecting and Measuring it Correctly?**  
C. Tan, *Singapore General Hospital, Singapore, Singapore*
- 
- A-117 Discordance of CKD Stage Assignment by Different Western and Asian Estimated Gfr Formulae in Patients of Eastern India**  
A. Hazra, *AIIMS, Kalyani, India*
- 
- A-118 Sigma Metric Performance of Chemistry Assays on 4 Instrument Systems**  
M. Berman, *Abbott Labs, North Chicago, IL*
- 
- A-119 Lipemia Interference**  
M. Berman, *Abbott Labs, North Chicago, IL*
- 
- A-120 Analytical and Clinical Verification of the Elecsys® Alzheimer's Disease Cerebrospinal Fluid Biomarkers pTau/Abeta42 and Total-Tau/Abeta42**  
K. Troike, *Cleveland Clinic, Cleveland, OH*
- 
- A-121 Common Parkinson's Disease Therapy Leads to Falsely Low Urine and Plasma Creatinine**  
F. Cai, *Alberta Precision Laboratories, Calgary, Canada*
- 
- A-122 Evaluation of the Performance of the BD MiniDraw™ Capillary Blood Collection System Under Various Transport Conditions**  
K. Gan, *Becton, Dickinson & Company, Franklin Lakes, NJ*
- 
- A-123 Comparative Assessment of Unmanned High-Speed Aerial Vehicles in Medical Logistics: Blood Sample Transportation Amidst Weather Variability**  
N. R. Stierlin, *Private Universität im Fürstentum Liechtenstein (UFL), Triesen, Liechtenstein*
- 
- A-124 Sustainable Transport: Assessing Environmental Impact in Medical Sample Transit via Drones and Vehicles**  
N. R. Stierlin, *Private Universität im Fürstentum Liechtenstein (UFL), Triesen, Liechtenstein*
-

**SCIENTIFIC POSTER SESSIONS**

9:30 a.m. - 5:00 p.m.

**GENERAL CLINICAL CHEMISTRY & LABORATORY MEDICINE**

- A-125** **Difference Between the Results of Vitros® Dry Biochemistry and Wet Biochemistry with Kinetic Method in Diagnosing the Comorbidity of Lung Adenocarcinoma and Aacroamylasemia: Case Report**  
S. Zhu, *The Second People's Hospital of Yibin, Yibin, China*
- 
- A-126** **The Role of Lysozyme and Other Inflammatory Markers in Understanding GI Microbiome Changes**  
D. Reynolds, *Doctors Data Inc, St. Charles, IL*
- 
- A-127** **Stability of Ionized Calcium in Blood Gas Specimens**  
J. Reust, *Children's Hospital of Philadelphia, Philadelphia, PA*
- 
- A-128** **Evaluation of the Analytical Performance of Three Inflammation Related Assays on the Atellica CI Analyzer**  
R. H. Carter, Jr., *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-129** **Evaluation of the Analytical Performance of Magnesium and Calcium General Chemistry Assays on the Atellica CI Analyzer**  
R. H. Carter, Jr., *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-130** **Intercomparison of Methods between Atellica Solution® and CI® Analyzers for Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)**  
M. Barrionuevo-Gonzalez, *Principe De Asturias University Hospital, Alcala De HenareS, Spain*
- 
- A-131** **An External Laboratory Validation of the Atellica IM Serum Neurofilament Light Chain Assay**  
C. Abou-Diwan, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-132** **Next Generation Ammonia Reagent With Improved Reagent Composition and Assay Performance**  
S. Nair, *Sekisui Diagnostics, Charlottetown, Canada*
- 
- A-133** **Trusted Test Goes Awry: Investigating Dilution Aberrations for Total Bilirubin**  
X. Li, *Emory University, Atlanta, GA*
- 
- A-134** **Comparative Analysis of ALT and AST Measurements: Impact of P5P Activators on Platform Discrepancies**  
X. Li, *Emory University, Atlanta, GA*
- 
- A-135** **Assessment of Inter-Laboratory Variation in Biochemistry Parameters in Mongolian Clinical Laboratories: A Twelve-Year Analysis**  
U. Bayarsaikhan, *SOS Medica Mongolia UB International Clinic, Ulaanbaatar, Mongolia*
- 
- A-136** **Icteric Interference is not Resolved with Sample Dilution in Serum Creatinine and Total Protein Assays**  
J. T. Zakrajsek, *Cleveland Clinic, Cleveland, OH*
- 
- A-137** **Stability of Analytes in Uncapped Specimens**  
V. Kumar, *Quest Diagnostics, Lewisville, TX*
- 
- A-138** **Implications of Native Protein Conformation in the IgM Quantification: Total Ig Vs Hlc Methods Comparison**  
L. Campos, *Binding Site part of Thermo Fisher, Barcelona, Spain*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## HEMATOLOGY & COAGULATION

- A-140 Reducing Cell Count Bias With The Glocyte® Automated Cell Counter For CSF: An Observational Study at Loyola University Medical Center**  
J. Maggiore, *Loyola University Medical Center, Maywood, IL*
- 
- A-141 Ferritin Test Utilization to Differentiate Microcytic Anemia**  
M. Keebaugh, *University of Washington, Seattle, WA*
- 
- A-142 Usefulness of Targeted RNAseq to Diagnosis of Patients with Suspected Hypereosinophilic Syndrome: Retrospective Analysis in a Single Hospital**  
J. Park, *Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of*
- 
- A-143 Comparative Evaluation of K2EDTA Performance in Multinational Vacutainers: A Case Study of "DBO" by Schraubg and "BD" by Becton, Dickinson**  
T. Patel, *Gunjan Lab LLP, Bharuch, India*
- 
- A-144 Liquid Chromatography Multiple Reaction Monitoring-Based Assay for Quantitative Assessment of Fibrinogen Levels in Clinical Samples**  
S. Chavan, *Mayo Clinic, Rochester, MN*
- 
- A-145 Are EDTA and Citrate Collection Devices Interchangeable for Estimating Blood Platelets Values using Sysmex XN™ Analyzers?**  
V. Genta, *Sentara VA Beach General Hospital, Virginia Beach, VA*
- 
- A-146 Functionality of Scatterplots and Suspect Flags in Evaluating Hairy Cell Leukemia**  
M. Ismail, *Abbott Diagnostics Division, Santa Clara, CA*
- 
- A-147 Comparative Precision of Platelet Counting by Optical, Fluorescent, and Impedance Techniques in Thrombocytopenia and Microcytosis Patients**  
H. J., *All India Institute of Medical Sciences, Delhi, New Delhi, India*
- 
- A-148 Performance Evaluation of the Zybio EXT 4800: A Novel Optical-Magnetic Coagulation Analyzer**  
T. Ma, *Zybio, Inc, Chongqing, China*
- 
- A-149 Comparison of Mass Spectrometry to Sickle Solubility for Confirmation of Low Percentages of Hemoglobin S**  
T. Olson, *Mayo Clinic, Rochester, MN*
- 
- A-150 Extended Pre-Analytical Stability Validation for Coagulation Tests in Brazilian Clinical Laboratory**  
D. Canali, *Diagnóstico da America, Florianópolis, Brazil*
- 
- A-151 The Evaluation of Alinity h as Screening Tool for Burkitt Lymphoma**  
S. Silva, *Abbott Diagnostic Division, Santa Clara, CA*
- 
- A-152 Enhancing PNH Diagnosis with Multicolor Flow Cytometry Immunophenotyping Protocol in a Medical Center in Taiwan**  
C. Fang, *Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### HEMATOLOGY & COAGULATION

- A-153 Study of the Evaluation Of Fragment Flag And Percentage Schistocyte Count in MINDRAY® BC-6800 PLUS in a Public Pediatric Hospital in Argentina**  
I. Marcone, *Hospital de Niños Dr. Ricardo Gutierrez, CABA, Argentina*
- 
- A-154 Non-standard Body Fluid Validation of D-Dimer Analysis of Organox Liver Perfusate to Support Clinical Evaluations of Donor Livers Prior to Transplantation**  
H. Koster, *Loyola University Medical Center, Maywood, IL*
- 
- A-155 Development of Drop-of-Blood QATT Heparinase And Functional Fibrinogen Assays**  
H. Pham, *Department of Biomedical Engineering, Tulane University, New Orleans, LA*
- 
- A-156 Comparison of Blast and Variant Lymphocyte Flagging Between the Alinity hq from Abbott and XN-1000 from Sysmex**  
L. Sun, *Abbott, Santa Clara, CA*
- 
- A-157 Utility of Kaolin TEG and Rapid TEG to Predict Coagulopathy In Severe Traumatic Brain Injury**  
ADLM#  
ACADEMY  
T. Sehgal, *AllMS, Delhi, India*
- 
- A-158 Multi-site Verification and Performance of Body Fluids In-Between Horiba Medical Yumizen h2500 with Sysmex XN-10 Automated Hematology Analyzers and Manual Microscopy For Morphology Assessment**  
M. L. Hege, *Baylor Scott & White Research Institute, Temple, TX*
- 
- A-159 Re-evaluating Ferritin Cutoffs for the Diagnosis of Iron Deficiency and Iron Deficiency Anemia**  
K. Troike, *Cleveland Clinic, Cleveland, OH*
- 
- A-160 Optimization of Serotonin Release Assay Utilization for Heparin-Induced Thrombocytopenia Diagnosis**  
C. Koch, *Sanford Laboratories, Sioux Falls, SD*
- 
- A-161 Diagnosis of Lupus Anticoagulant Cases Using Deep Neural Networks**  
J. Wang, *Carleton College, Northfield, MN*
- 
- A-162 Improved Laboratory Workflow Using Automated Detection of Hemolysis, Icterus, and Lipemia for Coagulation Testing**  
A. Wockenfus, *Mayo Clinic, Rochester, MN*
- 
- A-163 Stability of Apixaban in Li-heparin Plasma Stored Refrigerated Over Mint Green-Top Tube Separator Gel**  
D. Stickle, *Jefferson University Hospital, Philadelphia, PA*
- 
- A-164 Establishment and Verification of Reference Intervals for Red Blood Cell Series and Total Leukocytes in Whole Blood Counts of Chilean Adults Using refineR and Multi Criteria Expectation Maximization Methods**  
C. Prieto, *Hospital DIPRECA, Santiago, Chile*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## HEMATOLOGY & COAGULATION

- A-165 Value of Monocyte Distribution Width in Bacteremia Assessment in Emergency Department Patients**  
B. Cook, *Henry Ford Hospital, Detroit, MI*
- 
- A-166 Performance Verification of a Polyclonal anti-PF4 Immunoassay in Evaluation of Heparin Induced Thrombocytopenia (HIT)**  
J. Arnouk, *Department of Pathology, UMass Chan Medical School - Baystate Regional Campus, Springfield, MA*
- 
- A-167 Hematologic Setpoints Are a Deep Physiologic Phenotype Which Enable Personalized Blood Count Reference Intervals**  
ADLM<sup>®</sup>  
ACADEMY  
B. H. Foy, *University of Washington, Seattle, WA*
- 
- A-168 Comparison of Two Different Lupus Anticoagulant Hexagonal Phase Phospholipid Confirmatory Assays on an Automated Coagulation Analyzer**  
P. W. Riley, *Diagnostica Stago, Inc., Parsippany, NJ*
- 
- A-169 Artificial Intelligence Based Complete Blood Count**  
T. Tohami, *Meir Medical Center, Kfar Saba, Israel*
- 
- A-170 Hypereosinophilic Syndrome and t(5;15): Case Report and Literature Review**  
S. S. De Andrade, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-171 Novel Fluorometric Assay for Pediatric Anti-Factor Xa Testing: Minimizing Bilirubin and Hemolysis Interference in Whole Blood**  
V. Pamula, *Baebies, Durham, NC*
- 
- A-172 Feasibility of PT, aPTT, and Fibrinogen on a Multifunctional Digital Microfluidic Cartridge**  
V. Pamula, *Baebies, Durham, NC*
- 
- A-173 Evaluation of Artificial Intelligence (AI)-assisted Flow Cytometry Analysis for Plasma Cell Neoplasms**  
T. Yeager, *OHSU, Portland, OR*
- 
- A-174 Comparison of Bleeding Risk Scales in Elderly Patients With Persistent Atrial Fibrillation**  
A. R. Menendez Mite, *Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador*
- 
- A-175 The Significance of Thromboelastometry in Cardiac Surgery**  
I. Rodriguez Martin, *Hospital Virgen Macarena, Sevilla, Spain*
- 
- A-176 Do You Have a Hemoglobin Variant?**  
S. Fan, *Vanderbilt University Medical Center, Nashville, TN*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### LABORATORY MANAGEMENT & PATIENT SAFETY

- A-177 Using the Building Research Establishment Environmental Assessment Method to Maximise the Environmental Social Governance Benefits of Building a Pathology Hub Laboratory**  
P. Cane, *Synnovis, London, United Kingdom*
- 
- A-178 Quality Improvement of Cystic Fibrosis-Related Diabetes Screening at a Large Pediatric Center**  
A. Chokkalla, *Section of Clinical Chemistry, Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX*
- 
- A-179 Improving Specimen Labeling Errors in the Pediatric Emergency Department at a Tertiary Care Hospital**  
L. Wang, *BC Children's Hospital, Vancouver, Canada*
- 
- A-180 Study of the Cost of Potentially Irrelevant Prescriptions for Serum Immunofixation in the Medical Laboratory of NOVO Hospital**  
F. Abdeldjouad, *NOVO Hospital, Pontoise, France*
- 
- A-181 The Effectiveness Module to Reduce Laboratory Error Reporting Rates**  
C. Lee, *Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan*
- 
- A-182 Applications of Artificial Intelligence Optical Character Recognition in Laboratory Clerical Functions Offsetting Staffing Shortages and Error Reduction**  
L. B. Springer, *LabSavvy, Falls Church, VA*
- 
- A-183 Examination of the Roles and Responsibilities of Clinical Chemists as Determined by an International Peer Response-Based Survey**  
C. Nottingham, *National Institutes of Health, Bethesda, MD*
- 
- A-184 Evidence-based Test Utilization: Test Ordering Patterns in Functional Medicine and Community Clinics, and Implications for Laboratory Stewardship**  
S. Ezra, *Alberta Precision Laboratories and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada, Calgary, Canada*
- 
- A-185 Impact Assessment of Centrifugation During Transportation on Examination Results**  
C. Dias, *Dasa, São Paulo, Brazil*
- 
- A-186 Patient Safety Rite in Diagnostic Services**  
C. Dias, *Dasa, São Paulo, Brazil*
- 
- A-187 Program for Recognition of Patient Safety Cores in Diagnostic Services**  
C. Dias, *Dasa, São Paulo, Brazil*
- 
- A-188 Modal Failure and Effects Analysis, FMEA Methodology, as a Strategy to Increase Patient Safety**  
T. De Haro, *Hospital Campus De La Salud, Granada, Spain*
- 
- A-189 Six Sigma for Thyroid Stimulating Hormone (TSH)**  
D. R. Ramadan-Boscolo, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## LABORATORY MANAGEMENT & PATIENT SAFETY

- A-190 Assessing Biosafety and Biosecurity Practices in Zambian Laboratories: A Checklist-Based Evaluation**  
M. Mandona, *Ministry of Health, Lusaka, Zambia*
- 
- A-191 Improvement of Outpatient Satisfaction Rate at Specimen Collection Area**  
W. Tamimi, *King Abdulaziz Medical City, Riyadh, Saudi Arabia*
- 
- A-192 Effectiveness in Communicating Critical Results: Impact of Technology and Consultive Actions on Improving Performance Indicators in a Laboratory in Northeast Brazil**  
R. Pena, *Shift, São José do Rio Preto, Brazil*
- 
- A-193 Optimizing Emergency Laboratory Operations Through Six-Sigma Strategies for Enhanced Efficiency and Effectiveness: A Pilot Study**  
A. Gusti, *King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia*
- 
- A-194 Point-of-Care Glucose Test Time Interval Data Used as a Proxy Indicator for Glucose Meter Cleaning and Disinfection Adequacy Between Patient Testing Episodes**  
E. Z. Reineks, *Cleveland Clinic, Cleveland, OH*
- 
- A-195 Combination of Lean Mindset, Robotics and Digitalization Allowed Us to Manage a 2.5 Times Increase in Workload in Our Central Reference Lab**  
A. Bansal, *Agilus Diagnostics Ltd, Gurugram, India*
- 
- A-196 Using Aggregated Proficiency Testing Results to Identify Systematic Error**  
J. R. Astles, *Centers for Disease Control and Prevention, Atlanta, GA*
- 
- A-197 Enhancing Patient Safety and Workforce Sustainability Through ASCP BOC Credentials**  
J. B. Baker, *American Society for Clinical Pathology, Chicago, IL*
- 
- A-198 ESG Opportunities Harnessed During Pathology Transformation**  
T. Ellison, *Synnovis, London, United Kingdom*
- 
- A-199 Use of R Programming for Monthly Quality Control (QC) Data Review in a University Hospital Laboratory**  
D. Stickle, *Jefferson University Hospital, Philadelphia, PA*
- 
- A-200 Six Sigma Improves the Performance of Quality Control, Financial and Operation Efficiency in a Nationwide Laboratory Network in Mexico**  
E. Chávez-Guarista, *Salud Digna, Culiacán, Mexico*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### LABORATORY MANAGEMENT & PATIENT SAFETY

- A-201 The Impact of Implementing the CKD-EPI 2021 Equation for Calculation of Estimated Glomerular Filtration Rate (eGFR) and the Kidney Failure Risk Equation (KFRE) on a Large Community Laboratory Population**  
N. White-Al Habeeb, *Dynacare, Brampton, Canada*
- 
- A-202 Quality Control Design Survey Reveals 399 Ways to Do it Wrong**  
Z. Brooks, *AWESome Numbers Inc., Worthington, Canada*
- 
- A-203 A Disconnect Between Detectable Patient Error Rates and QC Understanding**  
Z. Brooks, *AWESome Numbers Inc., Worthington, Canada*
- 
- A-204 Commitment to Sustainability From Laboratory Medicine**  
A. C. Yeoh, *University Malaya Medical Center, Kuala Lumpur, Malaysia*
- 
- A-205 Evaluating the Cost and Importance of Supply Chain Resilience in the Clinical Laboratory**  
E. Jurinic, *Accumen Inc, Scottsdale, AZ*
- 
- A-206 Exploring the Surge in Clinical Laboratory Inflation: A Comprehensive Review**  
E. Jurinic, *Accumen Inc, Scottsdale, AZ*
- 
- A-207 Enhancing Healthcare Delivery Network Laboratories: The Role of Third-Party Consultants in Benchmarking and Reviewing RFP Results**  
E. Jurinic, *Accumen Inc, Scottsdale, AZ*
- 
- A-208 Price Transparency of Laboratory Tests Across All Licensed Hospitals in Tennessee**  
S. A. Hart, *Vanderbilt University Medical Center, Nashville, TN*
- 
- A-209 Preanalytical Phase Errors Constitute the Vast Majority of Errors in Clinical Laboratory Testing**  
Y. Lin, *Washington University in St Louis, St. Louis, MO*
- 



#### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## LIPIDS, LIPOPROTEINS & CARDIOVASCULAR RISK FACTORS

- A-210** **LDL-C to Non-HDL-C Ratio Method: A Simple Way to Determine Bias for LDL-C Methods on Hypertriglyceridemic Samples**  
ADLM#  
ACADEMY  
T. A. Gcingca, *Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD*
- 
- A-211** **Lipids in the Afternoon: Effect on LDL-C, Triglycerides, and Collection Time When Removing Fasting Requirements for Lipid Panels**  
ADLM#  
ACADEMY  
B. Andress, *Mayo Clinic, Rochester, MN*
- 
- A-212** **Comparison of Formulas for Measuring LDL in Cancer Patients With Hypertriglyceridemia**  
B. Sánchez -Jacinto, *Universidad Peruana Cayetano Heredia, Lima, Peru*
- 
- A-213** **Comparison of Low-Density Lipoprotein Cholesterol (LDL-c) Estimates By In-Lab and Point-of-Care Devices in the Context of Emerging LDL-c Equations**  
Z. Hubler, *Washington University in St Louis, St Louis, MO*
- 
- A-214** **Evaluate LDL-C Using NIH Equation 2, Friedewald Equation, and Direct Homogeneous Measurement**  
R. Faught, *UAMS, Little Rock, AR*
- 
- A-215** **Feasibility of a Unique Homogenous Assay for Lipoprotein(a) Particle Number Without Bias From Apo(a) Size Isoforms**  
J. Contois, *Sun Diagnostics LLC, New Gloucester, ME*
- 
- A-216** **Prevalence and Status of Lipoprotein(a) in the Korean Population Visiting Local Clinics and Hospitals**  
S. Jung, *Seegene Medical Foundation, Seoul, Korea, Republic of*
- 
- A-217** **Estimation of the Prevalence and the Patterns of Dyslipidemia in the Korean Population**  
S. Jung, *Seegene Medical Foundation, Seoul, Korea, Republic of*
- 
- A-218** **Lipids Levels Comparison of Diabetic and Non-Diabetic Individuals, a Retrospective Study at a Secondary Care Hospital**  
T. Shirazi, *Saifee Hospital, Karachi, Pakistan*
- 
- A-219** **Method Intercomparison Study between Atellica Solution® and CI® Analyzers for Total Cholesterol and Triglycerides**  
M. Ruiz-Alvarez, *Principe De Asturias University Hospital, Alcala De Henares, Spain*
- 



### FOLLOW ADLM

@myADLM on Instagram and use #ADLM2024 to join the conversation.

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### LIPIDS, LIPOPROTEINS & CARDIOVASCULAR RISK FACTORS

- A-220 Method Intercomparison Study Between Atellica Solution® and CI® Analyzers for HDL and LDL Methods**  
M. Ruiz-Alvarez, *Principe De Asturias University Hospital, Alcalá De Henares, Spain*
- 
- A-221 Association of Dyslipidemia in Thyroid Dysfunction**  
S. Thapa, *Medical University of the Americas, Nevis, Saint Kitts and Nevis*
- 
- A-222 Evaluation of the Analytical Performance of Apolipoprotein A-1, Apolipoprotein B, and Lipoprotein(a) Assays on the Atellica CI Analyzer**  
J. Huff, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-223 Direct LDL or not Direct-LDL, That is the Question**  
S. Valaperta, *ASST Papa Giovanni XXIII, Bergamo, Italy*
- 
- A-224 Non HDL Cholesterol: Could be e New Cardiovascular Disease Risk Stratification Factor?**  
S. Valaperta, *ASST Papa Giovanni XXIII, Bergamo, Italy*
- 
- A-225 Validation of Self-Collected Capillary Dried Plasma Spot Collection for Lipoprotein(a) Testing**  
A. Naranjo, *LetsGetChecked Labs, Monrovia, CA*
- 
- A-226 Validation of Calculated Glycerol Corrected Triglycerides**  
R. Scott, *Mayo Clinic, Rochester, MN*
- 
- A-227 One Step Toward Implementation of Advanced Lipoprotein Testing in Children: A Pilot Study on Pediatric Reference Ranges**  
ADLM#  
ACADEMY  
H. Nelson, *University of Utah, Salt Lake City, UT*
- 
- A-228 Evaluation of an Equation for Low-Density Lipoproteins-Triglycerides in Predicting ASCVD Risk in the UK Biobank Population**  
A. Wolska, *National Institutes of Health, Bethesda, MD*
- 
- A-229 Elevated Levels of Arachidonic Acid Containing Lipids Underlie Cardiovascular Disease Risk in White and Black Females**  
D. A. Baldwin, *University of Wisconsin-Madison, Madison, WI*
- 
- A-230 The Effect of Fasting on Serum Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA): A Report from a Large Reference Laboratory**  
S. Albeiroti, *Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab, Cleveland, OH*
- 
- A-231 A Modified Sampson LDL-C Equation to Improve Concordance With the Reference Method at Low Levels of LDL-C**  
M. Sampson, *DLM/CC/NIH, Bethesda, MD*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MICROBIOLOGY & INFECTIOUS DISEASE

- A-232 Characterize and Reduce Positive Interference of Hemolysis on Fungitell Testing for (1, 3)- $\beta$ -glucan (BDG) in Serum**  
Y. Zhang, *Associates of Cape Cod, Inc, East Falmouth, MA*
- 
- A-233 Wastewater-based Surveillance for SARS-CoV-2 Subvariants Using the Nanopore Sequencing in South Korea**  
Y. Kim, *Seoul Clinical Laboratories, Yongin City, Gyeonggi-do, KOREA, Korea, Republic of*
- 
- A-234 Evaluation and Validation of a Rapid Antigen Detection of Monkeypox Virus**  
S. Shen, *DiaCarta, Inc, Pleasanton, CA*
- 
- A-235 Systemic Inflammation is Associated With Worse Outcomes from SARS-CoV-2 Infection But Not Neutralizing Antibody**  
C. Farnsworth, *Washington University, St. Louis, MO*
- 
- A-236 Rapid Multiplexed PCR (Polymerase Chain Reaction) Tests for Respiratory Disease Improve Process and Time to Diagnosis Versus Laboratory-Based Molecular Testing**  
J. Chase, *Cepheid, Sunnyvale, CA*
- 
- A-237 Analytical Performance Evaluation of Cytomegalovirus IgG and Syphilis Assays on the Atellica CI Analyzer**  
M. Quintanilla, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- A-238 Lyophilized Bead Multiplex Assays for CT/NG/TV Detection**  
R. Moore, *Takara Bio, San Jose, CA*
- 
- A-239 Cxcl10 Induced Gut Dysbiosis Exacerbates Acute Lung Injury and Secondary Infection in Influenza By Inhibiting il22**  
M. Zheyang, *Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China*
- 
- A-240 Validation of the OSOM Flu SARS-CoV-2 Combo Home Test**  
S. Yaji, *SEKISUI Diagnostics, LLC, San Diego, CA*
- 
- A-241 Verification and Validation Study for a Host Response Assay Based on TRAIL, IP-10, and CRP: Application to Pediatric Emergency Department**  
A. M. Styer, *Geisinger, Danville, PA*
- 
- A-242 Assessing the Efficacy of the One-Step Diagnostic Algorithm for Hepatitis C**  
S. Bérnago-Vázquez, *Laboratory Medicine Department, Althaia Healthcare University Network of Manresa, Barcelona, Spain*
- 
- A-243 Quantitative Bacteriology Parameters for Seal-Packaged Agar Plates Challenged with Experimental Low-resource Tropical Field Clinic Stress**  
B. K. Font, *Biomed Diagnostics, A DCNDX BRAND, White City, OR*
- 
- A-244 Inhibitory Activity of Lactobacillus Species Isolated from Ogi (Fermented Cereal Slurry) Produced from Millet Against Escherichia coli and Salmonella Typhi**  
N. C. Ugwunna, *Department of Community Medicine, College of Medicine, University of Nigeria, Nsukka, Enugu, Nigeria*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MICROBIOLOGY & INFECTIOUS DISEASE

- A-245 Evaluation of an Automated MALDI-TOF Target and Antimicrobial Susceptibility Suspension Preparation Instrument**  
F. M. Rice, *Mayo Clinic Hospital, Phoenix, AZ*
- 
- A-246 Can CRP be Used to Rule in or Rule Out Elevated Procalcitonin Concentrations in the Emergency Department?**  
R. Hawkins, *Tan Tock Seng Hospital, Singapore, Singapore*
- 
- A-247 Performance and Compatibility Assessment of Serially Diluted Microbix QAP™ Controls with Seegene Novaplex™ Assays**  
D. Cheon, *Seegene USA, Irvine, CA*
- 
- A-248 Assessment of Nanopore Sequencing for HIV Genotyping: A Comparative Study with Sanger Sequencing**  
M. Andrade, *Sabin Diagnóstico e Saúde, Brasília, Brazil*
- 
- A-249 Monocyte Distribution Width (MDW) as a Reliable Diagnostic Biomarker for Sepsis In HIV-Infected Patients**  
J. Sun, *Shanghai Public Health Clinical Center, Shanghai, China*
- 
- A-250 Evaluation of Liver Fibrosis in Schistosomiasis Mansoni Using the ELF (Enhanced Liver Fibrosis) Score**  
B. C. Ozaki, *Siemens Healthineers, São Paulo, Brazil*
- 
- A-251 Simplification of Molecular Diagnostics for Sexually Transmitted Infection Point-of-Care Testing**  
S. O. Seely, *University of Miami, Miami, FL*
- 
- A-252 Evaluation of the Use of One-tube Blood Collection and Automated Specimen Processing System for LIAISON® QuantiFERON®-TB Gold Plus Testing at a Large Regional Reference Laboratory**  
R. Cortez, *Southern California Permanente Medical Group, Kaiser Permanente, North Hollywood, CA*
- 
- A-253 Antimicrobial Susceptibility Pattern in *Escherichia coli* Isolated from Community-Acquired Urinary Tract Infections in the Era Post-Covid-19**  
D. R. Ramadan-Boscolo, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-254 Increase of *Stenotrophomonas Maltophilia* Isolates Non-Susceptible to Trimethoprim-Sulfamethoxazole and/or Levofloxacin at Brazilian Hospitals**  
D. R. Ramadan-Boscolo, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-255 Microbiological Profile and Frequency Distribution of Uropathogens in Brazilian Public Hospitals — Data From a Clinical Laboratory (2018-2023)**  
D. R. Ramadan-Boscolo, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-256 Epstein Barr Virus Infection Types and Metabolic Characteristics After Allogeneic Hematopoietic Stem Cell Transplantation**  
S. Feng, *Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MICROBIOLOGY & INFECTIOUS DISEASE

- A-257 Revolutionizing Fungal Infection Diagnosis: A Sensitive, Cost-Effective, and Time-Efficient Solution**  
K. Ramakrishnan, *12-15 Molecular Diagnostics, East Haven, CT*
- 
- A-258 Hepatitis A Infections Among Patients Suspected of Acute Hepatitis Attended in Brazilian Health Services**  
J. Rebello Pinho, *Hospital Israelita Albert Einstein, São Paulo, Brazil*
- 
- A-259 Botriocephalosis, Reemerging Parasitosis Associated With Consumption of Raw Fish: A 10-Year Analysis Series at Bupa Lab**  
C. S. Ramirez, *Clínica Bupa, Santiago, Chile*
- 
- A-260 Mapping Pediatric Urinary Tract Infections: Trends, Prevalence and Sensitivity to Antimicrobials**  
C. Araujo, *Sabin Diagnóstico e Saúde, BRASILIA, Brazil*
- 
- A-261 Outcome of a Survey on Dengue Lateral Flow Immunoassay Test Kit Reading and Interpretation By Medical Laboratory Staff in a Hospital Laboratory**  
K. Cheng, *Khoo Teck Puat Hospital, Singapore, Singapore*
- 
- A-262 Novel Hepatitis C Virus External Quality Control that is Stable at Ambient Temperature and Suitable for Use in Low-Resource Settings**  
S. Rivers, *Microbix Biosystems Inc, Mississauga, Canada*
- 
- A-263 Akkermansia Muciniphila Synergizes with Metformin to Enhance the Sensitivity of Non-small Cell Lung Cancer H1975 Cells to Cisplatin via AMPK Signaling Pathway**  
X. Wang, *Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China*
- 
- A-264 Validation of a Novel Real-Time PCR Assay for Identification of Mycobacterium Species Isolates Recovered from Clinical Culture**  
A. B. Harris, *Labcorp, Burlington, NC*
- 
- A-265 Construction of Nomogram Model for Predicting Clostridioides Difficile Infection**  
L. Wang, *Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China*
- 
- A-266 Rapid Identification of Clostridioides Difficile ST37 Based on Matrix-Assisted Laser Desorption Ionization Time-of-Fight Mass Spectrometry and an Artificial Neural Network Model**  
L. Wang, *Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, China*
- 
- A-267 How Does Rapid HIV Antibody Testing Fit into the Current Testing Algorithm?**  
T. Bui-Bullock, *Washington University School of Medicine in St Louis, St. Louis, MO*
- 
- A-268 Comparison of the Elecsys® HCV Duo Assay to Standard of Care Algorithmic Testing**  
T. Bui-Bullock, *Washington University School of Medicine in St Louis, St. Louis, MO*
- 

ADLM  
ACADEMY

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MICROBIOLOGY & INFECTIOUS DISEASE

- A-269** Prevalence of Urinary Tract Infection for 13 years in a Public Hospital in Minas Gerais, Brazil  
D. H. Bucker, *Hospital das Clínicas – Universidade Federal de Minas Gerais - EBSEERH, Belo Horizonte - MG, Brazil*
- 
- A-270** Evaluation of a Multiplex Panel to Determine Antibody Profile to Monkeypox Virus in Vaccinated, Exposed, and Naïve Individuals  
N. Venkateswaran, *Tetracore Inc., Rockville, MD*
- 
- A-271** Expansion of Sample Viability for Self-Collected Urine Specimens Containing CT/NG & TV/MG Utilizing the Roche cobas® 6800 System  
R. Muldrow, *LetsGetChecked, Monrovia, CA*
- 
- A-272** Evaluation of a Real-Time Multiplex Polymerase Chain Reaction Assay for Simultaneous Detection of Respiratory Pathogens in Nasopharyngeal Specimens  
R. Alturkmani, *Labtech Diagnostics, San Antonio, TX*
- 
- A-273** Rapid, Portable Invasive Fungal Infection Diagnostic and *Candida* Antimicrobial Susceptibility Testing  
M. Roegner, *GeneCapture, Inc., Huntsville, AL*
- 
- A-274** The Yield of the Limulus Amebocyte Lysate (LAL), Which is Used for Endotoxin Detection and Fungal Diagnosis is Increased by Caffeine Collection Buffer  
S. Zhang, *Westford Academy, Westford, MA*
- 
- A-275** Optimization of the Phage Based Diagnostic *Actiphage TB Blood Test* and its Evaluation in a Phase II Clinical Trial for the Detection of Tuberculosis Infection  
E. More, *PBD Biotech, Birmingham, United Kingdom*
- 
- A-276** Unraveling Pathogen Dynamics in Pediatric Meningitis Complications During the Omicron Variant Outbreak in Taiwan  
C. Huang, *Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou Medical Center; Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan*
- 
- A-277** Viability of Multi-Drug Resistant Organisms in a Fecal Collection and Transport System Stored at Ultra-Low Temperature  
L. Cowden, *University of Pennsylvania, Philadelphia, PA*
- 
- A-278** Prevalence of *Clostridium Difficile* in Long-Term Care Facilities Using BD Max Cdiff Molecular Assay  
R. Khoury, *Aculabs Inc., East Brunswick, NJ*
- 
- A-279** Performance Evaluation of the Respiratory Viral for BD MAX™ System in Geriatric Population  
R. Khoury, *Aculabs Inc., East Brunswick, NJ*
- 
- A-280** The Good, the Bad, and the Downright Inappropriate Reporting of Gram Positive Resistance Genes in a Proficiency Testing Program  
E. Mills, *American Proficiency Institute, Traverse City, MI*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MICROBIOLOGY & INFECTIOUS DISEASE

- A-281 Comparison of C-reactive Protein, Procalcitonin, and Presepsin in Blood and Synovial Fluid as Diagnostic Biomarkers for Septic Arthritis**  
H. Choi, *Chonnam National University Hospital, Gwangju, Korea, Republic of*
- 
- A-282 Purpura Fulminans Caused by Haemophilus Influenzae: Case Report of Unusual Etiology**  
J. Levi, Dasa, *Sao Paulo, Brazil*
- 
- A-283 Serologic and Molecular Testing for the Diagnosis of Rickettsia, Ehrlichia, and Anaplasma Infections in Patients in Maryland**  
K. Mullins, *University of Maryland, Baltimore, MD*
- 
- A-284 Development of a Low Positive Molecular Control for Mycoplasma Genitalium and Trichomonas Vaginalis Screening**  
C. Huang, *LGC Clinical Diagnostics, Gaithersburg, MD*
- 
- A-285 Adoption of 2023 CLSI Revised Aminoglycoside Clinical Breakpoints on Carbapenem Resistant Enterobacterales Isolates Identified at a Commercial Reference Laboratory in Korea, Republic of**  
H. Bae, *Seoul Clinical Laboratories, Youngin, Korea, Republic of*
- 
- A-286 Correlation of PCR and Culture Values in Evaluating Respiratory Tract Infections Results: A Molecular Diagnostic Lab Approach to Microbial Detection**  
V. Singh, *HealthTrackRx, Denton, TX*
- 
- A-287 Mycoplasma Pneumoniae Outbreak in 2023: Post Pandemic Resurgence of an Atypical Bacterial Pathogen**  
V. Singh, *HealthTrackRx, Denton, TX*
- 
- A-288 Active Surveillance Cultures: Frequency of Microorganisms and Phenotypic Resistance Profile From Brazilian Public Hospitals After COVID-19 Pandemic Peak**  
ADLM#  
ACADEMY  
S. S. De Andrade, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-289 Multiple Gastric Polyps as an Unusual Presentation of Syphilitic Gastritis**  
S. S. De Andrade, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-290 Prevalence and Antimicrobial Resistance Pattern of Microorganisms Recovered From Bloodstream Infections From Public Hospitals of São Paulo City, Brazil**  
S. S. De Andrade, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- A-291 Natural Infection Versus Hybrid (Natural and Vaccination) Humoral Immune Response to SARS-CoV-2: A Comparative Paired Analysis**  
S. Atef, *National Reference Laboratory, Abu Dhabi, United Arab Emirates*
- 



**FOLLOW ADLM**

@myADLM on Instagram and use #ADLM2024 to join the conversation.

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MICROBIOLOGY & INFECTIOUS DISEASE

- A-292 Validation of Aztreonam-Avibactam MIC Antimicrobial Susceptibility Test for MicroScan Dried Gram-Negative MIC Panels from a Multicenter Assessment of Enterobacterales, Pseudomonas Species, and Stenotrophomonas Maltophilia**  
J. E. Diaz, Beckman Coulter, West Sacramento, CA
- 
- A-293 Rapid and Efficient Diagnosis of Bloodstream Infections Utilizing Nanopore Targeted Sequencing with Species-Specific Primers**  
D. Han, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 
- A-294 Exocytosis Inhibitor Increases Yield of Limulus Amebocyte Lysate (LAL), Used for Adjunct Diagnosis of Invasive Fungal infection**  
M. Zhang, Westford Academy, Westford, MA
- 
- A-295 New Transport Media to Preserve Viable Parasites, Bacteria and Fungus**  
M. E. Ordonez-Smith, Microbiology Institute, Bogota, Colombia
- 
- A-296 Streck Urine Preserve Provides Sample Stability for Cepheid Xpert CT/NG Test**  
C. M. Connelly, Streck, La Vista, NE
- 
- A-297 Feasibility of a Novel Seegene Multiplex PCR Panel for the Simultaneous Detection of HSV-1, HSV-2, VZV and Mpox: A Focus on Inclusion, Confirmation and LOD Assessment**  
T. Johnson, Seegene USA, Irvine, CA
- 
- A-298 A Novel DNA Array Technology to Detect and Discriminate Complex Panels of Microbial Pathogens**  
M. E. Hogan, PathogenDx, Tucson, AZ
- 
- A-299 Assessment of a New Miniaturized Line Blot System for Fully Automated Serodiagnosis of Borrelia Infections**  
M. Sabalza, EUROIMMUN US Inc, Mountain Lakes, NJ
- 
- A-300 Comparative Analysis of Serology Test Performance: Evaluation of Elecsys Platform for Hepatitis Markers**  
I. Metushi, UCLA David Geffen School of Medicine, Los Angeles, CA
- 
- A-301 Evaluation of Second-Generation Visby Medical Sexual Health Point-of-Care Test: Clinical Concordance, Analytical Error Rates, and Result Turnaround Time**  
B. Kelley, Mayo Clinic, Rochester, MN
- 
- A-302 Evaluation of Real-time PCR Assays for Detection of Sexually-transmitted Infections**  
H. Soong, KK Women's and Children's Hospital, Singapore, Singapore
- 
- A-303 Saliva-based Detection of MPOX in Individuals Presenting with Lesions for Diagnostic Testing**  
S. Saladi, Neelyx Labs, Wood Dale, IL
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## PEDIATRIC & MATERNAL FETAL MEDICINE

- A-306 High Sensitivity Capability of an Anti-müllerian Hormone Assay on the Beckman Coulter Dxl 9000 Immunoassay Analyzer\*, a Next Step Toward Enabling Ovarian Failure Staging?**  
S. Kuklok, Beckman Coulter, Chaska, MN
- 
- A-307 Clinical Utility of Serum Calprotectin in Febrile Infants Presenting to the Emergency Department**  
M. Bohn, University of Toronto, Toronto, Canada
- 
- A-308 Placental Growth Factor Kryptor Immunoassay Reveals Quality Control Imprecision and Drift**  
C. Chan, University of Chicago, Chicago, IL
- 
- A-309 Multicenter Performance Evaluation of the ProNephro AKI™ Assay and Sample Stability in Pediatric Patients**  
H. Malaeb, Yale University School of Medicine, New Haven, CT
- 
- A-310 Neurodevelopmental Disorders and Hyperlipidemia in HIV-Exposed Uninfected Children in the Bronx, New York**  
ADLM#  
ACADEMY  
E. Qama, Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
- 
- A-311 Evaluating the Predictive Value of the sFlt-1/PlGF Ratio in Hypertensive Pregnancies for Preeclampsia**  
Y. Li, Weill Cornell Medicine, New York, NY
- 
- A-312 Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase-1 for Preeclampsia in the Second and Third Trimester**  
W. Luo, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
- 
- A-313 Use of the Preeclampsia Ratio in the Prognosis of Preterm Delivery and Adverse Outcomes**  
S. A. Love, Siemens Healthcare Diagnostics Inc., Tarrytown, NY
- 
- A-314 Influence of EDTA on TSH and 17-OHP in Newborn Screening: A Case Study**  
S. Kim, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
- 
- A-315 Cardiac Troponin Concentrations in Pediatric Patients Infected with Respiratory Syncytial Virus**  
M. Brown, Washington University School of Medicine, St. Louis, MO
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### PEDIATRIC & MATERNAL FETAL MEDICINE

- A-316 A Quantitative Gas Chromatography Tandem Mass Spectrometry Method for Metabolic Profiling of Urine Organic Acids and Acylglycines**  
A. Ptolemy, *Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA*
- 
- A-317 Development of a Patient-Focused Volumetric Absorptive Microsampling Strategy to Assess Urinary Amino Acid Excretion**  
A. Ptolemy, *Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA*
- 
- A-318 Validation of Umbilical Cord Blood as an Alternate Sample Type for Quantitative In Vitro Detection of Glucose-6-Phosphate Dehydrogenase in Neonates**  
E. Donovan, *LabCorp, Raritan, NJ*
- 
- A-319 Capillary Blood Collection for Egg-cellent Reproductive Insights**  
W. C. Brandon, *Labcorp, Burlington, NC*
- 
- A-320 Determination of Guanidinoacetate Methyltransferase Enzyme Biomarkers in Newborn Dried Blood Spot by Tandem Mass Spectrometry — A Two Tier Approach**  
ADLM#  
ACADEMY  
K. Dhillon, *California Department of Public Health, Richmond, CA*
- 
- A-321 Rethinking the Role of Race in Prenatal AFP Screening for Open Neural Tube Defects**  
W. Butler, *Hospital of the University of Pennsylvania, Philadelphia, PA*
- 

### ePOSTER ACCESS

Visit the ePoster stations in the Poster Hall to browse the ePosters. Stop by at 12:30 pm or 2:30 pm to see ADLM Division-led ePosters Discussions. Chicago All Access attendees can also view ePosters anytime from now through August 30 by visiting [meeting.myadlm.org/ePosters](https://meeting.myadlm.org/ePosters).



### DOWNLOAD THE MOBILE APP

[meeting.myadlm.org/2024app](https://meeting.myadlm.org/2024app)

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## POINT-OF-CARE TESTING

- A-323 Advancing Point-of-Care Testing: Independent Evaluation of the Truvian Platform**  
A. B. Wells, *UCSD, La Jolla, CA*
- 
- A-324 Performance and Turnaround Time of Plasma Lactate Assay on POCT, Blood Gas Instrument, and Chemistry Analyzer**  
K. Lockart, *University of Illinois - Chicago, Chicago, IL*
- 
- A-325 Overcoming Hemolysis Photometric Interference on Glucose Results**  
C. Torres, *LetsGetChecked, Monrovia, CA*
- 
- A-326 Testing for Multidrug-Resistant *Acinetobacter Baumannii* with a Microfluidic Device**  
C. Gärtner, *Microfluidic ChipShop GmbH, Jena, Germany*
- 
- A-327 Statistical Technique-based Image Analysis for Digital Reading of Immunochemistry Cassette**  
S. D. Bhattacharya, *Siemens Healthineers, Bangalore, India*
- 
- A-328 Accuracy of the Glucose Test in the *i-STAT® G* Cartridge Using the *i-STAT 1* System for Venous, Arterial and Capillary Whole Blood Specimens in Clinical Settings**  
S. F. Kornfeld, *Abbott Point of Care, Ottawa, Canada*
- 
- A-329 Accuracy of the pH,  $PO_2$ , and  $PCO_2$  Tests in the *i-STAT® G3+* Cartridge Using the *i-STAT 1* System for Venous, Arterial and Capillary Whole Blood Specimens in Clinical Settings**  
S. F. Kornfeld, *Abbott Point of Care, Ottawa, Canada*
- 
- A-330 Implementation of a Point-of-Care Emergency Preparedness Policy: Are You Ready for a Disaster?**  
B. A. Elli, *UPMC Altoona, Altoona, PA*
- 
- A-331 Monitoring Operators Proficiency at Point-of-Care is Crucial for Reliable Patient Values – A Practical Example with Patient Blood Chloride, Potassium and Sodium Measurands Assayed with *i-STAT®***  
V. Genta, *Sentara Virginia Beach General Hospital, Virginia Beach, VA*
- 
- A-332 Identifying At-Risk Patients Pre-IV Contrast Administration via POCT Creatinine Measurement**  
R. Hawkins, *Tan Tock Seng Hospital, Singapore, Singapore*
- 
- A-333 Comparison Between Measured Total Carbon Dioxide and Calculated Bicarbonate in Hospitalized Patients**  
N. K. McLaughlin, *Washington University in St. Louis, St. Louis, MO*
- 
- A-334 Vital One: A Point-of-Care Platform for Rapid, Comprehensive, Central-Lab Quality Blood Testing**  
M. Koussa, *Vital Biosciences Inc., Toronto, Canada*
- 
- A-335 Evaluation of the Next Generation *i-STAT®* Point-of-Care Prothrombin Time Test**  
S. Ball, *Abbott Point of Care, Ottawa, Canada*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### POINT-OF-CARE TESTING

- A-336 Comparative Evaluation of Homogeneous Point-of-Care and Central Laboratory Chemiluminescent Immunoassays for High-Sensitivity Cardiac Troponin I**  
L. Ya Hui, *Fuwai hospital, CAMS & PUMC, Beijing, China*
- 
- A-337 The Utility of Urinary Human Chorionic Gonadotropin Testing in the Emergency Department**  
R. Kim, *UT Southwestern Medical Center, Dallas, TX*
- 
- A-338 Assessing the Technical and Analytical Performance of Point-of-Care Testing Devices for Blood Lipids Measurements**  
K. Dahya, *Centers for Disease Control and Prevention, Atlanta, GA*
- 
- A-339 Timely Audits and Open Communications are Key to Improved Device Result Transmission and Reduction of Potential Errors at the Point-of-Care**  
B. Doe, *Loyola University Medical Center, Maywood, IL*
- 
- A-340 Analysis of OrganOx Liver Perfusate at the Point-of-Care on the Abbott iSTAT and Nova Glucometer to Support Clinical Evaluations of Donor Livers Prior to Transplantation**  
B. Doe, *Loyola University Medical Center, Maywood, IL*
- 
- A-341 Precision Evaluation of the i-STAT® Glucose Test in the i-STAT G Cartridge using the i-STAT 1 System for Venous, Arterial and Capillary Whole Blood Specimens in Clinical Settings**  
L. Thibodeau, *Abbott Laboratories, Ottawa, Canada*
- 
- A-342 Precision Evaluation of the pH, PO<sub>2</sub> and PCO<sub>2</sub> tests in the i-STAT® G3+ Cartridge using the i-STAT 1 System for Venous, Arterial and Capillary Whole Blood Specimens in Clinical Settings**  
L. Thibodeau, *Abbott Laboratories, Ottawa, Canada*
- 
- A-343 Novel In-Line Hemolysis Detection on a Blood Gas Analyzer for Capillary Samples**  
L. Adib, *Werfen, Bedford, MA*
- 
- A-344 Delivering Better and Timely Diagnosis for Critical Patients: POC Clinical Performance Versus Central Laboratory Assays in Key Cardiac Markers**  
J. Aldunate, *Laboratorio Redsalud, Santiago, Chile*
- 
- A-345 Effect of Hemolysis on Routine Blood Gas Analytes**  
B. Agana, *Johns Hopkins University, Baltimore, MD*
- 
- A-346 Evaluating 14-3-3 $\eta$  Detection in Finger Prick Blood Using Lateral Flow Technology: Advancing Clinical Laboratory Diagnostics**  
N. Sidhu, *Augurex Life Sciences Corp., Vancouver, Canada*
- 
- A-347 A Comprehensive Exdia TRF-LFIA for Simultaneous Quantification of GFAP and NT-proBNP in Distinguishing Ischemic and Hemorrhagic Stroke**  
D. R. Sayyed, *Precision Biosensor Inc, Daejeon, Korea, Republic of*
- 
- A-348 Portable Aptamer-Based Home Monitoring System for Blood Phenylalanine Measurement**  
M. Boyce-Jacino, *Aptatek BioSciences, Inc., Wilmington, DE*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## POINT-OF-CARE TESTING

- A-349 Evaluation of i-STAT® Point-of-Care Blood Gas Cartridges and Competitor Blood Gas Devices Against Reference Standard for PCO<sub>2</sub> and PO<sub>2</sub>**  
C. Beattie, *Abbott Point of Care, Ottawa, Canada*
- 
- A-350 Customer Satisfaction Score: A Key Performance Indicator for multisite installation of POCT Hematology Analyzer "Sight OLO" in 23 Remote Communities of Newfoundland and Labrador, Canada**  
V. Thakur, *Pathology and Laboratory Medicine program, NLHS, Department of Laboratory Medicine, Memorial University, St John's, Canada*
- 
- A-351 Versatile and Sensitive Microfluidic Immunoassay for Improved Point-of-Care Diagnostics**  
S. J. Bennett, *Burst Diagnostics, Fort Collins, CO*
- 
- A-352 Assessment of Hemolysis Detection Using a Point-of-Care Blood Gas Instruments**  
M. Brown, *Washington University School of Medicine, St. Louis, MO*
- 
- A-353 Lay User Testing of Rapid Multiplexed HIV/TP Test**  
K. D. Jones, *Palladium Diagnostics LLC, Las Cruces, NM*
- 
- A-354 Evaluating Emergent POC Technology for Sickle Cell Testing in Resource Limited Settings**  
E. Schuler, *Cincinnati Children's Hospital Medical Center, Cincinnati, OH*
- 
- A-355 Comparison of Arterial and Venous Whole Blood Samples Analyzed on the Quanta System With the QPlus and QStat Cartridges**  
A. A. Uribe, *The Ohio State University Wexner Medical Center, Columbus, OH*
- 
- A-356 A Hand-Held Microfluidic Platform for Rapid and Sensitive Identification of Respiratory Viruses From Nasal Swab Samples**  
W. Zhang, *Delta Electronics (int'l) Singapore Pte Ltd, Singapore, Singapore*
- 
- A-357 Evaluation of a Home Kit for Lay User Collection, Centrifugation, and Refrigeration of Capillary Blood Specimens**  
G. Iacovetti, *Labcorp, Pleasanton, CA*
- 
- A-358 Extended Linearity Studies for pO<sub>2</sub>, pCO<sub>2</sub>, K<sup>+</sup> Cl<sup>-</sup> on GEM 5000 Blood Gas Analyzers Using a Combination of Verification Materials**  
V. Samara Simha Subhash Chandra, *University of Chicago School of Medicine, Chicago, IL*
- 
- A-359 Clinical Performance Evaluation of the Polymerase Chain Reaction (PCR)-Based cobas CT/NG/MG Test for Use on the cobas liat System in a Clinical Laboratory Setting and Point-of-Care (POC) Location**  
B. Van Der Pol, *University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL*
- 
- A-360 Point-of-Care Application of a Novel Plasmonic Fiber-Optic Absorbance Biosensor (P-FAB) to Perform a Rapid, Automated Immunoassay for Detection of Δ-9-Tetrahydrocannabinol in Oral Fluid**  
J. Seimetz, *Ricovr Healthcare Inc, Princeton, NJ*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### POINT-OF-CARE TESTING

- A-361** Developing a Process for Preparation and Validation of Point-of-Care Middleware Upgrades  
R. Simpson, *Loyola University Medical Center, Maywood, IL*
- 
- A-362** Hemolysis Detection and Flagging of Potassium Results on GEM Premier 7000 with iQM3  
M. Butler, *Werfen, Bedford, MA*
- 
- A-363** At-home Dried Blood Spot Collection: Enhancing Healthcare Outcomes Through Accessible Laboratory Testing for High-Risk Populations  
I. Tarhoni, *Rush University Medical Center, Chicago, IL*
- 
- A-364** Good Practices in the Implementation and Use of POCT Tests in Compensar-EPS Ambulatory Care Units, Bogotá  
L. J. Forero, *Compensar, Bogota, Colombia*
- 
- A-365** Rapid HIV Testing and Confirmation Reflex Testing Integration in Laboratory Information System (LIS) Using a Point-of-Care Glucometer  
E. K. Leung, *Children's Hospital Los Angeles, Los Angeles, CA*
- 
- A-366** Thromboelastometry-Guided Treatment Algorithm In Postpartum Haemorrhage  
I. Rodriguez Martin, *Hospital Virgen del Rocío, Sevilla, Spain*
- 
- A-367** Development of a Multimodal Point-of-Care Diagnostic Platform to Perform Rapid, Accurate, and Cost-Effective Molecular, Immunochemistry, Clinical Chemistry, and Cytometry Tests  
E. Charrault, *Fluxergy, Irvine, CA*
- 
- A-368** Feasibility of a Five-Minute Sample-to-Answer Basic Metabolic Panel for Point-of-Care Testing on the Fluxergy Analyzer  
E. Charrault, *Fluxergy, Irvine, CA*
- 
- A-369** Implementation of Point-of-Care Testing in Health Care Setting in State of Qatar: Prospective Challenges and Impact in Clinical Practice  
J. S. Habib, *Hamad Medical Corporation, Doha, Qatar*
- 
- A-370** Performance Evaluation of the Nova Stat Profile Prime Plus Blood Gas Analyzer  
K. Park, *Samsung Changwon Hospital, Changwon, Korea, Republic of*
- 



#### TELL US ABOUT YOUR CONFERENCE EXPERIENCE!

Be the first to share your thoughts with this quick survey. The first 20 respondents will receive a \$20 Amazon gift card. All respondents will be entered in a drawing for a \$250 Amazon gift card.

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### ANIMAL CLINICAL CHEMISTRY

- B-001 Serum 25-hydroxyvitamin D and C-3 Epimer Concentrations Throughout Gestation in a Bovine Dairy Herd**  
J. P. Buchweitz, *Michigan State University Veterinary Diagnostic Laboratory, Lansing, MI*
- 
- B-002 Method Validation of Cystatin-C in the Serum of NHP**  
A. Sringeri, *Charles River Laboratories, Ashland, OH*
- 
- B-003 Method Development of Macroscopic Urine Stability in Rats**  
A. Sringeri, *Charles River Laboratories, Ashland, OH*
- 
- B-004 Method Validation of Lactate in the Plasma of Rats**  
A. Sringeri, *Charles River Laboratories, Ashland, OH*
- 

### AUTOMATION & ANALYTICAL TECHNIQUES

- B-005 Improved Sensitivity on the Beckman Coulter Dxl 9000 Immunoassay Analyzer\* Enables Reduction of Required Sample and Reagent Volumes for Immunoassays**  
S. Kuklok, *Beckman Coulter, Chaska, MN*
- 
- B-006 Use of Sysmex UN-3000 Research Parameters for Semiquantitative Analysis of Urine Microscopic Elements**  
M. Nakashima, *Cleveland Clinic, Cleveland, OH*
- 
- B-007 Automation for the Isolation of Peripheral Blood Mononuclear Cells with Hamilton Robotics for T-Spot Testing**  
A. Dang, *Bach Diagnostics, Irvine, CA*
- 
- B-008 An Evaluation of the Analytical Performance of the New Beckman Coulter DxC 500i Clinical Analyzer**  
B. Tran, *Beckman Coulter, Inc., Brea, CA*
- 
- B-009 Verification of Result Interchangeability Between Two Analyzers in the Determination of Uric Acid and Urea**  
S. Garcia-Valdecasas, *Príncipe de Asturias University Hospital, Alcala de Henares, Spain*
- 
- B-010 Intercomparison Study of Methods Between Atellica Solution® and CI® Analyzers for Sodium, Potassium, and Chloride**  
S. Garcia-Valdecasas, *Príncipe de Asturias University Hospital, Alcala de Henares, Spain*
- 
- B-011 Intermethod Comparison Verification Between Atellica Solution® and CI® Analyzers for Amylase and Glucose Methods**  
S. Garcia-Valdecasas, *Príncipe de Asturias University Hospital, Alcala de Henares, Spain*
- 
- B-012 Total Laboratory Automation: Assessing Serum Bicarbonate Stability Under Conditions Experienced Using the Roche Diagnostics Cobas Connection Module**  
M. A. Nicklas, *Mayo Clinic, Rochester, MN*
- 
- B-013 Improving the Workflow of Blood and Coagulation Tests in Clinical Laboratory through the Utilization of Laboratory Automation Track Systems**  
M. Yang, *Taichung Veterans General Hospital, Taichung, Taiwan*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### AUTOMATION & ANALYTICAL TECHNIQUES

- B-014 Performance Evaluation of the Automated Cell Image Analyzer DI-60 for Eukocyte Differential Count**  
S. Chang, *Kyungpook National University Hospital, Daegu, Korea, Republic of*
- 
- B-015 Analytical Verification of MR-proADM Biomarker in Human EDTA Plasma on Immunoassay Analyzer LIAISON® XL of Diasorin**  
R. Ferrer-Costa, *Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona, Spain*
- 
- B-016 Evaluation of Pyridoxamine Phosphate (PAMP) for AST/ALT Reagents with Recombinant Human Apoenzymes**  
T. Oba, *CS Development Department Nagahama Plant, Oriental Yeast Co., Ltd., Nagahama-shi, Shiga, Japan*
- 
- B-017 Benchtop Glyco-Analyzer: From Development of Biomarker to Potential Use in Clinical Setting**  
H. Shimazaki, *Precision System Science Co., Ltd., Matsudo, Japan*
- 
- B-018 Design and Development of MAS™ Diabetes Max Controls, Ready-to-Use Plastic Tube Format**  
M. Nagaraj, *ThermoFisher Scientific, Fremont, CA*
- 
- B-019 Reduction in Culture Media Costs, without Impacting Turnaround Time, Through Implementation of an Automated Microbiology Platform and Gram Stain Interpretation**  
J. K. Lau, *Mayo Clinic Arizona, Phoenix, AZ*
- 
- B-020 Study of Method Intercomparison Between Atellica Solution® and CI® Analyzers for T4L,  $\beta$ -HCG Total, and PSA Total**  
M. Ruiz-Alvarez, *Principe De Asturias University Hospital, Alcalá De Henares, Spain*
- 
- B-021 Impact of Assay Conditions on FT4 Measurement Accuracy of Equilibrium Dialysis LC/MS/MS Clinical Assay**  
L. Zhang, *CDC, Atlanta, GA*
- 
- B-022 A New DNA Size-Selection Technology: Methods for Isolating, Capturing, and Recovery of Target Macromolecules by Gel Electrophoresis**  
P. T. Nix, *Princeton Separations Scientific LLC, Monmouth Junction, NJ*
- 
- B-023 Workflow Evaluation of the New Siemens Atellica CI Analyzer**  
J. Rhea-Mcmanus, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-024 Applying Lumigen HyPerBlu™ Technology to Oxidoreductase Chemiluminescence Assay Development**  
Y. Khomutnyk, *Lumigen, Inc., Southfield, MI*
- 
- B-025 Revolutionizing NGS-driven Laboratory Developed Tests: The Impact of Automated Liquid Handling on Plate-Based Bead Clean-Up**  
L. Henry, *SPT Labtech, Melbourn, United Kingdom*
- 
- B-026 Transforming PCR Protocols In Pandemic Response With Automated Non-Contact Liquid Dispensing**  
L. Henry, *SPT Labtech, Melbourn, United Kingdom*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## AUTOMATION & ANALYTICAL TECHNIQUES

- B-027** CLSI-Based Result Precision on the cobas ISE neo and cobas c 703 Analytical Units Across Two Sites in Europe  
A. Thorenz, *Roche Diagnostics GmbH, Mannheim, Germany*
- 
- B-028** Result Precision on the New cobas pro Integrated Solutions cobas ISE neo and cobas c 703 Analytical Units Under Routine-Like Conditions Across Two Sites in Europe  
A. Thorenz, *Roche Diagnostics GmbH, Mannheim, Germany*
- 
- B-029** Evaluation of the Analytical Performance of Creatine Kinase, Lactate Dehydrogenase L-P, Myoglobin Assays on the Atellica CI Analyzer  
R. H. Carter, Jr., *Siemens Healthineers, Tarrytown, NY*
- 
- B-030** Performance Evaluation of Siemens Atellica® IM Anti-Müllerian Hormone Assay  
E. Shang, *Yale University School of Medicine, New Haven, CT*
- 
- B-031** A New Ready to Use Bio-Rad Quality Control to Streamline Daily Workflow  
A. M. Yagoot, *King Abdulaziz Medical City, Jeddah, Saudi Arabia*
- 
- B-032** Evaluation of Assay Performance for Atellica CI 1900 Analyzer in Routine Chemistry, Division of Laboratory Medicine, UMMC  
A. C. Yeoh, *University Malaya Medical Center, Kuala Lumpur, Malaysia*
- 
- B-033** Real World Assessment of the Impact of Infectious Disease Assays on Workflow Capabilities of Siemens Atellica IM Analyzers  
C. Abou-Diwan, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-034** Performance Evaluation of the Total Bile Acids (TBA) Assay on Mindray BS-2800M Analyzer  
J. Dai, *Mindray IVD Innovation Center, Oakdale, MN*
- 
- B-035** Atellica CI Analyzer Sample-to-Sample Carryover Performance Evaluation  
T. Kampfrath, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-036** Systematic Evaluation of Antibody-Antigen Interactions for Suitability in Immunoassays Using Parallel Microarray ELISA  
M. Coolen, *Future Diagnostics, Wijchen, Netherlands*
- 
- B-037** Zeon Original Coating Technology COP Microplates for Cell Imaging  
T. Ishigami, *Zeon Corporation, Kyoto, Japan*
- 
- B-038** A Novel Ultrasensitive Single-Molecule Counting Technology for Quantitation of Low Abundance Biomarkers  
R. Tobias, *Fluxus, Inc., Sunnyvale, CA*
- 
- B-039** Evaluating Inter-Analytic Module Immunoassay Carryover  
A. M. Spiesman, *Cleveland Clinic, Cleveland, OH*
- 
- B-040** Direct Aspiration of Cryogenic Matrix Tubes on the Siemens Atellica System With Epic-Beaker Integration of External Barcode IDs for Analysis Small Volume Biobanked Specimens  
S. Cotten, *University of North Carolina, Chapel Hill, NC*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### CLINICAL & DIAGNOSTIC IMMUNOLOGY

- B-043 Q-nab™ IgG Kit: Verification and Validation of a Novel Cell-Free Quantitative Neutralizing Antibody Assay**  
J. Lim, *Autonomous Medical Devices Incorporated, Menlo Park, CA*
- 
- B-044 Development and Evaluation of an Assay for the Detection of Human Total IgE in Serum on the Fully Automated Chemiluminescence Immunoassay Platform — Autolumo® 2000 Plus Analyzer**  
X. Yang, *AdvanBio, Irvine, CA*
- 
- B-045 Evaluation of the Analytical Performance of Three Sepsis Related Assays on the Atellica CI Analyzer**  
J. Frenna, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-046 Development and Validation of an Automated Live Cell-Based Flow Cytometry Assay Platform for Measuring AQP4-IgG**  
Y. Nam, *Mayo Clinic, Rochester, MN*
- 
- B-047 A Rapid Host-Response Test Supports Antimicrobial Stewardship at a Micro-Hospital Emergency Department**  
B. Duchateau, *MeMed Diagnostics, Andover, MA*
- 
- B-048 Proposal of a New Monitoring Algorithm for Patients With a HIV Positive Result with the Elecsys HIV DUO Test**  
J. A. Castro Menendez, *Salud Digna A.C., Culiacan, Mexico*
- 
- B-049 Evaluation of IL-6, D-Dimer, and S100β as Clinical Biomarkers for Severity and Prognosis of Subarachnoid Hemorrhage Patients: A Retrospective Study**  
S. Hua, *Sichuan Provincial People's Hospital, Chengdu, China*
- 
- B-050 A Comparison of Two Semi-Quantitative Tests, Abbott's Advise DX SARS-CoV-2 IgG II and Beckman Coulter's Access SARS-COV-2 IgG II, for Measuring IgG Antibody Levels After Sars-CoV-2 Pfizer-BioNTech Vaccination**  
W. Niklinski, *John H. Stroger Hospital of Cook County, Chicago, IL*
- 
- B-051 Clinical Validation of Vectra® DA: A Multi-Biomarker Based Test for the Objective Measurement of Disease Activity in Patients with Rheumatoid Arthritis**  
K. Chun, *LabCorp, Calabasas, CA*
- 
- B-052 Celiac Disease Risk Assessment of HLA-DQ Typing in IgA Deficient Patients**  
D. Liu, *Mayo Clinic, Rochester, MN*
- ADLM<sup>®</sup>  
ACADEMY
- 
- B-053 Four Years Summary of Flow Cytometry Live Cell Based Assay for Detecting Serum Anti-aquaporin 4 IgG and Anti-myelin Oligodendrocyte Glycoprotein IgG in a Korean Reference Laboratory**  
S. Moon, *Eone laboratories, Incheon, Korea, Republic of*
- 
- B-054 Performance Evaluation of the VITROS HIV Combo Assay on the Ortho VITROS 3600 System**  
X. Cao, *Hebei North University, Zhangjiakou, China*
- 
- B-055 Comparison of Two Different Methods for Quantitation of Anti-dsDNA Antibody**  
J. Choi, *Eone Laboratories, Incheon, Korea, Republic of*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## CLINICAL & DIAGNOSTIC IMMUNOLOGY

- B-056 Clinical and Analytical Performance Evaluation of Two Immunoassays for the Detection of Mite Specific Serum IgE for Allergy Diagnosis**  
B. C. Ozaki, *Siemens Healthineers, São Paulo, Brazil*
- 
- B-057 Evaluating the Use of Unconcentrated Urine for Protein Electrophoresis and Immunofixation: An Alternative Approach for Efficient Analysis**  
L. V. Rao, *Quest Diagnostics/UMass Chan Medical School, Marlborough, MA*
- 
- B-058 Multicenter Evaluation of the New Access HIV Ag/Ab combo Assay With Highly Sensitive HIV-1 p24 Antigen Detection on the Dxl 9000 Access Immunoassay Analyzer**  
B. Grillet, *Beckman Coulter ImmuneTech, Marseille, France*
- 
- B-059 Development and Validation of Multiplex Quantitative Allergy Tests Based on Automated Flow Fluorescence Immunoassay Analyzer**  
F. Xue, *Dymind, Shenzhen, China*
- 
- B-060 Prevalence of CCD and Profilins Antibodies in a Seasonal Allergy Study**  
ADLM#  
ACADEMY  
T. De Haro, *Hospital Campus de la Salud, Granada, Spain*
- 
- B-061 Related Factors of Renal Injury in Primary Sjögren's Syndrome**  
N. Duan, *Peking University First Hospital, Beijing, China*
- 
- B-062 The Evaluation and Clinical Value of Gastrin-Releasing Peptide Precursor in the Patients with Renal Diseases**  
N. Duan, *Peking University First Hospital, Beijing, China*
- 
- B-063 Changes in Nonalcoholic Fatty Liver Disease and M2BPGi Due to Lifestyle Intervention in Primary Healthcare**  
E. Nah, *Department of Laboratory Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of*
- 
- B-064 Bovine Serum Albumin Coats Silicon Dioxide More Uniformly Near its Isoelectric Point Based on Atomic Force Microscopy Analysis**  
A. L. Okerlund, *Proliant Health and Biologicals, Ankeny, IA*
- 
- B-065 Comparative Analysis of 14-3-3 $\eta$  Autoantibody Assays on Luminex Platform for Diagnosing Axial Spondyloarthritis**  
N. Sidhu, *Augurex Life Sciences Corp., Vancouver, Canada*
- 
- B-066 Verapath Borrelia Burgdorferi Antibody Test: Multiplex Capture, Enrichment, and Detection of B. Burgdorferi Antigens-Specific Immunoglobulins From Saline Oral Rinse Samples**  
K. Shamsundar, *Veravas, Inc, Oakdale, MN*
- 
- B-067 Human IgE Monoclonal Antibodies as Unique Tools for Allergy Diagnostics**  
S. Filep, *InBio, Charlottesville, VA*
- 
- B-068 Plasma Calprotectin as an Index of Draining Tunnel Formation in Hidradenitis Suppurativa**  
A. Havelka, *Gentian AS, Moss, Norway*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### CLINICAL & DIAGNOSTIC IMMUNOLOGY

- B-069 Characterization of a Panel of Antibodies as Diagnostics for NASH and NAFL**  
A. Van Der Hoek, *Icosagen Cell Factory OÜ, Össu, Estonia*
- 
- B-070 Supar: What UACR and GFR Don't Say...**  
S. Valaperta, *ASST Papa Giovanni XXIII, Bergamo, Italy*
- 
- B-071 Unraveling Histamine Intolerance: Exploring DAO Quantity, Elimination Ratios and Cofactor Influences**  
H. Seidl, *Immundiagnostik AG, Bensheim, Germany*
- 
- B-072 Analytical Evaluation of a Novel Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Eleven Autoantibodies Associated with Connective Tissue Diseases in a Spanish Reference Laboratory**  
G. Gomez, *Scientific and Medical Affairs Department, AliveDx Suisse SA, Eysins, Switzerland*
- 
- B-073 Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases**  
G. Gomez, *Scientific and Medical Affairs Department, AliveDx Suisse SA, Eysins, Switzerland*
- 
- B-074 Comparative Evaluation of Clinical Utility Between Indirect Immunofluorescence and Immunoassay Methods for Antineutrophil Cytoplasmic Antibody Detection**  
S. Jeon, *Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of*
- 
- B-075 Evaluation of Patients With Monoclonal Gammopathy of Undetermined Significance Using Optilite Freelite Assays**  
G. Lakos, *The Binding Site, part of Thermo Fisher Scientific, San Diego, CA*
- 
- B-076 Detection of KLHL11 Autoantibodies Using a New Cell-based Indirect Immunofluorescence Assay**  
J. Weiss, *EUROIMMUN US, Mountain Lakes, NJ*
- 
- B-077 F-actin as a New Marker Antigen on an Established Multiparametric Immunoassay Profile for Liver Diseases**  
J. Weiss, *EUROIMMUN US, Mountain Lakes, NJ*
- 
- B-078 Serodiagnosis of Rheumatoid Arthritis Using the New Accentis Chemiluminescence Immunoassay Platform for Anti-CCP Antibody Detection**  
J. Weiss, *EUROIMMUN US, Mountain Lakes, NJ*
- 
- B-079 Characterization of an Isoelectric Focusing Method for Detection of IgG Oligoclonal Banding in Paired Cerebrospinal Fluid and Serum Specimens**  
S. Hosseini, *University of Maryland School of Medicine, Baltimore, MD*
- 
- B-080 Development and Validation of a GQ1b IgG ELISA as a Diagnostic Aid for Subacute Demyelinating Polyneuropathies**  
A. Gorsh, *Mayo Clinic, Rochester, MN*
- 
- B-081 Evaluating Haptoglobin Testing Practices in the Presence of Hemolysis: A Laboratory Perspective**  
K. Patel, *The Ohio State University Wexner Medical Center, Columbus, OH*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## CLINICAL & DIAGNOSTIC IMMUNOLOGY

- B-082 Clinical Investigation of Rods and Rings Pattern in Anti-Nuclear Antibody Test in Korean Patients**  
H. Cho, *Kyung Hee University Hospital, Seoul, Korea, Republic of*
- 
- B-083 Sensitivity of the Sebia Hydrigel 6 Electrophoresis/Immuno-fixation Assay for Detection of Beta-2 Transferrin in Dilute Cerebrospinal Fluid (CSF): Assessment By Image Analysis**  
D. Stickle, *Jefferson University Hospital, Philadelphia, PA*
- 
- B-084 Comparison of Diagnostic Accuracy of ELISA and Rapid Screening Techniques for the Detection of HBsAg, HCV, and HIV Among Blood Donors in Abubakar Tafawa Balewa University Teaching Hospital Bauchi**  
I. Musa, *Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria*
- 
- B-085 Optimizing Thyroglobulin Antibody Interference Thresholds to Minimize Turn-around Time**  
S. Patel, *University of Pittsburgh Medical Center, Pittsburgh, PA*
- 
- B-086 Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure**  
E. Oh, *Seoul St Marys Hospital, Seoul, Korea, Republic of*
- 
- B-087 Sars-cov-2 Nt Chip Test Performance: A Novel Microarray-Based Enzymatic Immunoassay for *in vitro* Identification of Neutralizing Antibodies Against Emerging Variants**  
J. Levi, *DASA, São Paulo, Brazil*
- 
- B-088 Procalcitonin and TWBC as a Prognostic Markers of Hospital Outcomes in Hyperglycemic Emergencies**  
A. A. Azeez, *PMB 5116 University College Hospital, Ibadan, Nigeria*
- 
- B-089 Pseudo-clonal Increased IgG4 with Polyclonal Distribution Demonstrated by MALDI-TOF-MS in a Pediatric Patient with Tricho-Hepato-Enteric Syndrome (THES)**  
M. G. Bayes, *University of Michigan - Michigan Medicine, Ann Arbor, MI*
- 
- B-090 Efficient Hydrophilic Surface Coating with Low Concentrations of Bovine Gamma Globulins**  
V. Nguyen, *Proliant Health and Biologicals, Ankeny, IA*
- 
- B-091 Serum Calprotectin as a Biomarker for the Effectiveness of aTNF $\alpha$  Treatment**  
F. Akbiyik, *Ankara Bilkent City Hospital SHS Laboratory, Ankara, Turkey*
- 
- B-092 Effect of the Increased Specificity in a Recombinant anti-tTG Assay on a Celiac Disease Diagnostic Algorithm**  
A. Ferguson, *Children's Mercy Hospital, Kansas City, MO*
- 
- B-093 Analytical Performances of a Novel Fluorescent Immunoassay of Anti-Müllerian Hormone and Establishment of the Reference Intervals in Chinese Children**  
L. Jiang, *Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### CLINICAL & DIAGNOSTIC IMMUNOLOGY

- B-094 Assessment of a Live Cell-based Flow Cytometry Assay for MuSK-IgG4 Testing in Myasthenia Gravis**  
J. Wu, *Mayo Clinic, Rochester, MN*
- 
- B-095 The Level of Procalcitonin is a Biomarker for Differentiation Between Pathogenic and Non-Pathogenic Bacteria**  
S. Deebukkham, *Uttaradit Hospital, Uttaradit, Thailand*
- 
- B-096 Combination of Presepsin, HE4 Levels and Oxygenation Index as a Biomarker for Sepsis Diagnosis and Prognosis Prediction Among the Intensive Care Unit**  
L. Li, *The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China*
- 
- B-097 Cytokine Profiling in Pan-cancer Analysis: Guiding Clinical Prognosis and Immunotherapeutic Efficacy**  
Y. Li, *Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*
- 
- B-098 Clinical Comparison of Five Assays for the Detection of Anti-DsDNA Antibodies and Their Correlation With Complement Consumption**  
V. Ricchiuti, *Labcorp, Dublin, OH*
- 
- B-099 Validation and Clinical Implementation of Organ Procurement Serology Testing: Our Analytical and Regulatory Experience in Implementing a New Donor Testing Program**  
D. Kirchhoff, *The Mount Sinai Hospital, New York, NY*
- 
- B-100 Utilization and Performance of Monospot and Epstein-Barr Virus Antibody Profile Testing for Diagnosis of Infectious Mononucleosis in Adolescents and Adults**  
X. Zhang, *University Hospitals Cleveland Medical Center, Cleveland, OH*
- 
- B-101 Assessing the Performance of Cerebrospinal Fluid Kappa Immunoglobulin Free Light Chain as a Diagnostic Marker for Multiple Sclerosis Using Automated Chart Review**  
J. Miller, *Mayo Clinic, Rochester, MN*
- 
- B-102 The Impact of Protein/Protein Interactions on Serum Free Light Chain Assay Calibration**  
F. Stewart, *Thermo Fisher Scientific, Birmingham, United Kingdom*
- 
- B-103 Correlation of Novel Markers, Anti-Sa (Citrullinated Vimentin) and Anti-CarP (Carbamylated Protein), with High Vectra® DA Disease Activity Scores in Rheumatoid Arthritis (RA)**  
J. M. Yang, *Labcorp, Calabasas, CA*
- 
- B-104 Correlation of Anti-Centromere Antibodies (ACA) Detection by Indirect Immunofluorescence (IFA) on HEp-2 Cells and by ELISA Demonstrates High Concordance but Highlights Advantage of IFA**  
J. M. Yang, *Labcorp, Calabasas, CA*
- 
- B-105 Farr Radioimmunoprecipitation Method Enhances Serial Monitoring of Quantitative Anti-dsDNA (double-stranded) Antibody Measurements in Lupus**  
J. M. Yang, *Labcorp, Calabasas, CA*
- 

ADLM®  
ACADEMY

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## DATA ANALYTICS, INFORMATICS & STATISTICS

- B-107 Advancing Parasitology Laboratory Quality and Processes Through Artificial Intelligence (AI) and Automation**  
M. C. Feres, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- B-108 Delta Check Performance Assessment by Using Real-World Data at the Temple University Health System**  
M. Ulas, *Temple University Hospital, Philadelphia, PA*
- 
- B-109 Six Sigma Analysis for Enhancing Biochemistry Internal Quality Control in a Private Laboratory in India**  
T. Patel, *Gunjan Lab LLP, Bharuch, India*
- 
- B-110 Descriptive Analysis of Multiple Myeloma Participants in the NIH All of Us Research Program Cohort: Insights into Demographics Disparities**  
T. A. Houze, *All of Us Research Program, National Institutes of Health, Bethesda, MD*
- 
- B-111 Advancing Precision Medicine in Multiple Myeloma: Addressing Demographic Variabilities and Imbalanced Data in the NIH All of Us Research Program Cohort**  
T. A. Houze, *All of Us Research Program, National Institutes of Health, Bethesda, MD*
- 
- B-112 Regression Analysis Techniques for Assessing Calibration Reproducibility Within and Between Instruments. A Practical Example with Blood Ca<sup>2+</sup> Assayed with Two cobas® b 221 Analyzers**  
V. Genta, *Sentara Virginia Beach General Hospital, Virginia Beach, VA*
- 
- B-113 Beckman Coulter Dxl 9000 Immunoassay Analyzer Assay Performance Meets New CLIA 2024 Performance Goals With Highest Proportion of Six Sigma Performance Amongst All Major Manufacturers**  
S. Westgard, *Westgard QC, Madison, WI*
- 
- B-114 Reference Interval (RI) Estimation for TSH in Adults Using an Indirect Method With Unsupervised Machine Learning Tool and R Programming Language**  
C. Meira Dias, *DASA, São Paulo, Brazil*
- 
- B-115 Software Data Processing and Review LC-MS/MS Workflow Improvements for Clinical Research**  
L. Calton, *Waters Corporation, Wilmslow, United Kingdom*
- 
- B-116 Cost Estimation of Laboratory Test Overuse in 14 Ordered Parameters: Experience From 6 Hospitals and 65 Primary Care Centers**  
ADLM#  
ACADEMY  
L. Puigvi, *CLILAB Diagnostics, Vilafranca del Penedès, Barcelona, Spain*
- 
- B-117 Rapid Classification of Cleanliness Grades of Vaginal Discharge through Computational Analysis of SERS Spectra via Variational Auto-Encoder Model and Long Short-Term Memory Networks**  
L. Wang, *Guangdong Provincial People's Hospital, Guangzhou, China*
- 
- B-118 Comparison of Statistical Methods, Chauvenet Test, and Interquartile Deviation for Urinary Sediment Inter Microscopists Evaluation**  
D. R. Ramadan-Boscolo, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### DATA ANALYTICS, INFORMATICS & STATISTICS

- B-119 Comparative Performance of GPT-4 and CNV-ETLAI in Extracting Copy Number Variations from Medical Journals: Bridging the Gap Between Large Language Models and Specialized NLP Tools in Genomic Data Interpretation**  
J. Choi, *Seegene Medical Foundation, Seoul, Korea, Republic of*
- 
- B-120 Reference Interval (RI) Estimation for Pediatric Magnesium Using an Indirect Method with Unsupervised Machine Learning Tool and Programming Language**  
D. Canali, *Diagnóstico da América, São José, Brazil*
- 
- B-121 Optimizing Test Ordering: Leveraging Heuristics in Naming Conventions — A PSA Case Study**  
C. Orahoske, *University of California San Francisco, San Francisco, CA*
- 
- B-122 Improving the Diagnostic Utility of Multiplexed Assays in Laboratory Medicine with Machine Learning**  
H. A. Miller, *University of Louisville, Louisville, KY*
- 
- B-123 Prediction of Opioid Use Duration in Post-Surgical Orthopedic Patients Using CYP2D6 Inhibitor Index and Routine Laboratory Markers**  
ADLM#  
ACADEMY  
H. A. Miller, *University of Louisville, Louisville, KY*
- 
- B-124 Structure-based Variant Effect Prediction and Design of Functional CYP2C9 Variants by Virtual Evolution**  
C. Li, *Peking University, Beijing, China*
- 
- B-125 Laboratory Profiles for Diagnostic Workup of Acute Abdominal Pain in the Emergency Department: A Comparative Study of University and Non-University Acute Care Hospitals in Germany and Switzerland**  
I. Bauer, *Philipps University Marburg, Marburg, Germany*
- 
- B-126 Development of Machine Learning Model for Urinary Tract Infection Prediction**  
D. H. Bücker, *Hospital das Clínicas – Universidade Federal de Minas Gerais - EBSEERH, Belo Horizonte - MG, Brazil*
- 
- B-127 The Effect of Hemolysis on Potassium Measurement in a Community Setting: The Marching Error**  
F. Cai, *Alberta Precision Laboratories, Calgary, Canada*
- 
- B-128 Delivering Predictable Operational Efficiency Gains at Our Core Central Reference Laboratory With Strategic Deployment Of Navify® Lab Operation Informatics Automation Solution**  
A. L. Christy, *Metropolis Healthcare Limited, Mumbai, India*
- 
- B-129 Distribution of Assay Values in Clinical Practice**  
S. Sarkar, *Abbott Laboratories, Carlsbad, CA*
- 
- B-130 Time-of-Day Dependence of Running Averages for Some Components of Metabolic Panels at Our Hospital: Relation to Strategy for Patient-Based Quality Control**  
D. Stickle, *Jefferson University Hospital, Philadelphia, PA*
- 
- B-131 The Fallacy of Average Sigma Levels From Mixed Sample Levels**  
Z. Brooks, *AWEsome Numbers Inc., Worthington, Canada*

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## DATA ANALYTICS, INFORMATICS & STATISTICS

- B-132 Within Limits — Is My Thyroid Just Plump, or Are These Reference Intervals Telling Me Something?**  
A. Bransfield, *Cork University Hospital, Cork, Ireland*
- 
- B-133 Uric Acid: A Description of the Values Found in Adult Patients Treated During 2022 in a High Complexity Hospital**  
A. I. Corominas, *Hospital Nacional Prof A Posadas, Buenos Aires, Argentina*
- 
- B-134 Reference Interval of Cystatin C, Urea and Creatinine in Adult Nigerians: A Pilot Study**  
A. A. Azeez, *PMB 5116 University College Hospital, Ibadan, Nigeria*
- 
- B-135 Evaluation of Verification Decision Limits (VDL) for Routine Coagulation Post-Analytical Review: A Preliminary Analysis**  
O. Limpornpugdee, *Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*
- 
- B-136 From Result to Response: The Development of Laboratory-Based Scoring Models to Predict COVID-19 Patient Outcomes**  
M. S. Scott, *University of Toronto, Toronto, Canada*
- 
- B-137 Sepsis Risk Prediction Using Machine Learning (ML) and Routine Blood Markers Up to 1 Week Before Emergency Admission**  
R. Gopalan, *BSRM Consulting, Durham, NC*
- 
- B-138 A Harmonization Program Leading to Improved Accuracy and Precision of Hemoglobin A1c (HbA1c) Testing: A Six-Year Multi-Site, Multi-Instrument Review and Comparison**  
W. Meyers, *ICON plc., Farmingdale, NY*
- 
- B-139 Ai-All Inclusive, Artificial Intelligence Cannot Outsmart the Clinical Chemist**  
R. Ibrahim, *Baylor College of Medicine/Texas Children's Hospital, Houston, TX*
- 
- B-140 Use of the Metabolic Health Index for Correlation With Comorbidity Reduction for Patients Undergoing Bariatric Surgery**  
A. Aravamudhan, *U of M, Minneapolis, MN*
- 
- B-141 Analysis of Risk Factors and Construction of Prediction Model for Pneumonia in Patients With Pneumoconiosis Based on the Clinical Laboratory Indexes**  
Y. Xu, *the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China*
- 
- B-142 Using Big Data Analytics to Measure the Multi-year Consistency of Sigma Metrics for Vitros Cardiac Assays**  
J. Miller, *QuidelOrtho, Rochester, NY*
- 
- B-143 Using Big Data Analytics to Measure the Multi-year Consistency of Sigma Metrics for Vitros Oncology Assays**  
J. Miller, *QuidelOrtho, Rochester, NY*
- 
- B-144 Sigma Metrics for Vitros Reproductive Endocrinology Assays Across Multiple Fluid Levels**  
J. Miller, *QuidelOrtho, Rochester, NY*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MASS SPECTROMETRY & SEPARATION SCIENCES

- B-146** **Unlocking the Potential of Large-Cohort Proteomics Studies with the Orbitrap Astral Mass Platform**  
Y. Xuan, *Thermo Fisher Scientific, Bremen, Germany*
- 
- B-147** **Enhancing the Detection of Vitamin D Metabolites by LC-MS/MS Using a Novel Derivatization Kit**  
S. Muramatsu, *Clinical Laboratory, Keio University Hospital, Shinjuku-ku Tokyo, Japan*
- 
- B-148** **Bacer: Decentralized Isotope Dilution Method With Lab Blinding for Blood Alcohol Content**  
M. Nie, *West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China*
- 
- B-149** **Diverse Glycosylation Of Circulating Alpha Fetoprotein in Chronic Liver Diseases Profiled By Intact Mass High Resolution Mass Spectrometry**  
ADLM#  
ACADEMY  
Y. K. Yang, *Mayo Clinic, Rochester, MN*
- 
- B-150** **Chromatographic Separation and Quantitation of Human Insulin and Lispro Analog in Serum Using Liquid Chromatography High-Resolution Mass Spectrometry**  
M. Campbell, *Mayo Clinic, Rochester, MN*
- 
- B-151** **Development and Validation of Plasma Catecholamines by Mass Spectrometry**  
J. Kemp, *Mayo Clinic, Rochester, MN*
- 
- B-152** **Analysis of Carbonyl Compounds in Exhaled Breath for Detection of COVID-19**  
X. Fu, *University of Louisville, Louisville, KY*
- 
- B-153** **Improving Accuracy of IgG Subclasses Quantitation in Serum Using Liquid Chromatography — Tandem Mass Spectrometry (LC-MS/MS) on SCIEX 7500**  
ADLM#  
ACADEMY  
R. Yi, *Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Vancouver, Canada*
- 
- B-154** **Development and Evaluation of an Automated High-Throughput Magnetic Bead-Based Pre-treatment Platform for Lipid-Soluble Vitamins in Clinical Mass Spectrometry**  
T. Ma, *Zybio, Inc, Chongqing, China*
- 
- B-155** **Analysis of Monoclonal Antibodies Using a Quantification LC-MS/MS Kit — Spotlight on Infliximab**  
L. Calton, *Waters Corporation, Wilmslow, United Kingdom*
- 
- B-156** **Extraction Strategy for Therapeutic Drug Monitoring of Sirolimus and Tacrolimus Using Volumetric Absorptive Microsampling**  
B. Guarino, *Boston Children's Hospital, Boston, MA*
- 
- B-157** **High Resolution Liquid Chromatography — Mass Spectrometry (LC-MS) for Rapid, High-Throughput Clinical Testing of  $\beta$ 2-Transferrin in Human Nasal Secretions**  
M. W. Mann, *Stanford University, Stanford, CA*
- 
- B-158** **Association Between Multiple Heavy Metals Exposure and Blood Lipid Levels: Evidence from a Cross-Sectional Study of Korean Adults**  
H. Park, *Seoul Clinical Laboratories, Yongin-si, Gyeonggi-do, Korea, Republic of*

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MASS SPECTROMETRY & SEPARATION SCIENCES

- B-159 Fast Cleanup for 19 Steroid Analytes in Serum Using Supported Liquid Extraction (SLE)**  
R. Chakravarti, *Phenomenex (Danaher), Torrance, CA*
- 
- B-160 Simultaneous Analysis of Four Anti-arrhythmic Drugs in 524 Korean Arrhythmic Patients Using Liquid Chromatography-Tandem Mass Spectrometry**  
H. Lee, *Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of*
- 
- B-161 Liquid Chromatography/Mass Spectrometry Analysis of Ethyl Glucuronide and Ethyl Sulfate Using a Perfluorophenyl Stationary Phase**  
P. Simms, *Silver State Diagnostics, Henderson, NV*
- 
- B-162 Evaluation of Two Commercially Available Stable Isotope Labeled Whole-Protein Infiximab as Internal Standard for a Clinical Infiximab LC-MS/MS Assay**  
A. Mcshane, *Cleveland Clinic, Cleveland, OH*
- 
- B-163 Development of a Multiplex Serum Steroid Profiling Assay Utilizing Liquid Chromatography-Mass Spectrometry**  
S. Kim, *Seoul National University Bundang Hospital, Seongnam, Korea, Republic of*
- 
- B-164 Comparison of Analytical Performance of Two Processing Methods for Measurement of Zinc and Copper on Triple Quadrupole Inductively Coupled Plasma Mass Spectrometer**  
J. O. Oyelakin-Ogunbileje, *Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,, Indianapolis, IN*
- 
- B-165 The EXENT System Reliably Distinguishes Daratumumab from Endogenous Monoclonal Immunoglobulins in Multiple Myeloma Patients**  
G. Lakos, *The Binding Site, part of Thermo Fisher Scientific, San Diego, CA*
- 
- B-166 Differentiation of Aziridine Functionality from Related Functional Groups in Protonated Analytes by Using Selective Ion-Molecule Reactions**  
R. Anyaeche, *Purdue University, West Lafayette, IN*
- 
- B-167 Quantification of Thyroglobulin in Serum for Clinical Research Using SISCAPA Workflow Combined with LC-MS/MS**  
L. Davey, *Waters Corporation, Wilmslow, United Kingdom*
- 
- B-168 Development and Validation of a Quantitative Ultra-Performance Liquid Chromatography Quadrupole Time-of-Flight (UPLC-QToF) Method for Urine Organic Acid Analysis**  
Y. Xiao, *Children's Hospital Los Angeles, Los Angeles, CA*
- 
- B-169 Combining the EXENT System and LC-MS for the Detection of Monoclonal Immunoglobulins at Low Levels**  
D. R. Barnidge, *The Binding Site, part of Thermo Fisher, Rochester, MN*
- 
- B-170 Age-Specific Reference Intervals for Ethanolamine Plasmalogen Species in Red Blood Cells Using Liquid Chromatography Tandem Mass Spectrometry**  
I. De Biase, *Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MASS SPECTROMETRY & SEPARATION SCIENCES

- B-171 Iohexol Mass Spectrometry Method Validation and Comparison in Clinical Pediatric Laboratory**  
X. Li, *Children's Healthcare of Atlanta, Atlanta, GA*
- 
- B-172 Correlation of Microbiome Sequencing Data and Quantified Short-Chain Fatty Acids by LC-MS/MS in IBD and Non-IBD Stool Samples**  
M. Diesner, *Immundiagnostik, Bensheim, Germany*
- 
- B-173 Cystine Analysis in Urine Sample Using the Laser Diode Thermal Desorption Technique "LDTD"/Mass Spectrometry (Luxon)**  
A. Correa Wengerkievicz Lopes, *Dasa and SBPC/ML, São Jose, Brazil*
- 
- B-174 Quantification of Vitamin C in Serum as a Biomarker Using the Laser Diode Thermal Desorption Technique "LDTD"/Mass Spectrometry (Luxon)**  
A. Correa Wengerkievicz Lopes, *Dasa and SBPC/ML, São Jose, Brazil*
- 
- B-175 Development of a Rapid and Sensitive LC-MS/MS Assay for Dolutegravir Quantitation in Breastmilk**  
A. R. Rackow, *Johns Hopkins University, Baltimore, MD*
- 
- B-176 Rapid Diagnosis of 21-Hydroxylase Deficiency Using LC-MS/MS for Urinary Unconjugated Steroid Analysis**  
T. Nakagawa, *Clinical Laboratory, Keio University Hospital, Shinjuku-ku, Tokyo, Japan*
- 
- B-177 Development of a Contrived Fecal Matrix for Clinical Validation of a LC-MS/MS Assay to Quantify Microbiota-derived Metabolites in Stool Specimens**  
A. Moran, *University of Chicago, Chicago, IL*
- 
- B-178 A Sensitive LC-MS/MS Assay for Total Testosterone Quantification**  
W. Cao, *University of Wisconsin Hospital and Clinics and Department of Pathology and Laboratory Medicine, Madison, WI*
- 
- B-179 Comparative Evaluation of Cisplatin Release from Alginate Hydrogels with Embedded Silver Nanoparticles: An HPLC and Colorimetric Spectrophotometry Study**  
H. Kalil, *Cleveland State University, Cleveland, OH*
- 
- B-180 A Component Equation Approach to Resolving Calibration Curve Nonlinearity When Using Stable Isotope-Labeled Internal Standards for Quantifying Amino Acids With Mass Spectrometry**  
Y. Kim, *Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*
- 
- B-181 An Ultra Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Quantification of Glycosaminoglycans in Amniotic Fluid**  
H. Zhang, *Duke University Health System, Biochemical and Genetics Laboratory, Durham, NC*
- 
- B-182 Development and Validation of an LC-MS/MS Assay for Simultaneous Measurement of Serum Androstenedione and 17-Hydroxyprogesterone in Serum**  
R. M. Jones III, *Penn State Hershey Medical Center, Hershey, PA*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MOLECULAR DIAGNOSTICS & GENETICS

- B-183 Molecular Study of a Family With Central Diabetes Insipidus and a Rare Mutation in the Arginine Vasopressin Gene**  
M. H. Castelo, *Dasa, Brasil; Instituto de Ensino e Pesquisa Dasa, Brazil, Fortaleza, CE, Brazil*
- 
- B-184 Purifying High-Quality Genomic DNA From Frozen Blood Samples Stored up to 1.5 Years at -20°C**  
A. Wood, *Mawi DNA Technologies LLC, Pleasanton, CA*
- 
- B-185 A Comparison Between Two Oral Sample Collection Devices on Preserving High-Quality Genomic DNA**  
A. Wood, *Mawi DNA Technologies LLC, Pleasanton, CA*
- 
- B-186 Pericentric Inversion of Chromosome 9-inv(9)(p12q13): Findings Beyond Infertility Encountered on a Retrospective Study**  
M. C. Feres, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- B-187 Association Between Genetic Variations of CYP2R1 (rs12794714) and 25-Hydroxyvitamin-D Levels in Nepalese Adults**  
B. K. Yadav, *Madhesh Institute of Health Science, Janakpur, Nepal*
- 
- B-188 Functional Performance Studies of Synergy Blood Collection Tube in Preservation of Cell Free DNA, RNA and Genomic DNA**  
I. Maksud, *SiO2 Materials Science, Auburn, AL*
- 
- B-189 Alinity m You-Create Lab-Developed Test for Hepatitis Delta Virus**  
M. Sasaki, *Abbott Molecular, Des Plaines, IL*
- 
- B-190 Protocol for Standardization of the Minimal Residual Response Monitoring in Patients With Chronic Myeloid Leukemia through the bcr-abl p210 Transcripts Monitoring in a Large Laboratory in Brazil**  
K. Alves Bezerra De Sousa, *Grupo Hapvida Notredame Intermedica, São Paulo, Brazil*
- 
- B-191 Genomic Profile of Circulating Tumor DNA in Advanced Lung Cancer: Comparison with Tissue DNA**  
J. Park, *Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of*
- 
- B-192 Covid on the PCR Pro: A Consumer-friendly PCR Test**  
D. Garey, *Co-Dx, Salt Lake City, UT*
- 
- B-193 The ArGO SARS-CoV-2 NGS Test: A Protocol-based Clinical Variant Test for COVID-19**  
J. Parkin, *Neelyx Labs, Wood Dale, IL*
- 
- B-194 Validation of a Diagnostic Test for the p.R337H Variant in the TP53 Gene by Nanopore Sequencing: Development of a Simplified Analysis Pipeline**  
M. Andrade, *Sabin Diagnóstico e Saúde, Brasília, Brazil*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MOLECULAR DIAGNOSTICS & GENETICS

- B-195 Accelerating Molecular Diagnostics: Development of a Novel Rapid, Integrated PCR System for Acute Respiratory Infections Detection**  
T. Ma, *Zybio, Inc, Chongqing, China*
- 
- B-196 Establishment and Application of Methodology for Detecting Copy Number Variation In Patients With Congenital Heart Disease Using Digital PCR Technology**  
W. Chen, *Fuwai hospital, Beijing, China*
- 
- B-197 Biomarker Potential of Circulating miRNAs in Prediabetes and Type 2 Diabetes: Insights from a Cross-Sectional Pilot Study Conducted in Nepal**  
D. R. Pokharel, *Manipal College of Medical Sciences and Teaching Hospital, Pokhara-16, Nepal*
- 
- B-198 Rapid Molecular Detection of Respiratory Infections in Brazilian Hospitals and Outpatient Units: Insights from the Diagnostic Medicine and Health Network**  
C. M. De Araujo, *Sabin Diagnóstico e Saúde, Brasilia, Brazil*
- 
- B-199 Rapid Molecular Detection of Meningitis Agents in Diverse Brazilian Regions (2019-2023): A Multicenter Study**  
C. M. De Araujo, *Sabin Diagnóstico e Saúde, Brasilia, Brazil*
- 
- B-200 Expediting Identification of Occult Sepsis with a Novel Diagnostic for Patients Presenting to the ED with Possible Infection**  
T. Jagneau, *Our Lady of The Lake Regional Medical Center, Baton Rouge, LA*
- 
- B-201 Clinical Performance Evaluation of IRON-qPCR™ RV, a Novel Molecular POCT System, for the Qualitative Detection of Respiratory Viruses in Nasopharyngeal Swab**  
C. Lee, *BIONEER, Daejeon, Korea, Republic of*
- 
- B-202 Clinical and Analytical Performance Evaluation of Savanna RVP4 Panel Versus Three Methodologies**  
J. Aldunate, *Laboratorio Redsalud, Santiago, Chile*
- 
- B-203 Advancing Equity, Inclusion, and Diversity in Genetic Testing: Disparities in Detection Rates and Access to Carrier Screening Among 8,000 Patients Nationwide**  
L. Hasadsri, *Mayo Clinic, Rochester, MN*
- 
- B-204 A Real-time Probe-based PCR Assay for Detection of Pneumocystis Pneumonia**  
Z. Zhou, *Tianjin Enterprise Key Laboratory for Precision Diagnosis Technology of Invasive Fungal Diseases, Tianjin, China*
- 
- B-205 Performance of a Novel Fluorogenic Assay for Detection of Carbapenemase-Producing Enterbacteriaceae**  
Z. Zhou, *Tianjin Enterprise Key Laboratory for Precision Diagnosis Technology of Invasive Fungal Disease Tianjin, China*
- 
- B-206 Tick-borne Disease Molecular Testing Positivity and Coinfection Incidence in the Northeastern United States: 2021-2023**  
G. Pratt, *Quest Diagnostics, Marlborough, MA*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MOLECULAR DIAGNOSTICS & GENETICS

- B-207 Clinical Evaluation of *ExiStation*™ FA 96 RV for the Detection of Human Respiratory Viruses in Human Nasopharyngeal Swab Specimen**  
J. Lee, *BIONEER, Daejeon, Korea, Republic of*
- 
- B-208 Room Temperature Stable PCR Reagents Preparation Using Capillary-Mediated Vitrification Process**  
S. Renu, *Upkara, Inc, Ann Arbor, MI*
- 
- B-209 Automated Microfluidic Platform for Isolation of High-Quality Ultra-High Molecular Weight DNA**  
E. Rakhmanaliev, *One BioMed Pte Ltd, Singapore, Singapore*
- 
- B-210 Oncomrd: a Breakthrough Liquid Biopsy Test for Solid Tumor Residual Disease Surveillance Benefiting From Patient-Derived Gene Expression Signature**  
C. H. Yeh, *OncoDxRx, Arcadia, CA*
- 
- B-211 Quantum dot-DNA Nanocomposite Enhanced Single-Molecule Flow (SiM-Flow) for Ultrasensitive microRNA Detection in Metastatic Castrate-Resistant Prostate Cancer**  
C. Kuo, *University of Illinois Urbana-Champaign, Urbana, IL*
- 
- B-212 Laboratory Performance in Molecular Detection of *Mycobacterium Tuberculosis* Through Analysis of External Quality Assessment Program Results: WHO-Recommended Tests Outperform Others**  
G. Barra, *Sabin Diagnóstico e saúde, Brasília, Brazil*
- 
- B-213 Including Turner Syndrome Screening in Newborn Sequencing by Using NGS Read Counts to Infer Sex Chromosomes Copy Number: Leveraging Existing Data to Enhance Early Diagnosis**  
G. Barra, *Sabin Diagnóstico e Saúde, Brasília, Brazil*
- 
- B-214 Mutational Landscapes of Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Database-Driven Comprehensive Myeloid Panel Analysis of DNA Variants and Gene Fusions**  
G. Barra, *Sabin Diagnóstico e Saúde, Brasília, Brazil*
- 
- B-215 Evaluating RT-qPCR for Dengue Virus Detection: Outcomes of a Brazilian External Quality Assessment Program**  
G. Barra, *Sabin Diagnóstico e Saúde, Brasília, Brazil*
- 
- B-216 Ethanol/Isopropanol-Free and Enzyme-Free Universal Nucleic Acid Extraction and Purification System for Fast Molecular Detection From Swab Samples**  
W. Zhang, *Delta Electronics (int'l) Singapore Pte Ltd, Singapore, Singapore*
- 
- B-217 Effective Diagnostic Platform and Method to Differentiate the Infectious From Non-Infectious Viruses With Nucleic Acid Detection Workflow**  
W. Zhang, *Delta Electronics (int'l) Singapore Pte Ltd, Singapore, Singapore*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### MOLECULAR DIAGNOSTICS & GENETICS

- B-218 Inconclusive Results in the Fetal Sex Determination from Maternal Plasma Assay May Indicate Miscarriage**  
J. Levi, Dasa, São Paulo, Brazil
- 
- B-219 Pseudo-exclusion From Paternity Due to Maternal Uniparental Disomy of Chromosome 2**  
J. Levi, Dasa, São Paulo, Brazil
- 
- B-220 Clinical Application of the “Clg-Fish” Technique for the Diagnosis of Multiple Myeloma**  
J. Eduardo Levi, Dasa, São Paulo, Brazil
- 
- B-221 Combined RT-PCR and Whole Exome Sequencing Pharmacogenetic Testing in Polypharmacy Patient: A Case Report**  
J. L. Rubio Prieto, Virgen del Rocío University Hospital, Seville, Spain
- 
- B-222 Receptor-donor CYP3A5 and CYP3A4 Genotype Testing in Liver Transplant Patients and its Influence in Tacrolimus Blood Levels: A Retrospective Study**  
J. L. Rubio Prieto, Virgen del Rocío University Hospital, Seville, Spain
- 
- B-223 Molecular Study of CDKN1B Gene in Possible Multiple Endocrine Neoplasm Type 4 Carriers — First Casuistic in Patients Born in Argentina**  
M. L. Viale, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 
- B-224 Rapid, Extraction-Free, and Portable Molecular Detection of HIV-1 and HCV Directly From Whole Blood**  
K. Michalak, Public Health Agency of Canada, Winnipeg, Canada
- 
- B-225 Bridging the Gap Between Clinical Microbiology and Molecular Diagnostics: Correlation of PCR Cycle Threshold Values for Establishing Semi-Quantitative CFU/mL Ranges of Bacterial Targets**  
J. Griffith-Vandi, Southwest Labs, Albuquerque, NM
- 
- B-226 Automated Barcode Fabrication Platform for Spatial Gene Sequencing or Image-based Multi-omics Profiling**  
D. Liu, National University of Singapore, Singapore, Singapore
- 
- B-227 Customized Molecular Tests for Minimal Residual Disease: A Tool for Therapeutic Decisions in Follicular Lymphoma Patients**  
T. Tohami, Meir Medical Center, Kfar Saba, Israel
- 
- B-228 Performance Comparison of Three Viral RNA Pathogens in MK Buffered Solution for Diagnostic Based Detection using Quantitative PCR vs Droplet Digital PCR**  
M. Casto, Marshall University, Huntington, WV
- 
- B-229 Extraction-free Nucleic Acid Sample Preparation from Inhibitor Rich Samples via Hyperbaric Heating**  
J. Hambalek, Autonomous Medical Devices Incorporated, Santa Ana, CA
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## MOLECULAR DIAGNOSTICS & GENETICS

- B-230** Rt-pcr Detection and Monitoring of Infection in Periodontal Disease: A Model of Herpesviral-Bacterial Synergism  
D. J. Vigerust, *Spectrum Solutions, Draper, UT*
- 
- B-231** Evaluation of the KingFisher Flex for DNA Isolation From FFPE Tissue Utilizing Autolys M Tubes and the MagMAX FFPE DNA/RNA Ultra Kit  
E. Zimmerman Zuckerman, *Mayo Clinic, Rochester, MN*
- 
- B-232** One Year Post-Implementation Experience Using a Custom Designed DNA Contamination Detection Module for a Clinical Myeloid Neoplasm Next Generation Sequencing Assay  
ADLM#  
ACADEMY  
M. A. Dina, *Mayo Clinic, Rochester, MN*
- 
- B-233** Exploring a Genetic Link Between Glioma and Substance Use Disorders: Uncovering Novel Insights through Next-Generation Sequencing and Literature Mining  
T. Wang, *Baylor Scott and White Medical Center, Temple, TX*
- 
- B-234** Evaluating the Diagnostic Utility of dd-cf-dna in Renal Allograft Surveillance: A Single-center Perspective  
A. Aravamudhan, *U of M, Minneapolis, MN*
- 
- B-235** Study the Impact of FGFR2 and FGFR4 Genetic Variants on the Treatment Response to Cyclophosphamide-Doxorubicin-Docetaxel Based Chemotherapy in Egyptian Females with Locally Advanced Breast Cancer  
O. A. Abdelkarem, *Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt*
- 
- B-236** New Real-time PCR Test for APOE Genotyping in Patients with Alzheimer's Disease Before Anti-amyloid Therapy  
M. Sabalza, *EUROIMMUN US Inc, Mountain Lakes, NJ*
- 
- B-237** Engineered Reverse Transcriptases and Taq DNA Polymerases Deliver Robust Yield in the Presence of Clinically Relevant Inhibitors  
E. Van Der Walt, *Watchmaker Genomics, Boulder, CO*
- 

### ePOSTER ACCESS

Visit the ePoster stations in the Poster Hall to browse the ePosters. Stop by at 12:30 pm or 2:30 pm to see ADLM Division-led ePosters Discussions. Chicago All Access attendees can also view ePosters anytime from now through August 30 by visiting [meeting.myadlm.org/ePosters](http://meeting.myadlm.org/ePosters).

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### PROTEOMICS & PROTEIN MARKERS

- B-240** **Multi-omic Blood Test for Early Detection of Cancer and Pre-Cancer**  
ADLM#  
ACADEMY M. Baker, *Dxcover Limited, Glasgow, United Kingdom*
- 
- B-241** **Next-generation Monitoring: M-inSightclinical Application in Multiple Myeloma**  
 M. Coradin, *Corgenix Medical Corporation, Broomfield, CO*
- 
- B-242** **Improved Patient Satisfaction With Novel Capillary Blood Collection Devices as an Alternative to Venipuncture for Applications in Clinical Proteomic Assays**  
 D. Flohrschutz, *Biodesix, Inc., De Soto, KS*
- 
- B-243** **Validating a Highly Automated, Rapid Turnaround Urine Biomarker Assay for Diagnosis of Acute Interstitial Nephritis**  
 W. Obeid, *Johns Hopkins University, Baltimore, MD*
- 
- B-244** **Analytical Performance and Method Comparison Evaluation of a New High Throughput Fully Automated Plasma GFAP Immunoassay**  
 Z. Vucetic, *Beckman Coulter, Brea, CA*
- 
- B-245** **Novel Monoclonal Antibodies Validated Specifically for Immunohistochemistry By Performance Assessment on Tissue Microarrays**  
 A. Ball, *GeneTex, Inc., Irvine, CA*
- 
- B-246** **Pab to Mab Conversion Via Mass Spectrometry: Direct Antibody Discovery From Serum**  
 J. Crha, *Rapid Novor, Inc., Kitchener, Canada*
- 
- B-247** **A Missing Peptide Link: A Case Study Involving Detection of an Unusual IGF-1 Protein Form Using High-Resolution Mass Spectrometry**  
ADLM#  
ACADEMY I. Motorykin, *Quest Diagnostics Nichols Institute, San Juan Capistrano, CA*
- 
- B-248** **Enhanced Detection of Hemoglobin Variants in Clinical Research using Dried Blood Spot and HRAM MS**  
 Y. Song, *Thermo Fisher Scientific, San Jose, CA*
- 
- B-249** **Assessing Targeted Mass Spectrometry Assay Performance for Putative Biomarker Proteins on a New Hybrid Nominal Mass Instrument**  
 D. L. Plubell, *University of Washington, Seattle, WA*
- 
- B-250** **Analytical and Diagnostic Performance Evaluation of Plasma pTau217 in a Clinical Diagnostic Laboratory**  
 H. Frykman, *University of British Columbia, Vancouver, Canada*
- 
- B-251** **Comprehensive Proteomics Analysis Reveals an Exosomal Biomarker Signature Useful for Detection of Non-Small Cell Lung Cancer**  
ADLM#  
ACADEMY M. Vij, *Columbia University in the City of New York, New York, NY*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## PROTEOMICS & PROTEIN MARKERS

- B-252 Identification of Semaphorin 4b: A Novel Biomarker for Obesity Progression**  
A. Amin, *Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal*
- 
- B-253 Using Biomarkers in Recurrent Renal Stone Formers to Detect Silent Stones**  
M. Gohel, *Tung Wah College, Hong Kong, Hong Kong*
- 
- B-254 Analytical and Clinical Performance Evaluation of Plasma pTau217 in a Clinical Diagnostic Laboratory**  
M. Encarnacion, *BC Neuroimmunology Lab., Vancouver, Canada*
- 
- B-255 Identification of the Protein Expression of Androgen Receptor Variants Using Targeted Proteomics in Clinical Castration Resistant Prostate Cancer Models**  
Z. E. Sychev, *University of Minnesota, Minneapolis, MN*
- 
- B-256 Neuroprotein S-100B in Mild Traumatic Brain Injury**  
I. Rodriguez Martin, *Hospital Infanta Elena, Huelva, Spain*
- 

## THERAPEUTIC DRUG MONITORING & TOXICOLOGY

- B-257 Don't Go Breaking My Heart: Use and Misuse of Beta-Blockers in Clinical and Forensic Casework (2019-2023)**  
K. M. Midthun, *NMS Labs, Horsham, PA*
- 
- B-258 Rapid Clozapine Blood Levels on the Beckman Coulter DxC 500 AU**  
J. Fritz, *Saladax Biomedical Inc., Bethlehem, PA*
- 
- B-259 Cannabinoid Prevalence in Umbilical Cord Tissue Toxicity Testing**  
A. Reinhart, *NMS Labs, Horsham, PA*
- 
- B-260 Prevalence and Relative Distributions of Major Phosphatidylethanol (PEth) Homologs in a Large-Scale Clinical Study**  
W. Dui, *Quest Diagnostics, Chantilly, VA*
- 
- B-261 Comparing Selectivity of Core-Shell and Modified Fully Porous HPLC Columns to Optimize Separation of 3 Classes of 47 TDM Analytes**  
S. Huq, *Phenomenex, Torrance, CA*
- 
- B-262 Validation of a Point-of-Care Lateral Flow Immunoassay for Urine Drug Testing Prior to Application in an Outpatient Rapid Access Addiction Medicine Clinic**  
M. Bohn, *University of Toronto, Toronto, Canada*
- 
- B-263 Analytical Performance Evaluation of Eleven Drug of Abuse Assays on the Atellica CI Analyzer**  
S. Lewisch, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-264 Utilizing a Pharmacogenomics and Evolutionary Genetics Approach to Understand Precision Pharmacovigilance**  
G. Awasthi, *Personalized Medicine Group, Tata Consultancy Services (TCS), Mumbai, India*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### THERAPEUTIC DRUG MONITORING & TOXICOLOGY

- B-265** Evaluation of LC-MS/MS Methodologies for 37 Per- and Poly-fluoroalkyl Substances (PFAS) in Serum  
K. Cho, *GC Labs, Yongin-si, Korea, Republic of*
- 
- B-266** Therapeutic Drug Monitoring of Natalizumab and Anti-Natalizumab Antibodies  
K. Chun, *LabCorp, Calabasas, CA*
- 
- B-267** Validation of the Newly Developed Fully Automated Chemiluminescent Enzyme Immunoassay (CLEIA) Reagent for Measurement of Cyclosporine in the Blood  
M. Tanaka, *Fujirebio Inc, Hachioji, Tokyo, Japan*
- 
- B-268** Detection of Xylazine in Fentanyl-Positive Urine Drug Screen Specimens Using a Quantitative LCMS/MS Method  
C. Mills, *Medical University of South Carolina, Charleston, SC*
- 
- B-269** Development and CYP3A4 Characterization of a Population-based Urinary Buprenorphine and Norbuprenorphine Nomogram  
K. Twum, *UNC Health, Chapel Hill, NC*
- 
- B-270** Comparison of a New Rapid Drug Test Device against Two Urine Fentanyl Immunoassays on the Abbott Alinity c Analyzer  
E. Laryea, *Vanderbilt University University Medical Center, Nashville, TN*
- 
- B-271** High Sensitivity Homogeneous Enzyme Immunoassay for Benzodiazepines and Metabolites  
K. Chung, *ARK Diagnostics, Inc., Fremont, CA*
- 
- B-272** Associations of DMET Markers and Statin-Induced Myotoxicity in Thai Patients Treated With Simvastatin  
S. Tipnoppanon, *Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand*
- 
- B-273** Clinical Validation of a Novel Lateral Flow Assay for Rapid and Sensitive Urine Fentanyl Screening  
D. Unsuhay Vila, *University of Pennsylvania, Philadelphia, PA*
- 
- B-274** Determining Novel Biomarker Candidates Associated With Heroin and Cocaine Exposure Using Urine Metabolomics  
K. Tamama, *University of Pittsburgh School of Medicine, Pittsburgh, PA*
- 
- B-275** Trends of Urine Drug Testing Findings in a Pediatric Hospital from 2019 to 2023  
M. Narasimhan, *UT Southwestern Medical Center, Dallas, TX*
- 
- B-276** Evaluation of the Roche Benzodiazepines II Immunoassay for Urine Drug Testing in Clinical Specimens  
M. Ge, *University of California San Diego, San Diego, CA*
- 
- B-277** Detectable Levels of Toxic Metals in Children's Playgrounds  
J. O. Oyelakin-Ogunbileje, *Department of Pathology, Indiana University School of Medicine, Indianapolis, IN*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## THERAPEUTIC DRUG MONITORING & TOXICOLOGY

- B-278** Evaluation of Serum Copper, Zinc and Selenium Reference Intervals Using the National Health and Nutrition Examination Survey (NHANES) Data  
J. Boyd, *University of Utah, Salt Lake City, UT*
- 
- B-279** Evaluation of the Analytical Performance of Two Therapeutic Drug Monitoring Assays on the Atellica CI Analyzer  
J. Huff, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-280** Nmr-based Biomaker Measurement Determines High-Dose Methotrexate Elimination Rates in Lymphoma and Leukemia Treatment  
A. Robertson, *Numares AG, Regensburg, Germany*
- 
- B-281** Performance Characteristics Evaluation of the ARK Diagnostics Immunoassay for Xylazine/4-HydroxyXylazine in Urine  
P. B. Kyle, *University of Mississippi Medical Center, Jackson, MS*
- 
- B-282** Cost and Benefits of Utilization of Ion Mobility Mass Spectrometry Testing for Drugs of Abuse Compared to Immunoassay Screening in a Large Urban Hospital  
F. Strathmann, *MOBILion Systems, Chadds Ford, PA*
- 
- B-283** Biological Consequences of Nitrous Oxide Abuse: Insights from Targeted Metabolomics Investigation  
G. Grzych, *CHU Lille, Lille, France*
- 
- B-284** Evaluation of Bupivacaine Metabolite Interference With Norfentanyl in a Liquid Chromatography Tandem Mass Spectrometry Assay in Neonatal Urine  
A. Adegoke, *ARUP Laboratories/University of Utah, Salt Lake City, UT*
- 
- B-285** Performance Evaluation of the Tacrolimus Assay on Roche Cobas 801  
R. Khoury, *Aculabs Inc., East Brunswick, NJ*
- 
- B-286** Single Experiment, Single Plate Solid Phase Extraction (SPE) Optimization using 47 Drug Analytes as an Example  
S. Marin, *Phenomenex, Torrance, CA*
- 
- B-287** Comparing a Recently FDA-Cleared Free Phenytoin Assay to a Laboratory Developed Test  
J. A. Zakrajsek, *Cleveland Clinic, Cleveland, OH*
- 
- B-288** Turning False Positive Screening into True Positive Results  
ADLM\*  
ACADEMY M. Bennett, *Alberta Centre for Toxicology, University of Calgary, Calgary, Canada*
- 
- B-289** Assessing the Shift in Positivity Rates of Cocaine and its Metabolites in a Community Based Population: A Transition from Utilization of Cutoff Concentrations to Qualitative Structure Identification  
N. White-Al Habeeb, *Dynacare, Brampton, Canada*
- 
- B-290** Static Analytical Scopes and Lab Processes — An Existing Public Health Hazard  
L. Labay, *NMS Labs, Horsham, PA*
- 
- B-291** Validation of a Simple Qualitative Immunoassay for 21 Drugs of Abuse in Meconium on a Single Biochip Array  
P. Sharma, *Mayo Clinic, Rochester, MN*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### THERAPEUTIC DRUG MONITORING & TOXICOLOGY

- B-292** **Detection of Natural Toxins Derived From Potatoes By Biotin-Streptavidin Direct ELISA**  
K. Okada, *Kyoto Tachibana University, Kyoto, Japan*
- 
- B-293** **Enzyme Linked Immunosorbent Assay Development and Full Validation for the Quantification of the Antibody Conjugated Fraction of an antiFAP ADC in Human Serum**  
L. Blasco, *CTI Laboratory Services Spain S.L., Derio, Spain*
- 
- B-294** **Case Report: Postmortem Ethanol Production Following Traumatic Injury**  
A. Whitt, *University of Louisville, Louisville, KY*
- 
- B-295** **Sensitive and Rapid Homogeneous Immunoassay for the Detection of Zolpidem and its Major Metabolite in Urine**  
V. Hennessey, *ARK Diagnostics, Inc., Fremont, CA*
- 
- B-296** **Assessment of Clozapine Assay on the Automated, High-performance Beckman AU Analyzer**  
D. McCormick, *Department of Clinical Laboratory, The James Comprehensive Cancer Center, Columbus, OH*
- 
- B-297** **Tacrolimus Concentrations in Envarsus vs Prograf Patients: An Evaluation of the Clinical Impact of LC-MS/MS and Immunoassay Methods on Tacrolimus Measurement**  
A. Alabi, *Department of Pathology, UC San Diego Health, La Jolla, CA*
- 
- B-298** **Quantitation and Abundance of Xylazine and Xylazine Metabolites in Human Urine by LC-MS/MS**  
Y. Lin, *Washington University in St. Louis, St. Louis, MO*
- 
- B-299** **Comparison of a Recently FDA-Cleared Urine Benzodiazepine Screening Assay with  $\beta$ -Glucuronidase Hydrolysis to Liquid Chromatography-Mass Spectrometry**  
J. T. Zakrajsek, *Cleveland Clinic, Cleveland, OH*
- 
- B-300** **Fentanyl and Xylazine Positivity Patterns at a Northeast U.S. Children's Hospital**  
I. Poventud-Fuentes, *Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA*
- 
- B-301** **Deciphering Neuropathy Features in the Context of Nitrous Oxide Abuse: An Integrated Analysis of Electrophysiology and Metabolism**  
E. Gernez, *Lille University Hospital, Lille, France*
- 
- B-302** **Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of Over 10,000 Patient Results**  
J. M. Yang, *Labcorp, Calabasas, CA*
- 
- B-303** **Stability of Antipsychotic Drugs in Patient Serum and Plasma Clinical Samples**  
M. S. Konrath, *Saladax Biomedical, Inc., Bethlehem, PA*
- 
- B-304** **Development of Free Valproic Acid Estimating Equations for Adult Epileptic Patients**  
A. Theriault, *University of Alabama, Birmingham, Birmingham, AL*

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## TUMOR MARKERS & CANCER DIAGNOSTICS

- B-305 High-risk HPV Scenario Among Young People: Data From a Clinical Laboratory (2019-2023)**  
M. C. Feres, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- B-306 Prevalence of Distribution of 21 Human Papillomavirus Genotypes in Albanian Population**  
B. Cullhaj, *GeniusLab, Tirane, Albania*
- 
- B-307 Comparative Studies on Serum Quantitative Immunoglobulin Assay and Serum Protein Electrophoresis for the Diagnosis of Multiple Myeloma**  
S. Shrestha, *University of Florida, Gainesville, FL*
- 
- B-308 Analytical and Clinical Performance of a Novel Ovarian Cancer Screening Test in Asymptomatic Women**  
ADLM#  
ACADEMY  
B. Manning, *Mercy Bioanalytics, Inc., Waltham, MA*
- 
- B-309 Evaluation of the Analytical Performance of Breast and Ovarian Cancer Antigen Assays on the Atellica CI Analyzer**  
M. Quintanilla, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-310 Freezing and Thawing Serum Without Mixing Prior to Analysis Causes False Low Thyroglobulin Results**  
J. Bordas, *SUNY Upstate Medical University, Syracuse, NY*
- 
- B-311 Relation of Free Immunoglobulin Light Chain Concentration to Overflow Proteinuria**  
G. L. Hortin, *H Lee Moffitt Cancer Center, Tampa, FL*
- 
- B-312 Overcoming Challenges in Reporting High  $\beta$ -hCG Results in Cancer Patients: A Tertiary Cancer Institute Experience**  
P. Chavan, *Actrec-Tata Memorial Centre, Navi Mumbai, India*
- 
- B-313 Assessment of  $\beta$ 2-microglobulin Concentration in Pleural Effusions**  
S. Bérnago Vázquez, *Althaia-Xarxa Assistencial Universitaria de Manresa, Manresa, Spain*
- 
- B-314 Utility of he4 in Differential Diagnosis of Pleural Effusions**  
S. Bérnago-Vázquez, *Althaia-Xarxa Assistencial Universitaria de Manresa, Manresa, Spain*
- 
- B-315 Detection of Advanced Adenoma by Liquid Biopsy Multiomics for the Clinical Triage — A Pilot Study**  
H. Tanaka, *DiaCarta, Inc., Pleasanton, CA*
- 
- B-316 Evaluation of an FDA-cleared Chromogranin A Assay on an Automated Analyzer**  
N. Boyert, *Cleveland Clinic, Cleveland, OH*
- 
- B-317 Novel Prognostic Marker TGFBI Affects the Migration and Invasion Function of Ovarian Cancer Cells via Integrin  $\alpha$  $\beta$ 3-PI3K-Akt Signaling Pathway**  
Y. Guo, *the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China*
- 
- B-318 Serum PSA in Extracellular Vesicles: Immunoreactivity to Commercial Kits and Elimination Kinetics**  
ADLM#  
ACADEMY  
Á. González, *Clínica Universidad de Navarra, Pamplona, Spain*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### TUMOR MARKERS & CANCER DIAGNOSTICS

- B-319** Kappa and Lambda Free Light Chains Quantification in Serum Samples with 3 or 4 Monoclonal Components Detected by Serum Immunofixation  
G. Loureiro, *Grupo Fleury, São Paulo, Brazil*
- 
- B-320** Understanding CA 72-4: Exploring False Positives in Clinical Context  
J. Trape Pujol, *Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain*
- 
- B-321** Enhancing Early Detection of Prostate Cancer Using PSA-Guided Screening in High-Risk Men Under 50  
L. Chen, *The University of Texas MD Anderson Cancer Center, Houston, TX*
- 
- B-322** Mind the Gap: Influence of Monoclonal Immunoglobulin on Anion Gap in Multiple Myeloma  
L. Chen, *The University of Texas MD Anderson Cancer Center, Houston, TX*
- 
- B-323** Measurement of PIVIKA II Blood Level in Patients with Liver Diseases by Immunoassays  
W. Tamimi, *King Abdulaziz Medical City, Riyadh, Saudi Arabia*
- 
- B-324** Pilot Study Result of EQA for Fecal Immunochemical Test for Hemoglobin Using a Novel Ready-to-Use Sample Material  
S. Takehara, *Eiken Chemical, Tokyo, Japan*
- 
- B-325** Y Chromosome May Serve as a Promising Biomarker for Predicting Response to PD-1-PD-L1 Blockade  
L. You, *West China Hospital of Sichuan University, Chengdu, China*
- 
- B-326** Detecting Paraproteinaemia Using Routine Biochemistry Parameters  
S. J. Costelloe, *Cork University Hospital, Cork, Ireland*
- 
- B-327** Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients  
X. Wang, *Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China*
- 
- B-328** A Novel Pathway of Akt-Dependent PARP1 Activation Through the Nuclear Localization of EPRS1  
I. Zin, *Cleveland Clinic Lerner Research Institute, Cleveland, OH*
- 
- B-329** Analytical Validation of Quantitative UBC Rapid Assay That Aid in Diagnosis of Bladder Cancer  
K. Jagarlamudi, *AroCell AB, Stockholm, Sweden*
- 
- B-330** Reducing Inappropriate Fecal Immunochemical Test  
F. Cai, *Alberta Precision Laboratories, Calgary, Canada*
- 
- B-331** Diagnostic Performances of Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer  
I. Jeong, *Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of*
- 
- B-332** Use of Urinary Volatile Organic Compounds in Monitoring Prostate Cancer After Radical Prostatectomy  
S. Badmos, *University of Texas at El Paso, El Paso, TX*
-

# SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

## TUMOR MARKERS & CANCER DIAGNOSTICS

- B-333 Optimizing AFP Cutoffs for Hepatocellular Carcinoma Screening: Insights from the National Cancer Screening Program in Korea**  
Y. Choi, *Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of*
- 
- B-334 Plasma cfDNA as a Biomarker to Monitor Chemotherapy Efficacy for Colorectal Cancer Management**  
M. Sha, *Diacarta Inc, Pleasanton, CA*
- 
- B-335 Analytical Performance of the Novel EQA Material for Fecal Immunochemical Test for Hemoglobin**  
M. Yamada, *Eiken Chemical, Tokyo, Japan*
- 
- B-336 Analytical Verification of the EXENT® Solution for the Identification and Quantitation of Monoclonal Immunoglobulins By Mass Spectrometry**  
C. Agulló, *University Hospital of Salamanca, Salamanca, Spain*
- 
- B-337 Mass Spectrometry to Evaluate Treatment Response in Patients with Multiple Myeloma — A Comparative Study Versus Immunofixation**  
ADLM#  
ACADEMY  
C. Agulló, *University Hospital of Salamanca, Salamanca, Spain*
- 
- B-338 Real-world Data Shows the Effectiveness of a Tetravalent Vaccine Against Human Papilloma Virus Types 16 And 18 in Chilean Women**  
M. J. Osorio Castro, *Bupa lab, parte de Bupa, Santiago, Chile*
- 
- B-339 Identification of Novel Diagnostic Biomarker PIRNA-8111406 of High-Grade Serous Ovarian Cancer**  
Y. Wu, *State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China*
- 
- B-340 Evaluation of the Analytical Performance of Three Major Immunoglobulins Assays on the Atellica CI Analyzer**  
R. H. Carter, Jr., *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population**  
N. Krul, *Hospital de Clinicas, Montevideo, Uruguay*
- 
- B-342 Teclistamab Interference in Serum Protein Electrophoresis and Serum Immunofixation Electrophoresis in Patients With Recurrent or Relapsed Multiple Myeloma**  
A. Whitt, *University of Louisville, Louisville, KY*
- 
- B-343 Development of CD40 and HER2 Bispecific Antibodies for Enhanced Efficacy Against HER2-Positive Tumors**  
H. Cheng, *Yrogen Biosystems, Worcester, MA*
- 
- B-344 Exploring the Association Between Plasma Zinc Levels and Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer: A Cross-Sectional Study**  
M. Siddiqui, *All India Institute of Medical Sciences, Mangalagiri, India, Vijayawada, India*
-

## SCIENTIFIC POSTER SESSIONS

9:30 a.m. - 5:00 p.m.

### TUMOR MARKERS & CANCER DIAGNOSTICS

- B-345** The PSA and Free PSA Concentrations in Serum of Apparently Healthy Subjects Using the Atellica IM hsPSA and fPSAII Assays  
K. Olson Nissen, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-346** Diagnostic Performance of the Atellica IM Free PSA Assay in Men Undergoing Prostate Cancer Screening  
K. Olson Nissen, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-347** Analytical Performance Evaluation of the High Sensitivity PSA Assay and the Free PSAII Assay on the Atellica IM Analyzer  
K. Olson Nissen, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-348** Performance of the Atellica IM Analyzer's High Sensitivity PSA Assay as an Aid for Monitoring Prostate Cancer Recurrence  
K. Olson Nissen, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-349** Diagnostic Performance of the Atellica IM High-Sensitivity PSA Assay in Men Undergoing Prostate Cancer Screening  
K. Olson Nissen, *Siemens Healthcare Diagnostics Inc., Tarrytown, NY*
- 
- B-350** The Application of MALDI-TOF Imaging to Biomarker Discovery in a Mouse Model of Papillomavirus Associated Tumorigenesis  
S. Lu, *The Pennsylvania State University, Hershey, PA*
- 
- B-351** Genotoxic Producing *Escherichia coli* Protects and Promotes Breast Adenocarcinoma  
L. Heaton, *Bob Jones University, Greenville, SC*
- 
- B-352** Effects of COVID-19 on Breast Cancer Positivity: A Retrospective and Predictive Study  
S. S. De Andrade, *Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil*
- 
- B-353** High Risk HPV Genotypes Prevalence in Mexico  
A. Garcia Gil, *National Reference Center Salud Digna, Culiacan, Mexico*
- 
- B-354** Decreased Turnaround Times: A Challenge for Flow Cytometry as a Diagnostic Tool for Acute Leukemias  
L. J. Forero, *Compensar, Bogota, Colombia*
- 
- B-355** Assessment of Calcitonin Cutoff Values for Post-Thyroidectomy Surveillance in Patients with Medullary Thyroid Carcinoma: Findings from a Single-Center Investigation  
S. Li, *The Ohio State University, Columbus, OH*
- 
- B-356** Siemens CYFRA 21-1: An Assay for Measurement of Cytokeratin Fragment 21-1  
D. J. Cline, *Fujirebio Diagnostics Inc., Malvern, PA*
- 
- B-357** Siemens CA 72-4: An Assay for Measurement of Tumor Associated Glycoprotein (TAG) 72  
D. J. Cline, *Fujirebio Diagnostics Inc., Malvern, PA*
- 
- B-358** Siemens NSE: An Assay for Measurement of Human Neuron-Specific Enolase  
D. J. Cline, *Fujirebio Diagnostics Inc., Malvern, PA*
-





Name: \_\_\_\_\_

Organization: \_\_\_\_\_

Phone: \_\_\_\_\_

Email: \_\_\_\_\_